COMPOSTO HETEROCÍCLICO CONTENDO NITROGÊNIO E USO DO MESMO

A nitrogen-containing heterocyclic compound serves as a selective aldosterone synthase inhibitor, addressing the need for new antihypertensive drugs by effectively reducing blood pressure and aldosterone levels in patients with resistant hypertension.

BR112025024802A2Pending Publication Date: 2026-11-10JIANGSU DEYUAN PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
BR112025024802
Authority / Receiving Office
BR · BR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-01
Filing Date
2024-05-11
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

There is a lack of new antihypertensive drugs for patients with resistant hypertension, and existing treatments often fail to adequately control blood pressure due to challenges in selectively inhibiting aldosterone synthase, leading to inadequate treatment options for patients with elevated aldosterone levels.

Method used

A nitrogen-containing heterocyclic compound is developed, which can act as a highly selective aldosterone synthase inhibitor, reducing aldosterone levels and effectively lowering blood pressure without impacting cortisol levels or causing other adverse effects.

Benefits of technology

The compound demonstrates significant reductions in blood pressure and aldosterone secretion, offering a promising new approach for treating resistant hypertension and primary aldosteronism with favorable safety and tolerability profiles.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A nitrogen-containing heterocyclic compound and the use thereof, and specifically disclosed are a compound as represented by formula (II), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0002] This disclosure relates to a nitrogen-containing heterocyclic compound and a use thereof, and specifically discloses a compound of formula (II), a stereoisomer thereof and a pharmaceutically acceptable salt thereof. HISTORY

[0003] Hypertension is a clinical syndrome characterized primarily by elevated systemic blood pressure (systolic pressure >140 mmHg and / or diastolic pressure >90 mmHg), which may be accompanied by functional or organ damage to organs such as the heart, brain, and kidneys. For the treatment of hypertension, commonly used drugs include five categories: calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), diuretics, and β-blockers, as well as fixed-dose combination preparations composed of the aforementioned drugs. In addition, α-blockers or other classes of antihypertensive agents (such as renin inhibitors, centrally acting agents, etc.) may sometimes be used in certain hypertensive populations. Petition 870260002323, dated 09 / 01 / 2026, page 225 / 413 2 / 189

[0004] For adult patients with hypertension requiring pharmacotherapy, initial treatment is recommended with any of the three classes of first-line antihypertensive medications: diuretics, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and calcium channel blockers. For hypertensive patients whose blood pressure remains uncontrolled with monotherapy, the combined use of antihypertensive drugs has become a fundamental approach to blood pressure control. To achieve the desired blood pressure level, most patients with hypertension require the use of two or more antihypertensive drugs. Resistant hypertension is defined when a patient's blood pressure remains above 140 mmHg despite the concomitant use of at least three antihypertensive drugs from different classes, one of which is a diuretic.For patients with resistant hypertension, a fourth drug, such as a β-blocker, aldosterone receptor antagonist, triamterene, clonidine, or α-blocker, should be added to the three-drug combination therapy.

[0005] Since 2007, no new antihypertensive drugs have been approved for market release, leaving a large number of patients with resistant hypertension still inadequately treated. Both resistant hypertension and hyperaldosteronism are characterized by water and sodium retention. In clinical studies, Baxdrostat produced a dose-dependent reduction in blood pressure and aldosterone secretion levels, indicating that aldosterone is a significant factor in drug resistance among patients with resistant hypertension. The primary pharmacological targets for the treatment of resistant hypertension through the reduction of aldosterone levels include mineralocorticoid receptor blockade and aldosterone synthase inhibition.

[0006] Aldosterone is encoded by the CYP11B2 gene, which has 11-β-hydroxylase, 18-hydroxylase, and 18-dehydrogenase activities. Its primary action occurs in the final step of aldosterone synthesis, where 11-deoxycorticosterone (11-DOC) serves as a substrate. Petition 870260002323, dated 09 / 01 / 2026, page 226 / 413 3 / 189 to produce aldosterone. CYP11B1 and CYP11B2 share 93% similarity in their amino acid sequences, and inhibition of CYP11B1 activity can lead to adrenal cortical insufficiency. Highly selective inhibition of aldosterone synthase is essential but challenging to achieve. Baxdrostat, a highly selective small-molecule aldosterone synthase inhibitor, demonstrated four key advantages in phase 2 trials: significant reduction in blood pressure, no impact on cortisol levels, rare occurrence of elevated blood potassium, and absence of steroid precursor accumulation. Baxdrostat at a 2 mg dose demonstrated efficacy in reducing office systolic and diastolic blood pressure in patients with resistant hypertension, along with favorable safety and tolerability profiles.

[0007] In summary, the development of selective aldosterone synthase inhibitors represents a highly promising new approach for the treatment of diseases associated with elevated aldosterone levels, including resistant hypertension and primary aldosteronism, thus expanding clinical treatment options. SUMMARY

[0008] The present disclosure provides a compound of formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0009] in which

[0010] ring A is selected from the group consisting of ring Ai and ring A2; Petition 870260002323, dated 09 / 01 / 2026, page 227 / 413 4 / 189

[0011] ring Ai is

[0012] ring A2 is selected from the group consisting of They are each independently and optionally replaced by 1, 2 or 3 Ri;

[0013] ring B is selected from the group consisting of ring Bi and ring B2;

[0014] the Bi ring is selected from the group consisting of phenyl, pyridyl and pyridazinyl, wherein phenyl, pyridyl and pyridazinyl are each independently and optionally replaced by 1, 2 or 3 R6;

[0015] ring B2 is a 5-membered heteroaryl, where the 5-membered heteroaryl is optionally replaced by 1, 2 or 3 R6;

[0016] T is selected from the group consisting of a single bond, CH2, NH and O;

[0017] Ti is selected from the group consisting of O and CR4R5;

[0018] Ri is selected from the group consisting of H, =NR, C1-3 alkyl and C1-3 haloalkyl; Petition 870260002323, dated 09 / 01 / 2026, p. 228 / 413 5 / 189

[0019] each R2, R3, R4 and R5 is independently selected from the group consisting of H, F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl and C1-3 haloalkoxy, where not all four of R2, R3, R4 and R5 are simultaneously H;

[0020] Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group;

[0021] Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl;

[0022] Alternatively, R3 and R4 together with the carbon atom to which they are attached form a double bond or a cyclopropyl bond;

[0023] each R6 is independently selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0024] the structural fraction Re is selected from the group consisting of S / =N Ü eR81 O R71.

[0025] R71 is a 4- to 6-membered cycloalkyl heterocycloalkyl, wherein the 4- to 6-membered cycloalkyl heterocycloalkyl is optionally replaced by 1, 2 or 3 Ra;

[0026] R81 is selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0027] ring C is selected from the group consisting of ring C1 and ring C2;

[0028] the C1 ring is C5-6 cycloalkyl substituted by 1 R9, wherein R9 is selected from the group consisting of -NHC(=O)-C1-3 alkyl, -NH-C(=O)-5- to 6 heteroaryl members, H.N^NR NH-4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl, and, Rem, wherein -NHC(=O)-C1-3-alkyl, -NH-C(=O)-5- to 6-membered heteroaryl, -NH-4- to 6-membered heterocycloalkyl, and 4- to 6-membered heterocycloalkyl are each, Petition 870260002323, dated 09 / 01 / 2026, p. 229 / 413 6 / 189 independently and optionally replaced by 1, 2 or 3 Rb;

[0029] ring C2 is selected from the group consisting of 'd, e in which the They are each independently and optionally replaced by 1, 2 or 3 Re;

[0030] each Ra is independently selected from the group consisting of F, Cl, Br, I, C1-3 alkyl and -S(=O) 2-C1-3 alkyl;

[0031] each Rb is independently selected from the group consisting of F, Cl, Br, I, ci-3 alkyl, -C(=O)-C1-3 alkyl and -NH-C(=O)-C1-3 alkyl;

[0032] Rc and Rd, together with the carbon atom to which they are attached, form a C3-5 cycloalkyl or a 5- to 6-membered heterocycloalkyl;

[0033] each Re is independently selected from the group consisting of F, Cl, Br, I, =O, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino, -NHC(=O) -C1-3 alkyl, -NHC(=O) -C1-3 alkoxy, -NHC(=O) -C1-3 alkylamino and =NR;

[0034] R is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, wherein C13 alkyl and C1-3 alkoxy are each independently and optionally substituted by 1, 2 or 3 halogens;

[0035] n is 0 or 1;

[0036] ^is a single bond or a double bond;

[0037] the term hetero in 5-membered heteroaryl, 5- to 6-membered heteroaryl and 4- to 6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatomic groups, each independently selected from the group consisting of O, S and N;

[0038] provided that Petition 870260002323, dated 09 / 01 / 2026, p. 230 / 413 7 / 189

[0039] 1) when ring A is Ai and ring B is Bi, then ring C is C2; or,

[0040] 2) when ring A is Ai, ring B is Bi and ring C is C5-6 substituted cycloalkyl H .N^NR by 1 R9, then R9 is R

[0041] Present disclosure provides a compound of formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0042] in which

[0043] Ring A is selected from the group consisting of ring A1 and ring A2; Ri

[0044] ring Ai is0 Petition 870260002323, dated 09 / 01 / 2026, p. 231 / 413 8 / 189 They are each independently and optionally replaced by 1, 2 or 3Ri;

[0046] ring B is selected from the group consisting of ring Bi and ring B2;

[0047] the Bi ring is selected from the group consisting of phenyl, pyridinyl and pyridazinyl, wherein phenyl, pyridinyl and pyridazinyl are each independently and optionally replaced by 1, 2 or 3 R6;

[0048] ring B2 is a 5-membered heteroaryl, where the 5-membered heteroaryl is optionally replaced by 1, 2 or 3 R6;

[0049] T is selected from the group consisting of a single bond, CH2, NH and O;

[0050] Ti is selected from the group consisting of O and CR4R5;

[0051] Ri is selected from the group consisting of H, =NR, C1-3 alkyl and C1-3 haloalkyl;

[0052] each R2, R3, R4 and R5 is independently selected from the group consisting of H, F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl and C1-3 haloalkoxy, wherein not all four of R2, R3, R4 and R5 are simultaneously H;

[0053] Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl;

[0054] Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl;

[0055] Alternatively, R3 and R4 together with the carbon atom to which they are attached form a double bond or a cyclopropyl bond; Each R6 is independently selected from the group consisting of H, F, Cl, Br, I, and C1-3 alkyl; Petition 870260002323, dated 09 / 01 / 2026, p. 232 / 413 9 / 189 R7

[0056] the structural fractionRsé selected from the group consisting of

[0057] R71 is a 4- to 6-membered cycloalkyl heterocycloalkyl, wherein the 4- to 6-membered cycloalkyl heterocycloalkyl is optionally replaced by 1, 2 or 3 Ra;

[0058] R8i is selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0059] ring C is selected from the group consisting of ring Ci and ring C2;

[0060] the C1 ring is cyclohexyl substituted by 1 R9, wherein R9 is selected from the group consisting of -NHC(=O)-C1-3 alkyl, -NH-C(=O)-5- to 6-membered heteroaryl, -NH-4H,N^NR 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl, and R, wherein the -NHC(=O)-C1-3 alkyl, -NH-C(=O)-5- to 6-membered heteroaryl, -NH-4- to 6-membered heterocycloalkyl, and 4- to 6-membered heterocycloalkyl are each independently and optionally substituted by 1, 2 or 3 Rb;

[0061] ring C2 is selected from the group consisting of in which the They are each independently and optionally replaced by 1, 2 or 3 Re;

[0062] each Ra is independently selected from the group consisting of F, Cl, Br, I, C1-3 alkyl and -S(=O) 2-C1-3 alkyl;

[0063] each Rb is independently selected from the group consisting of F, Cl, Br, Petition 870260002323, dated 09 / 01 / 2026, p. 233 / 413 10 / 189 I,Ci-3 alkyl, -C(=O)-C1-3 alkyl and -NH-C(=O)-Ci-3 alkyl;

[0064] Rc and Rd, together with the carbon atom to which they are attached, form a C3-5 cycloalkyl or a 5- to 6-membered heterocycloalkyl;

[0065] each Re is independently selected from the group consisting of F, Cl, Br, I, =O, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino, -NHC(=O) -C1-3 alkyl, -NHC(=O) -C1-3 alkoxy, -NHC(=O) -C1-3 alkylamino and =NR;

[0066] R is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, wherein C13 alkyl and C1-3 alkoxy are each independently and optionally substituted by 1, 2 or 3 halogens;

[0067] n is 0 or 1;

[0068] a single bond or a double bond;

[0069] the term hetero in 5-membered heteroaryl, 5- to 6-membered heteroaryl and 4- to 6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatomic groups, each independently selected from the group consisting of O, S and N;

[0070] provided that

[0071] 1) when ring A is A1 and ring B is B1, then ring C is C2; or,

[0072] 2) when ring A is A1, ring B is B1 and ring C is cyclohexyl substituted by H,N^,NR 1R9, then R9 is R.

[0073] The present disclosure provides a compound of formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, Petition 870260002323, dated 09 / 01 / 2026, p. 234 / 413 11 / 189

[0074] in which

[0075] ring A is selected from the group consisting of ring Ai and ring A2;

[0076]

[0077] R1 ring Ai is θ ring A2 is selected from the group consisting of are each independently and optionally replaced by 1, 2 or 3Ri;

[0078] Ring B is selected from the group consisting of ring Bi and ring B2;

[0079] 0 ring Bi is selected from the group consisting of phenyl and pyridyl, where 0 phenyl and 0 pyridyl are each independently and optionally replaced by 1, 2 or 3 Rho;

[0080] 0 ring B2 is a 5-membered heteroaryl, wherein the 5-membered heteroaryl is optionally replaced by 1, 2 or 3 Rho;

[0081] T is selected from the group consisting of CH2, NH and O;

[0082] Ti is selected from the group consisting of O and CR4R5; Petition 870260002323, dated 09 / 01 / 2026, pp. 235 / 413 12 / 189

[0083] Ri is selected from the group consisting of H, =NR, C1.3 alkyl and C1-3 haloalkyl;

[0084] each R2, R3, R4 and R5 is independently selected from the group consisting of H, F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl and C1-3 haloalkoxy, wherein not all four of R2, R3, R4 and R5 are simultaneously H;

[0085] Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl;

[0086] Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl;

[0087] Alternatively, R3 and R4 together with the carbon atom to which they are attached form a double bond or a cyclopropyl bond;

[0088] each R6 is independently selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0089] the structural fraction Re is selected from the group consisting of

[0090] R71 is a 4- to 6-membered cycloalkyl heterocycloalkyl, wherein the 4- to 6-membered cycloalkyl heterocycloalkyl is optionally replaced by 1, 2 or 3 Ra;

[0091] R81 is selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0092] ring C is selected from the group consisting of ring C1 and ring C2;

[0093] the C1 ring is cyclohexyl substituted by 1 R9, wherein R9 is selected from the group consisting of -NHC(=O)-C1-3 alkyl, -NH-C(=O)-5- to 6-membered heteroaryl, -NH-4H.N^NR to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl, and R, where Petition 870260002323, dated 09 / 01 / 2026, p. 236 / 413 13 / 189 -NHC(=O)-Ci-3 alkyl, -NH-C(=O)-5- to 6-membered heteroaryl, -NH-4- to 6-membered heterocycloalkyl, and 4- to 6-membered heterocycloalkyl are each independently and optionally substituted by 1, 2, or 3 Rb;

[0094] ring C2 is selected from the group consisting of 'd, e in which the They are each independently and optionally replaced by 1, 2 or 3 Re;

[0095] each Ra is independently selected from the group consisting of F, Cl, Br, I, C1-3 alkyl and -S(=O) 2-C1-3 alkyl;

[0096] each Rb is independently selected from the group consisting of F, Cl, Br, I, ci-3 alkyl, -C(=O)-C1-3 alkyl and -NH-C(=O)-C1-3 alkyl;

[0097] Rc and Rd, together with the carbon atom to which they are attached, form a C3-5 cycloalkyl or a 5- to 6-membered heterocycloalkyl;

[0098] each Re is independently selected from the group consisting of F, Cl, Br, I, =O, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino, -NHC(=O) -C1-3 alkyl, -NHC(=O) -C1-3 alkoxy, -NHC(=O) -C1-3 alkylamino and =NR;

[0099] R is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, wherein C13 alkyl and C1-3 alkoxy are each independently and optionally substituted by 1, 2 or 3 halogens;

[0100] n is 0 or 1;

[0101] ^is a single bond or a double bond;

[0102] the term hetero in 5-membered heteroaryl, 5- to 6-membered heteroaryl and 4- to 6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatomic groups, each independently selected from the group consisting of O, S Petition 870260002323, dated 09 / 01 / 2026, p. 237 / 413 14 / 189 and N;

[0103] provided that

[0104] 1) when ring A is Ai and ring B is Bi, then ring C is C2; or,

[0105] 2) when ring A is Ai, ring B is Bi and ring C is cyclohexyl substituted by H .N^NR 1R9, then R9 is R.

[0106] The present disclosure provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

[0107] in which

[0108] ring B is selected from the group consisting of ring Bi and ring B2;

[0109] the Bi ring is phenyl, where the phenyl is optionally replaced by 1, 2 or 3 R6;

[0110] ring B2 is a 5-membered heteroaryl, where the 5-membered heteroaryl is optionally replaced by 1, 2 or 3 R6;

[0111] ring A is selected from the group consisting of ring Ai and ring A2;

[0112] ring Ai is

[0113] ring A2 is selected from the group consisting of in Petition 870260002323, dated 09 / 01 / 2026, p. 238 / 413 15 / 189 that They are each independently and optionally replaced by 1, 2 or 3 Ri;

[0114] E is selected from the group consisting of CH and N;

[0115] T is selected from the group consisting of CH2, NH and O;

[0116] ring C is selected from the group consisting of ring Ci and ring C2;

[0117] the Ci ring is cyclohexyl substituted by 1 R9, where R9 is -NHC(=O) CH2CH3;

[0118] ring C2 is selected from the group consisting of Rf, in which the They are each independently and optionally replaced by 1, 2 or 3 Re;

[0119] each Ri is independently selected from the group consisting of F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy and =NR;

[0120] each R6 is independently selected from the group consisting of F, Cl, Br, I and C1-3 alkyl;

[0121] Rc and Rd, together with the carbon atom to which they are attached, form a C3-5 cycloalkyl or a 5- to 6-membered heterocycloalkyl;

[0122] each Re is independently selected from the group consisting of F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino, -NHC(=O)-C1-3 alkyl, -NHC(=O)-C1-3 alkoxy and -NHC(=O)-C1-3 alkylamino; Petition 870260002323, dated 09 / 01 / 2026, p. 239 / 413 16 / 189 H ,N. .N

[0123] Rf is selected from the group consisting of =NR,R, and

[0124] R is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, wherein C13 alkyl and C1-3 alkoxy are optionally replaced by 1, 2 or 3 halogens;

[0125] n is 0 or 1;

[0126] ^is a single bond or a double bond;

[0127] the term hetero in 5-membered heteroaryl, 5- to 6-membered heteroaryl and 5- to 6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatomic groups, each independently selected from the group consisting of O, S, N and C(=O);

[0128] provided that

[0129] when ring A is Ai and ring B is Bi, then ring C is C2.

[0130] In some embodiments of this disclosure, the R above is selected from the group consisting of CH3, CH2CH3, CF3, OCH3 and OCF3, with the other variables as defined in this disclosure.

[0131] In some embodiments of this disclosure, the Ra above is -S(=O)2CH2CH3, with other variables as defined in this disclosure.

[0132] In some embodiments of the present disclosure, each of the above Rb is independently selected from the group consisting of F, Cl, Br, I, CH3, -C(=O)CH2CH3 and -NHC(=O)-CH2CH3, with other variations as defined in this disclosure.

[0133] In some embodiments of the present disclosure, the Rc and Rd above, together with the carbon atom to which they are attached, form with other variables, as defined in this disclosure. Petition 870260002323, dated 09 / 01 / 2026, pp. 240 / 413 17 / 189

[0134] In some embodiments of this disclosure, each of the above Re is selected from the group consisting of -NHC(=O)-CH2CH3, =NCH3 and =N-OCH3, with other variations as defined in this disclosure.

[0135] In some embodiments of this disclosure, each of the above Re is independently selected from the group consisting of F, Cl, Br, I, CH3, CH2CH3, OCH3, OCH2CH3, NCH3, NCH2CH3, -NHC(=O)-CH3, -NHC(=O)-CH2CH3, -NHC(=O) -OCH3 and -NHC(=O) -NCH3, with other variables as defined in this disclosure.

[0136] In some embodiments of this disclosure, the above Rf is selected from the group consisting of =NCH3, =N-OCH3, with other variables, as defined in this disclosure.

[0137] In some embodiments of this disclosure, the above Ri is CH3, with other variations as defined in this disclosure.

[0138] In some embodiments of this disclosure, each of the above R1s is independently selected from the group consisting of F, Cl, Br, I, CH3, OCH3 and =NOCH3, with other variables as defined in this disclosure.

[0139] In some embodiments of this disclosure, each of the above R2, R3, R4, and R5 is independently selected from the group consisting of H, F, Cl, Br, CH3, CHF2, CF3, CH2CH3, OCH3, and OCH2CH3, wherein not all four of R2, R3, R4, and R5 are simultaneously H, with other variables as defined in this disclosure.

[0140] In some embodiments of this disclosure, the above R2 is selected from the group consisting of H and F, with other variables as defined in this disclosure.

[0141] In some versions of this disclosure, the R5 above is selected from Petition 870260002323, dated 09 / 01 / 2026, pp. 241 / 413 18 / 189 group consisting of H, F, Cl, Br, CH3, CHF2, CF3, CH2CH3 and OCH3, with other variations as defined in this disclosure.

[0142] In some embodiments of this disclosure, each of the above R6 is independently F, with other variables as defined in this disclosure.

[0143] In some embodiments of this disclosure, each of the above R6 is independently selected from the group consisting of F, Cl, Br, I and CH3, with other variations as defined in this disclosure.

[0144] In some embodiments of this disclosure, the R71 above is , with other variables, as defined in this disclosure. THE II NS=O

[0145] In some embodiments of this disclosure, the R81 above is H, with other variables as defined in this disclosure.

[0146] In some embodiments of the present disclosure, the R9 above is selected from the group consisting of -NHC(=O)-CH2CH3, -NH-C(=O)-pyridyl, -NH-C(=O)-isoxazolyl, H,N^NR -NH-piperidinyl, -NH-pyrrolidinyl, -NH-azetidinyl, piperidinyl, Rem where NHC(=O)-CH2CH3, -NH-C(=O)-pyridyl, -NH-C(=O)-isoxazolyl, -NH-piperidinyl, -NH-pyrrolidinyl, -NH-azetidinyl and piperidinyl are each independently and optionally replaced by 1, 2 or 3 Rb, with other variables, as defined in this disclosure.

[0147] In some versions of this disclosure, the R9 above is selected from --NH group consisting of --NH Petition 870260002323, dated 09 / 01 / 2026, pp. 242 / 413 19 / 189 in which the --NH Each of them can be independently and optionally replaced by 1, 2, or 3 Rb, with other variables, as defined in this disclosure.

[0148] In some versions of this disclosure, the R9 above is selected from the group consisting of with other variables, as defined in this disclosure.

[0149] In some embodiments of the present disclosure, the Bi ring above is selected from the group consisting of Cl e'N, with other variables, as defined in this disclosure.

[0150] In some embodiments of this disclosure, ring B1 above is selected Petition 870260002323, dated 09 / 01 / 2026, pp. 243 / 413 20 / 189 of the group consisting of with other variables, as defined in this disclosure.

[0151] In some embodiments of this disclosure, the Bi ring above is phenyl, with other variations as defined in this disclosure.

[0152] In some embodiments of this disclosure, the B2 ring above is selected from the group consisting of tienyl, thiazolyl, imidazolyl and pyrazolyl, wherein tienyl, thiazolyl, imidazolyl and pyrazolyl are each independently and optionally replaced by 1, 2 or 3 R6, with other variables, as defined in this disclosure.

[0153] In some embodiments of the present disclosure, the ring B2 above is selected 'yS' from the group consisting of , F , - N , N and in which the Each of them can be independently and optionally replaced by 1, 2, or 3 R6, with other variables, as defined in this disclosure.

[0154] In some embodiments of the present disclosure, the ring B2 above is selected from the group consisting of z and- with other variables, as defined in this disclosure.

[0155] In some embodiments of this disclosure, ring B2 above is selected from the group consisting of , with Petition 870260002323, dated 09 / 01 / 2026, pp. 244 / 413 21 / 189 other variables, as defined in this disclosure. In some embodiments of this disclosure, ring A2 above is selected from the group consisting of disclosure. , with other variables, as defined herein

[0156] In some embodiments of this disclosure, ring A2 above is selected of the group that consists of Petition 870260002323, dated 09 / 01 / 2026, pp. 245 / 413 22 / 189 in this publication. with other variables, as defined

[0157] In some embodiments of this disclosure, ring A2 above is selected from the group consisting of , with other variables, as defined in this disclosure.

[0158] In some embodiments of the present disclosure, the ring Ci above is selected ύ :ύ from the group consisting of THE O— , with other variables, as defined in this disclosure.

[0159] In some embodiments of the present disclosure, the Ci ring above is selected Petition 870260002323, dated 09 / 01 / 2026, pp. 246 / 413 23 / 189 , with other variables, as defined in this disclosure.

[0160] In some embodiments of the present disclosure, the Ci ring above is phenyl with other variables as defined in this disclosure.

[0161] In some embodiments of the present disclosure, the Ci ring above is phenyl with other variables as defined in this disclosure.

[0162] In some embodiments of the present disclosure, the Ci ring above is phenyl with other variables as defined in this disclosure.

[0163] In some embodiments of this disclosure, the C2 ring above is selected Petition 870260002323, dated 09 / 01 / 2026, pp. 247 / 413 24 / 189 of the group consisting of in which the They are each independently and optionally replaced by 1, 2, or 3 Re, with other variables, as defined in this disclosure.

[0164] In some embodiments of the present disclosure, in the compound of formula (I) described above, the C2 ring is selected from the group consisting of in They are each independently and optionally replaced by 1 or 3 Rg, with other variables, as defined in this disclosure.

[0165] In some embodiments of this disclosure, the C2 ring above is selected Petition 870260002323, dated 09 / 01 / 2026, pp. 248 / 413 25 / 189 of the group that consists of with other variables, as defined in this disclosure.

[0166] In some embodiments of the present disclosure, in the compound of formula (I) described above, the C2 ring is selected from the group consisting of , with other variables, as defined in this disclosure.

[0167] In some embodiments of the present disclosure, in the compound of formula (I) Petition 870260002323, dated 09 / 01 / 2026, pp. 249 / 413 26 / 189 '____' H 0' )--< N^υ / described above, the ring C2 is selected from the group consisting of x—', ' X / X / \ / \ / X / O YNH O \NH '' ' ')—(\ / ir-, rr 0 O 9·· v·\_ / \ \ Η ^NH HH , , , , , ,, / / / ONH O— ( / NH Z>=N ' Í>=N \ , and \ , with other variables, as defined in this disclosure.

[0168] In some forms of this disclosure, the structural fraction Petition 870260002323, dated 09 / 01 / 2026, pp. 250 / 413 27 / 189 other variables, as defined in this disclosure. Petition 870260002323, dated 09 / 01 / 2026, pp. 251 / 413 28 / 189

[0169] In some forms of this disclosure, the structural fraction is selected from , with other variables, as defined in this disclosure.

[0170] In some embodiments of the present disclosure, the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof is provided, wherein the compound is selected from the group consisting of □ III-3Π Petition 870260002323, dated 09 / 01 / 2026, page 252 / 413 29 / 189

[0171] in which

[0172] is a single bond or a double bond;

[0173] T2 is selected from the group consisting of CH and N;

[0174] T4 is selected from the group consisting of CH and N;

[0175] T3 is selected from the group consisting of C and N;

[0176] ring E is selected from the group consisting of

[0177] m is selected from the group consisting of 0, 1, 2 and 3;

[0178] p is selected from the group consisting of 0, 1 and 2;

[0179] ring B is selected from the group consisting of ring Bi and ring B2;

[0180] the Bi ring is selected from the group consisting of phenyl, pyridyl and pyridazinyl;

[0181] ring B2 is a 5-membered heteroaryl ring;

[0182] T, Ti, Ri, R2, R3, R6, L, R7 and Rs are as defined in this disclosure.

[0183] In some embodiments of the present disclosure, the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof is provided, wherein the compound is

[0184] in which

[0185] ring B is selected from the group consisting of phenyl, pyridyl, pyridazinyl and heteroaryl 5 members; Petition 870260002323, dated 09 / 01 / 2026, pp. 253 / 413 30 / 189

[0186] Ri is selected from the group consisting of H, C1.3 alkyl and C1-3 haloalkyl;

[0187] each R2 and R5 is independently selected from the group consisting of H, F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl and C1-3 haloalkoxy;

[0188] each R6 is independently selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0189] R9 is selected from the group consisting of -NHC(=O)-C1-3 alkyl, -NH-C(=O)-5- 6-membered heteroaryl, -NH-4- 6-membered heterocycloalkyl, H.N^NR 4- to 6-membered heterocycloalkyl and R, wherein the -NHC(=O)-C1-3 alkyl, -NH-C(=O)-5- 6-membered heteroaryl, -NH-4- 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl are each independently and optionally substituted by 1, 2 or 3 Rb;

[0190] each Rb is independently selected from the group consisting of F, Cl, Br, I, C1-3 alkyl, -C(=O)-C1-3 alkyl and -NH-C(=O)-C1-3 alkyl;

[0191] R is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, wherein C13 alkyl and C1-3 alkoxy are each independently and optionally substituted by 1, 2 or 3 halogens;

[0192] m is selected from the group consisting of 0, 1, 2 and 3;

[0193] ^is a single bond or a double bond;

[0194] the term hetero in 5-membered heteroaryl, 5- to 6-membered heteroaryl and 4- to 6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatomic groups, each independently selected from the group consisting of O, S and N.

[0195] In some embodiments of the present disclosure, the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof is provided, wherein the compound is selected from the group consisting of Petition 870260002323, dated 09 / 01 / 2026, pp. 254 / 413 31 / 189 R2R3 dp-id

[0196] in which

[0197] ring B is selected from the group consisting of phenyl, pyridinyl, pyridazinyl and heteroaryl 5 members;

[0198] Ti is selected from the group consisting of O and CR4R5;

[0199] Ri is selected from the group consisting of H, C1-3 alkyl and C1-3 haloalkyl;

[0200] each R2, R3, R4 and R5 is independently selected from the group consisting of H, F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl and C1-3 haloalkoxy;

[0201] Alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl;

[0202] Alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl;

[0203] Alternatively, R3 and R4 together with the carbon atom to which they are attached form a double bond or a cyclopropyl bond;

[0204] each R6 is independently selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0205] each Re is independently selected from the group consisting of F, Cl, Br, I, =O, C1-3 alkyl, C1.3 alkoxy, C1-3 alkylamino, -NHC(=O) -C1-3 alkyl, -NHC(=O) -C1.3 alkoxy, -NHC(=O) -C1-3 alkylamino and =NR;

[0206] R is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, wherein C13 alkyl and C1-3 alkoxy are each independently and optionally substituted by 1, 2 or 3 halogens; Petition 870260002323, dated 09 / 01 / 2026, pp. 255 / 413 32 / 189

[0207] m is selected from the group consisting of 0, 1, 2 and 3;

[0208] ^is a single bond or a double bond;

[0209] the term hetero in the 5-membered heteroaryl represents 1, 2, 3, or 4 heteroatoms or heteroatomic groups, each independently selected from the group consisting of O, S, and N.

[0210] In some embodiments of the present disclosure, in the formula above (P-1), when it is a double bond and Ti is O, then R3 and R4 are absent, with other variables as defined in the present disclosure.

[0211] In some forms of this disclosure, in the formula above (P-1), the is selected from the group that consists of structural fraction r2, eR2R3, with other variables, as defined in this disclosure.

[0212] In some forms of this disclosure, in the formula above (P-1), the The structural fraction R2R3 is selected from the group consisting of 23, with other variables, as defined in this disclosure.

[0213] In some forms of this disclosure, in the formula above (III-2), Petition 870260002323, dated 09 / 01 / 2026, page 256 / 413 33 / 189 is a double bond and R3 and R4 are missing, with other variables as defined in this disclosure.

[0214] In some forms of this disclosure, in the formula above (III-2), the Ri The structural fraction n γr2r3 is selected from the group consisting of, R1 er2r3 with other variables, as defined in this disclosure.

[0215] In some embodiments of the present disclosure, in the formula above (III-2), the structural fraction R^1N R2R3 R<^1N R5 is selected from the group consisting of R2, R1 THE R4r5, THE R2R3 rnV 00R2R3, with other variables, as defined in this disclosure.

[0216] In some forms of this disclosure, in the formula above (III-2), the Rlx1N R1 Or5r2r3 is selected from the group consisting of R2, the structural fraction. 00R2R3, with other variables, as defined herein. Petition 870260002323, dated 09 / 01 / 2026, page 257 / 413 34 / 189 disclosure.

[0217] In some embodiments of the present disclosure, the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof is provided, wherein the compound is selected from the group consisting of □ III-3Π R7

[0218] in which

[0219] a single bond or a double bond;

[0220] T2 is selected from the group consisting of CH and N;

[0221] T4 is selected from the group consisting of CH and N;

[0222] T3 is selected from the group consisting of C and N;

[0223] ring E is selected from the group consisting of

[0224] m is selected from the group consisting of 0, 1, 2 and 3;

[0225] p is selected from the group consisting of 0, 1 and 2;

[0226] Ring B Petition 870260002323, dated 09 / 01 / 2026, pp. 258 / 413 35 / 189

[0227] is selected from the group consisting of ring Bi and ring B2;

[0228] the Bi ring is selected from the group consisting of phenyl, pyridyl and pyridazinyl;

[0229] ring B2 is a 5-membered heteroaryl ring;

[0230] T, Ti, Ri, R2, R3, R6, L, R7 and Rs are as defined in this disclosure.

[0231] In some embodiments of this disclosure, in the formula above ('-2), is a double bond and Ti is CR5, with other variables as defined in this disclosure.

[0232] In some embodiments of the present disclosure, the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof is provided, wherein the compound is selected from the group consisting of □11-20

[0233] T2 is selected from the group consisting of CH and N;

[0234] T3 is selected from the group consisting of C and N;

[0235] ring E is selected from the group consisting of 3 and

[0236] m is selected from the group consisting of 0, 1, 2 and 3;

[0237] ring B2 is a 5-membered heteroaryl ring;

[0238] T, Ti, Ri, R2, R3, R6, L, R7 and Rs are as defined in this disclosure.

[0239] In some embodiments of the present disclosure, the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof is provided, wherein the compound is selected from the group consisting of Petition 870260002323, dated 09 / 01 / 2026, p. 259 / 413 36 / 189 R2R3 πΙΙΙ-2ΒΠ

[0240] in which

[0241] '^is a single bond or a double bond;

[0242] T2 is selected from the group consisting of CH and N;

[0243] T4 is selected from the group consisting of CH and N;

[0244] ring B2 is a 5-membered heteroaryl ring;

[0245] R1, R2, R3, R4, R5, R6, L, R7, Rs are as defined in this disclosure.

[0246] In some embodiments of the present disclosure, the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof is provided, wherein the compound is selected from the group consisting of Petition 870260002323, dated 09 / 01 / 2026, pp. 260 / 413 37 / 189 □ π-3π , π-4π

[0247] in which

[0248] a single bond or a double bond;

[0249] T5 is selected from the group consisting of CR61 and N;

[0250] R61 is selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0251] R1, R2, R5, R6, Re and em are as defined in this disclosure.

[0252] In some embodiments of the present disclosure, the above compound, a stereoisomer or a pharmaceutically acceptable salt thereof is provided, wherein the compound is selected from the group consisting of Petition 870260002323, dated 09 / 01 / 2026, pp. 261 / 413 38 / 189

[0253] in which

[0254] is a single bond or a double bond;

[0255] T5 is selected from the group consisting of CR61 and N;

[0256] R61 is selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;

[0257] R1, R2, R3, R5, R6, R9, R71, R81 are as defined in this disclosure.

[0258] This disclosure also includes modalities obtained by any combination of the above variables.

[0259] The present disclosure also provides a compound of one of the following formulas, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, Petition 870260002323, dated 09 / 01 / 2026, p. 262 / 413 39 / 189 Petition 870260002323, dated 09 / 01 / 2026, pp. 263 / 413 40 / 189 Petition 870260002323, dated 09 / 01 / 2026, pp. 264 / 413 41 / 189 Petition 870260002323, dated 09 / 01 / 2026, pp. 265 / 413 42 / 189

[0260] The present disclosure also provides a compound of one of the following formulas, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, Petition 870260002323, dated 09 / 01 / 2026, p. 266 / 413 43 / 189 Petition 870260002323, dated 09 / 01 / 2026, p. 267 / 413 44 / 189 Petition 870260002323, dated 09 / 01 / 2026, pp. 268 / 413 45 / 189 Petition 870260002323, dated 09 / 01 / 2026, p. 269 / 413 46 / 189 Petition 870260002323, dated 09 / 01 / 2026, pp. 270 / 413 47 / 189 Petition 870260002323, dated 09 / 01 / 2026, page 271 / 413 48 / 189 Petition 870260002323, dated 09 / 01 / 2026, page 272 / 413 49 / 189 Petition 870260002323, dated 09 / 01 / 2026, page 273 / 413 50 / 189

[0261] This disclosure further provides a use of the above compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease associated with an aldosterone synthase inhibitor.

[0262] This disclosure further provides a use of the above compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof in Petition 870260002323, dated 09 / 01 / 2026, pp. 274 / 413 51 / 189 manufacturing of a drug for the treatment of resistant hypertension.

[0263] Technical effect

[0264] The compounds in this disclosure exhibit high inhibitory activity on the CYP11B2 enzyme, weak inhibition of CYP11B1, and excellent selectivity, with minimal impact on cortisol synthesis, resulting in superior clinical safety. These compounds also possess favorable in vivo pharmacokinetic properties, including high bioavailability, slow clearance, long half-life, and good oral absorption, making them suitable for once-daily oral administration. They are characterized by high permeability and low efflux, exhibit moderate binding to plasma proteins in different species, and have an appropriate drug-free plasma concentration ratio, indicating good pharmacovability. Furthermore, the compounds in this disclosure demonstrate low clearance in human liver microsomes and good metabolic stability. They do not inhibit CYP enzymes such as CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4, thus presenting an extremely low risk of drug interactions.

[0265] Definition and explanation

[0266] Unless otherwise specified, the following terms and phrases, when used in this document, have the following meanings. A specific term or phrase should not be considered undefined or unclear in the absence of a particular definition, but should be understood in its common meaning. When a trade name appears in this document, it is intended to refer to its corresponding merchandise or active ingredient thereof.

[0267] The term pharmaceutically acceptable is used in this document in terms of those compounds, materials, compositions and / or dosage forms that are suitable for use in contact with human and animal tissues within the scope of reliable medical judgment, without excessive toxicity, irritation, allergic reaction or other Petition 870260002323, dated 09 / 01 / 2026, pp. 275 / 413 52 / 189 problems or complications, proportionate to a reasonable benefit / risk ratio.

[0268] The term pharmaceutically acceptable salt refers to a salt of the compound of the present disclosure that is prepared by reacting the compound with a specific substituent of the present disclosure with a relatively non-toxic acid or base. When the compound of the present disclosure contains a relatively acidic functional group, a base addition salt can be obtained by contacting such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. When the compound of the present disclosure contains a relatively basic functional group, an acid addition salt can be obtained by contacting the compound with a sufficient amount of acid in a pure solution or a suitable inert solvent. Certain specific compounds of the present disclosure contain both basic and acidic functional groups, therefore they can be converted into either a base or an acid addition salt.

[0269] The pharmaceutically acceptable salt of this disclosure can be prepared from the parent compound containing an acidic or basic moiety by conventional chemical methods. Generally, such a salt can be prepared by reacting the free acid or base form of the compound with a stoichiometric amount of an appropriate acid or base in water or an organic solvent or a mixture thereof.

[0270] Unless otherwise specified, the term isomer is intended to include a geometric isomer, a cis-trans isomer, a stereoisomer, an enantiomer, an optical isomer, a diastereoisomer, and a tautomeric isomer.

[0271] The compounds of this disclosure may exist in specific geometric or stereoisomeric forms. This disclosure covers all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic compounds and other mixtures thereof, such as enantiomers or mixtures enriched with diastereomers, all of which are within the scope of this disclosure. Asymmetric carbon atoms Petition 870260002323, dated 09 / 01 / 2026, p. 276 / 413 53 / 189 additional isomers may be present in substituents such as alkyl. All such isomers and their mixtures are included in the scope of this disclosure.

[0272] Unless otherwise specified, the term enantiomer or optical isomer refers to stereoisomers that are mirror images of each other.

[0273] Unless otherwise specified, the term cis-trans isomer or geometric isomer is caused by the inability to freely rotate double bonds or single bonds of ring-forming carbon atoms.

[0274] Unless otherwise specified, the term diastereomer refers to a stereoisomer in which a molecule has two or more chiral centers and the relationship between the molecules is not mirror image.

[0275] Unless otherwise specified, (+) refers to dextrorotation, (-) refers to levorotatory and (±) refers to racemic.

[0276] Unless otherwise specified, the absolute configuration of a stereogenic center is represented by a solid wedge link ( ^) and a dashed wedge link ( ), and the relative configuration of a stereogenic center is represented by a straight solid link ( ***) and a straight dashed link ), a wave line ( ) is used to represent a solid wedge link ( ) or a dashed wedge link ( or the wave line ( ) is used to represent a straight solid link ( ) or a straight dashed link (A').

[0277] Unless otherwise specified, the terms enriched in one isomer, enriched in isomers, enriched in one enantiomer, or enriched in enantiomers refer to the content of one of the isomers or enantiomers being less than 100%, and the content of the isomer or enantiomer being greater than or equal to 60%, or greater than or equal to 70%, or greater than or equal to 80%, or greater than or equal to 90%, or greater than or equal to 95%, or greater than or equal to 96%, or greater than or equal to 97%, or greater than or equal to 98%, or greater than or equal to 99%, or greater than or equal to 99.5%, or greater than or equal to 99.6%, or greater than or equal to Petition 870260002323, dated 09 / 01 / 2026, p. 277 / 413 54 / 189 99.7%, or greater than or equal to 99.8%, or greater than or equal to 99.9%.

[0278] Unless otherwise specified, the term isomer excess or enantiomer excess refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomer excess (ee value) is 80%.

[0279] Optically active (R) and (O) isomers, or D and L isomers, can be prepared using chiral synthesis, chiral reagents, or other conventional techniques. If an enantiomer of a certain compound of the present disclosure is obtained, it can be obtained by asymmetric synthesis or derivative action of a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the desired pure enantiomer. Alternatively, when the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxyl), a salt of a diastereoisomer is formed with an appropriate optically active acid or base, and then diastereomeric resolution is performed by conventional methods known in the art, and then the pure enantiomer is recovered.Furthermore, the enantiomer and diastereomer are generally separated by chromatography using a chiral stationary phase and optionally combined with a chemical derivative method (such as carbamate generated from amine).

[0280] The compound of this disclosure may contain an unnatural ratio of atomic isotope in one or more of an atom constituting the compound. For example, the compound may be radiolabeled with a radioactive isotope, such as tritium (3H), iodine-125 (125I) or C-14 (14C). By another example, deuterated drugs may be formed by replacing hydrogen with deuterium; the bond formed by deuterium and carbon is stronger than that of ordinary hydrogen and carbon. Compared to non-deuterated drugs, deuterated drugs have the advantages of less toxic and side effects. Petition 870260002323, dated 09 / 01 / 2026, pp. 278 / 413 55 / 189 reduced, greater drug stability, improved efficacy, prolonged biological half-life of drugs, etc. All isotopic variations of the compound of this disclosure, whether radioactive or not, are encompassed within the scope of this disclosure.

[0281] The term optional or optionally means that the subsequent event or condition may occur, but is not required, that the term includes the case where the event or condition occurs and the case where the event or condition does not occur.

[0282] The term substituted means one or more hydrogen atoms on a specific atom are replaced by the substituent, including deuterium and hydrogen variables, provided that the valence of the specific atom is normal and the substituted compound is stable. When the substituent is an oxygen (i.e., =O), this means that two hydrogen atoms are substituted.

[0283] The term optionally substituted means that an atom may or may not be replaced by a substituent, unless otherwise specified, the type and number of substituents may be arbitrary, provided they are chemically attainable.

[0284] When any variable (such as R) occurs in the constitution or structure of the compound more than once, the definition of the variable in each occurrence is independent. Thus, for example, if a group is substituted by 0 to -2 R, the group may optionally be substituted by up to two R, where the definition of R in each occurrence is independent. Furthermore, a combination of the substituent and / or its variant is permitted only when the combination results in a stable compound.

[0285] When the number of a linking group is 0, such as -(CRR)o-, this means that the linking group is a single bond.

[0286] When a substituent is 0 in number, this means that the substituent is absent. In the case of -A-(R)o, the structure is actually -A.

[0287] When a substituent is vacant, it means that the substituent is absent. Petition 870260002323, dated 09 / 01 / 2026, p. 279 / 413 56 / 189 for example, when X is vacant in AX, the structure of AX is actually A.

[0288] When one of the variables is selected from a single link, this means that the two groups linked by the single link are directly connected. For example, when L in ALZ represents a single link, the structure of ALZ is actually AZ.

[0289] When the enumerative linking group does not indicate the direction for linking, the direction for linking is arbitrary, for example, the linking group L contained in Ca / —L\B / is -MW-, then -MW- can link ring A and ring B to form ( A V- MW-( B )x / —X in the same direction as the left-to-right reading order Qw-mh b ) X—X in the opposite direction to the left-to-right reading order. A combination of the linking groups, substituents, and / or variables thereof is permitted only when such a combination can result in a stable compound.

[0290] Unless otherwise specified, when a group has one or more of a linkable site, any one or more of the group's sites may be linked to other groups by means of chemical bonds. When the linking site of the chemical bond is not positioned and there is an H atom in the linkable site, then the number of H atoms in the site will decrease correspondingly with the number of chemical bonds that link to it in order to meet the corresponding valence. The chemical bond between the site and other groups may be represented by a straight solid bond ( / ), a straight dashed bond ( ) or a wavy line ( / ). For example, the straight solid bond in -OCH3 means that it is linked to other groups through the oxygen atom in the 'N' group; the straight dashed bond (H) means that it is linked to other groups through the oxygen atom in the 'N' group. Petition 870260002323, dated 09 / 01 / 2026, pp. 280 / 413 57 / 189 from the two ends of the nitrogen atom in the group; the wave lines This means that the phenyl group is linked to other groups through carbon atoms at positions 1 and 2; This means that it can be linked to other groups through any linkable sites on the piperidinyl system by a chemical bond, including at least four types of bonds, including: Even if the H atom is drawn in -N-, it also includes the connection of Only when a chemical bond has been formed will the H of this site be reduced by one to the corresponding monovalent piperidinyl group.

[0291] Unless otherwise specified, when ring A is fused with ring B, they share a bond and the atoms in that bond may be C₁₀b₁(A₇) or N₁₀ atoms. For example, in , the atoms in the fused bond between A and B may be ₂(A₅K₁)₂(K₂)₃. C or N, including but not limited to , , and .

[0292] Unless otherwise specified, the number of atoms in a ring is generally defined as the number of ring members, for example, a 5 to 7 member ring refers to a ring in which 5 to 7 atoms are arranged around it.

[0293] Unless otherwise specified, the term halogen element or halogen alone or as part of another substituent refers to fluorine, chlorine, bromine, or iodine atom. Petition 870260002323, dated 09 / 01 / 2026, pp. 281 / 413 58 / 189

[0294] Unless otherwise specified, the term C1-3 alkyl refers to a linear or branched saturated hydrocarbon group consisting of 1 to 3 carbon atoms. C1-3 alkyl includes C1-2 and C2-3 alkyl, etc.; it can be monovalent (like methyl), divalent (like methylene), or multivalent (like methyne). Examples of C1-3 alkyl include, but are not limited to, methyl (Me), ethyl (Et), propyl (including n-propyl and isopropyl), etc.

[0295] Unless otherwise specified, the term C1-3 alkoxy refers to an alkyl group containing 1 to 3 carbon atoms that are connected to the rest of the molecule through an oxygen atom. It can be monovalent, divalent, or multivalent. C13 alkoxy includes C1-2, C2-3, C3, C2 alkoxy, etc. Examples of C1-3 alkoxy include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), etc.

[0296] Unless otherwise specified, the term C1-3 alkylamino refers to an alkyl group containing 1 to 3 carbon atoms that are connected to the rest of the molecule through a nitrogen atom. C1-3 alkylamino includes C1-2, C3, C2, etc. alkylamino. Examples of C1-3 alkylamino include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH2(CH3)2, etc.

[0297] Unless otherwise specified, the term C1-3 haloalkyl refers to mono-haloalkyl and poly-haloalkyl containing 1 to 3 carbon atoms. C1-3 haloalkyl includes C1-2, C2-3, C3, C2, C1 haloalkyl, etc. Examples of C1-3 haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, pentachloroethyl, 3-bromopropyl, etc.

[0298] Unless otherwise specified, the term C1-3 haloalkoxy refers to mono-haloalkoxy and poly-haloalkoxy containing 1 to 3 carbon atoms. C1-3 haloalkoxy includes C1-2, C2-3, C3, C2, C1 haloalkoxy, etc. Examples of C1-3 haloalkoxy include, but are not limited to, trifluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, pentachloroethoxy, 3-bromopropoxy, etc. Petition 870260002323, dated 09 / 01 / 2026, pp. 282 / 413 59 / 189

[0299] Unless otherwise specified, C5-6 cycloalkyl refers to a saturated or partially saturated cyclic hydrocarbon group consisting of 5 to 6 carbon atoms, which is a monocyclic system, and C5-6 cycloalkyl includes C5, C6 cycloalkyl, etc.; it may be monovalent, divalent, or multivalent. Examples of C5-6 cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl, etc.

[0300] Unless otherwise specified, C3-5 cycloalkyl refers to a saturated or partially saturated cyclic hydrocarbon group consisting of 3 to 5 carbon atoms, which is a monocyclic system, and C3-5 cycloalkyl includes C3, C4 and C5 cycloalkyl, etc.; it may be monovalent, divalent or multivalent. Examples of C3-5 cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, etc.

[0301] Unless otherwise specified, the term 4- to 6-membered heterocycloalkyl by itself or in combination with other terms refers to a saturated cyclic group consisting of 4 to 6 atoms in the ring, wherein 1, 2, 3 or 4 atoms in the ring are heteroatoms independently selected from O, S and N, and the remainder are carbon atoms, wherein the carbon atoms are optionally substituted by oxo (i.e., C(O)), the nitrogen atoms are optionally quaternized and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O)p, p is 1 or 2). It includes monocyclic and bicyclic systems, wherein the bicyclic systems include spirocyclic, fused and bridging ring systems. Furthermore, in the case of 4- to 6-membered heterocycloalkyl groups, the heteroatom can occupy the position where the heterocycloalkyl group is attached to the rest of the molecule. 4- to 6-membered heterocycloalkyl groups include 5- to 6-membered, 4-membered, 5-membered, 6-membered, etc. heterocycloalkyl groups.Examples of 4- to 6-membered heterocycloalkyl compounds include, but are not limited to, azetidinyl, oxetanil, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranil (including tetrahydrofuran). Petition 870260002323, dated 09 / 01 / 2026, pp. 283 / 413 60 / 189 2-yl, etc.), tetrahydropyranil, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxinyl, ditianil, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, etc.

[0302] Unless otherwise specified, the term 5- to 6-membered heterocycloalkyl alone or in combination with other terms refers to a saturated cyclic group consisting of 5 to 6 atoms in the ring, where 1, 2, 3 or 4 atoms in the ring are heteroatoms independently selected from O, S and N, and the remainder are carbon atoms, where the carbon atoms are optionally substituted by oxo (i.e., C(O)), the nitrogen atoms are optionally quaternized and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O)p, p is 1 or 2). It includes monocyclic and bicyclic systems, where bicyclic systems include spirocyclic, fused and bridging ring systems. Furthermore, in the case of the 4- to 6-membered heterocycloalkyl, the heteroatom may occupy the position where the heterocycloalkyl is attached to the rest of the molecule. 5- to 6-membered heterocycloalkyl groups include 5-membered heterocycloalkyl groups, 6-membered heterocycloalkyl groups, and the like.Examples of 5- to 6-membered heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanil, thietanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothienyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranil (including tetrahydrofuran-2-yl, etc.), tetrahydropyranil, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxinyl, ditianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, etc.

[0303] Unless otherwise specified, the terms 5- to 6-membered heteroaryl ring and 5- to 6-membered heteroaryl are used interchangeably. The term 5- to 6-membered heteroaryl refers to a monocyclic group consisting of 5 to 6 Petition 870260002323, dated 09 / 01 / 2026, pp. 284 / 413 61 / 189 atoms in the ring with a conjugated π electron system, where 1, 2, 3, or 4 atoms in the ring are independently selected heteroatoms of O, S, and N, and the rest are carbon atoms. Here, the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms can be optionally oxidized (i.e., NO and S(O)p, where p is 1 or 2). The 5- to 6-membered heteroaryl can be linked to the rest of the molecule through a heteroatom or a carbon atom. The 5- to 6-membered heteroaryl includes 5-membered and 6-membered heteroaryl. Examples of 5- to 6-membered heteroaryl groups include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl, and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl, and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl, and 5-oxazolyl, etc.).), triazolyl (including 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4triazolyl, and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (including 3-isoxazolyl, 4isoxazolyl, and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazolyl, and 5-thiazolyl, etc.), furyl (including 2-furyl and 3-furyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl, and 4-pyridyl, etc.), pyrazinyl, pyrimidinyl (including 2pyrimidinyl, 4-pyrimidinyl, etc.).

[0304] Unless otherwise specified, the terms 5-membered heteroaryl ring and 5-membered heteroaryl in this disclosure may be used interchangeably, and the term 5-membered heteroaryl refers to a monocyclic group consisting of 5 ring atoms with a conjugated π electron system, wherein 1, 2, 3, or 4 ring atoms are heteroatoms independently selected from O, S, and N, and the remainder are carbon atoms. Herein, the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms may be optionally oxidized (i.e., NO and S(O)p, where p is 1 or 2). The 5-membered heteroaryl may be connected to the rest of the molecule through a heteroatom or a carbon atom. Examples of the 5-membered heteroaryl include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl). Petition 870260002323, dated 09 / 01 / 2026, pp. 285 / 413 62 / 189 e 3-pyrrolyl, etc.), pyrazolyl (incluindo 2-pyrazolyl e 3-pyrazolyl, etc.), imidazolyl (incluindo N-imidazolyl, 2-imidazolyl, 4-imidazolyl e 5-imidazolyl, etc.), oxazolyl (incluindo 2oxazolyl e 5-oxazolyl, etc.), triazolyl (incluindo 1H-1,2,3-triazolyl, 2 H-1,2,3triazolyl, 1H-1,2,4-triazolyl e 4 H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (incluindo 3isoxazolyl, 4-isoxazolyl e 5-isoxazolyl, etc.), thiazolyl (incluindo 2-thiazolyl, 4-thiazolyl e 5thiazolyl, etc.), furil (incluindo 2-furil e 3-furil, etc.), tienil (including 2-thienil and 3-thienil, etc.).

[0305] The compounds of the present disclosure can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by their combination with other chemical synthesis methods and equivalent alternatives known to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present disclosure.

[0306] The structure of the compounds in the present disclosure can be confirmed by conventional methods known to those skilled in the art, and if the present disclosure involves an absolute configuration of a compound, then the absolute configuration can be confirmed by conventional techniques in the art. For example, in the case of single-crystal X-ray diffraction (SXRD), diffraction intensity data are collected from the cultured single crystal using a Bruker D8 risk diffractometer with CuKa radiation as the light source and scanning mode: φ / ω scan, and after collecting the relevant data, the crystal structure is subsequently analyzed by the direct method (Shelxs97), so that the absolute configuration can be confirmed.

[0307] This disclosure uses the following abbreviations: eq stands for equivalent; DCM stands for dichloromethane; PE stands for petroleum ether; DMSO stands for dimethyl sulfoxide; EtOAc stands for ethyl acetate; EtOH stands for ethanol; MeOH stands for methanol; DMF stands for N,N-dimethylformamide; Boc stands for tert-2-dimethylformamide. Petition 870260002323, dated 09 / 01 / 2026, page 286 / 413 63 / 189 butoxycarbonyl, an amine protecting group; rt represents room temperature; TFA represents trifluoroacetic acid; Eaton's reagent represents a 7.5% solution of phosphorus pentoxide in methanesulfonic acid; PEG represents polyethylene glycol; solutol represents polyoxyl hydroxystearate 15; Cmax represents maximum concentration; AUC represents oral exposure; ti / 2 represents half-life; Vdss represents steady-state volume of distribution; CL represents clearance.

[0308] The solvents used in this disclosure are commercially available.

[0309] The compounds in this disclosure are named according to conventional nomenclature principles in the art or by ChemDraw® software, and commercially available compounds use supplier catalog names. BRIEF DESCRIPTION OF THE DRAWINGS

[0310] FIG. 1. Diagram of the binding mode of compound 1A with the CYP11B2 protein.

[0311] FIG. 2 Diagram of the binding mode of compound 2A with the CYP11B2 protein.

[0312] FIG. 3 Diagram of the binding mode of compound 3A with the CYP11B2 protein. DETAILED DESCRIPTION OF THE PREFERRED MODALITY

[0313] This disclosure is described in detail by the examples below, but this does not mean that there are any adverse restrictions in this disclosure. The compounds of the present disclosure can be prepared by a variety of synthetic methods known to those skilled in the art, including the specific embodiments listed below, embodiments formed by their combination with other chemical synthesis methods and equivalent alternatives known to those skilled in the art, and preferred embodiments include, but are not limited to, the examples of the present disclosure. It will be evident to those skilled in the art that various variations and Petition 870260002323, dated 09 / 01 / 2026, pp. 287 / 413 64 / 189 improvements can be made to specific aspects of this disclosure without departing from the spirit and scope of this disclosure.

[0315] The molecular docking process was conducted using Glide SP[1] in Maestro (Schrodinger version 2022-1) with default settings. The CYP11B2 cocrystal structure (PDB ID: 4ZGX) was selected as the docking template. To prepare the protein, hydrogen atoms were added using the Protein Preparation Wizard module in Maestro [2] with the OPLS4 force field. For ligand preparation, three-dimensional structures of the molecules were generated using the LigPrep module and energy minimization was performed [3]. Conformational searches for small molecules were conducted using the ConfGen module [4]. The Receptor Grid Generation module in Glide was used to generate the grid file required for docking, with the ligand of the crystal structure serving as the center of the docking box.The types of interactions between protein receptors and ligands were analyzed and then molecules with high potential were selected for synthesis and testing based on calculated coupling scores and binding modes. The binding modes of compounds IA, 2A and 3A are shown in FIGS. 1, 2 and 3, respectively.

[0316] [1] Glide, Schrodinger, LLC, New York, NY, 2020.

[0317] [2] Maestro, Schrodinger, LLC, New York, NY, 2020.

[0318] [3] LigPrep, Schrodinger, LLC, New York, NY, 2020.

[0319] [4] ConfGen, Schrodinger, LLC, New York, NY, 2020.

[0320] Conclusion: The compounds in this disclosure exhibited favorable binding to Petition 870260002323, dated 09 / 01 / 2026, pp. 288 / 413 65 / 189 CYP11B2 protein.

[0321] Example of reference 1: Fragment Al

[0322] Synthetic route:

[0323] Step 1: synthesis of compound A-1-3

[0324] Al-1 (19 g, 84.04 mmol) and tetrahydrofuran (250 mL) were added to a reaction flask. After stirring to dissolve, Al-2 (12.22 g, 100.85 mmol) was added, followed by the dropwise addition of tetraethyl titanate (57.51 g, 252.13 mmol). The reaction mixture was stirred at 75°C for 16 hours. 400 mL of ethyl acetate and 800 mL of saturated aqueous sodium bicarbonate solution were added. The mixture was filtered, and the filter cake was washed three times with ethyl acetate (100 mL each time). The filtrate was collected and separated. The aqueous phase was extracted twice with 400 mL of ethyl acetate, and the organic phases were combined. The organic phase was washed with 800 mL of saturated brine, collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude Al-3. δ NMR (400 MHz, CDCl3) δ ppm 9.19 (s, 1 H), 8.71 (s, 1 H), 3.25 - 3.35 (m, 1 H), 3.10 - 3.18 (m, 1 H), 2.83 - 2.99 (m, 2 H), 1.96 -2.16 (m, 2H), 1.34 (s, 9H).

[0325] Step 2: synthesis of compound A-1-4

[0326] Al-3 (11.13 g, 33.80 mmol) and tetrahydrofuran (100 mL) were added to a reaction flask. The atmosphere was purged with nitrogen. At 0°C, 9 Petition 870260002323, dated 09 / 01 / 2026, pp. 289 / 413 66 / 189 borabicyclo[3.3.1]nonane (0.5 M in tetrahydrofuran, 169.02 mL) was added dropwise, then the mixture was gradually heated to 25°C and reacted for 16 hours. Saturated aqueous ammonium chloride solution (250 mL) and 250 mL of water were sequentially added to the reaction mixture, and the aqueous phase was extracted 3 times with 500 mL of ethyl acetate. The combined organic phases were washed with saturated brine (1000 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 25% to 100%) to obtain A-1-4.1H NMR (400 MHz, CDCl3) δ ppm 8.58 (d, J = 8.78 Hz, 2 H), 4.60 - 4.70 (m, 1 H), 3.18 - 3.31 (m, 1 H), 2.81 - 2.92 (m, 1 H), 2.62 (ddd, J = 18.51, 9.60, 6.53 Hz, 1 H), 2.09 - 2.18 (m, 1 H), 1.93 - 2.07 (m, 1 H), 1.80 - 1.91 (m, 2 H), 1.23 (s, 9 H).

[0327] Step 3: synthesis of compound A-1-5

[0328] A-1-4 (8.31 g, 25.09 mmol) was dissolved in ethyl acetate (50 mL) and hydrogen chloride / ethyl acetate (2 M, 160 mL) was added at 28 °C. The mixture was stirred for 16 hours. The reaction mixture was filtered and the filter cake was washed with 3 mL of ethyl acetate. The filter cake was collected and dried to obtain a hydrochloride salt of crude A-1-5. ESI-LCMS: m / z = 226.8, 228.9 [M+1]+.

[0329] Step 4: synthesis of compound A-1

[0330] A-1-5 hydrochloride salt (7.67 g), dichloromethane (150 mL), and triethylamine (8.83 g, 87.30 mmol) were sequentially added to a reaction flask. After stirring to dissolve, propionic anhydride (5.68 g, 43.65 mmol) was added, and the mixture was stirred at 28°C for 16 hours. 400 mL of saturated aqueous ammonium chloride solution were added. The resulting phases were separated, and the aqueous phase was extracted three times with dichloromethane (200 mL each time). The organic phases were combed, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography. Petition 870260002323, dated 09 / 01 / 2026, pp. 290 / 413 67 / 189 (dichloromethane / methanol = 10%) to obtain A-1. 1H NMR (400 MHz, CDCI3) δ ppm 8.54 (s, 1 H), 8.41 (s, 1 H), 5.74 (br d, J = 7.28 Hz, 1 H), 5.24 - 5.32 (m, 1 H), 2.69 - 2.82 (m, H), 2.27 (q, J = 7.53 Hz, 2 H), 1.98 - 2.06 (m, 1 H), 1.91 (dt, J = 12.05, 6.02 Hz, 2 H), 1.78 - 1.86 (m, 1 H), 1.21 (t, J = 7.65 Hz, 3 H). [α]2% = +5.77 (c 1.0, MeOH).

[0331] Example of reference 2: Fragment A-2

[0332] Synthetic route:

[0333] Step 1: synthesis of compound A-2

[0334] A-1 (70 mg, 247.21 μmol), triisopropyl borate (155.75 mg, 828.14 μmol), and tetrahydrofuran (3.5 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen and at -78°C, n-butyllithium (2.5 M, 247.21 μL) was added dropwise. The mixture was stirred at -78°C for 2 hours. Methanol (3.5 mL) was added dropwise to the reaction mixture to obtain a solution of A-2 in methanol, which was used immediately after preparation. ESI-LCMS: m / z = 249.3 [M+H]+.

[0335] Example 1

[0336] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 291 / 413 68 / 189

[0337] Step 1: synthesis of compound 001-2 A-1

[0338] 001-1 (1 g, 4.16 mmol) and 1,2-dichloroethane (20 mL) were added to a reaction flask. After stirring to dissolve, N-bromosuccinimide (1.11 g, 6.25 mmol) and azobisisobutyronitrile (136.79 mg, 833.00 μmol) were added and the reaction mixture was stirred at 80°C for 4 hours. 20 mL of water were added and the resulting phases were separated. The aqueous phase was extracted three times with dichloromethane (20 mL each time). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 001-2. 1H NMR (400 MHz, CDCfi) δ ppm 7.73 (d, J = 2.26 Hz, 1 H), 7.68 (dd, J = 9.03, 2.26 Hz, 1 H), 7.62 (d, J = 9.54 Hz, 1 H), 7.30 (d, J = 2.51 Hz, 1 H), 6.78 (d, J = 9.54 Hz, 1 H), 3.73 (s, 3 H).

[0339] Step 2: synthesis of compound 001-3

[0340] 001-2 (1.6 g, 6.72 mmol), bis(pinacolate)diboron (2.56 g, 10.08 mmol), potassium acetate (1.98 g, 20.16 mmol), and 1,4-dioxane (10 mL) were added to a reaction flask. After purging the atmosphere with nitrogen, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (274.41 mg, 336.02 μmol) was added. The reaction mixture was stirred at 80°C for 2 hours. 30 mL of ethyl acetate were added with stirring for dilution, and the mixture was filtered under reduced pressure. The filter cake was washed with 30 mL of ethyl acetate. The phase Petition 870260002323, dated 09 / 01 / 2026, pp. 292 / 413 69 / 189 organic matter was collected and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 0% - 20%) to obtain 001-3. ESI-LCMS: m / z = 286.1 [M+H]+.

[0341] Step 3: Synthesis of Compound 001

[0342] To a reaction flask were added 001-3 (191.33 mg, 670.99 μmol), A-1 (190 mg, 670.99 μmol) and ethanol (2.5 mL). After dissolving, sodium carbonate (142.50 mg, 1.34 mmol) and water (0.5 mL) were added. After the atmosphere was purged with nitrogen, tetrakis(triphenylphosphine)palladium (38.77 mg, 33.55 μmol) was added. The reaction mixture was stirred at 80°C for 16 hours. The reaction was quenched by the addition of 20 mL of semi-saturated brine and extracted three times with ethyl acetate (10 mL each time). The combined organic phases were washed with 20 mL of saturated brine, and the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was purified by preparative thin-layer chromatography (dichloromethane / methanol = 20:1) and then subjected to chiral resolution [chiral column: DAICEL CHIRALCEL OD (250 mm*30 mm, 10 μm); mobile phase: [carbon dioxide-supercritical ethanol (0.1% water with ammonia)]; Ethanol (0.1% water with ammonia): 45%, isocratic elution] to obtain compound 001. 1H NMR (400 MHz, CDCL) δ ppm 8.53 (s, 1 H), 8.31 (s, 1 H), 7.69 (d, J=9.29 Hz, 1 H), 7.43 - 7.52 (m, 3 H), 6.77 (d, J=9.54 Hz, 1 H), 5.84 (br d, J=8.53 Hz, 1 H), 5.32 - 5.40 (m, 1 H), 3.77 (s, 3 H), 2.55 - 2.71 (m, 2 H), 2.29 (q, J=7.53 Hz, 2 H), 2.04 - 2.15 (m, 1 H), 1.82 - 1.90 (m, 2 H), 1.23 (t, J=7.65 Hz, 3 H); ESI-LCMS: m / z = 362.0 [M+H]+. SFC method: column: Chiralcel OD-3 150χ4.6 mm ID, 3μm; mobile phase: A: CO2 B: ethanol (0.05% diethylamine); gradient: B% = 5% to 40% (eluted for 4 min), 40% (eluted for 2 min), 5% (eluted for 2 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 1500 psi.ee = 99.52%, retention time: 4.686 minutes.

[0343] Example 2 Petition 870260002323, dated 09 / 01 / 2026, pp. 293 / 413 70 / 189

[0344] Synthetic route:

[0345] Step 1: synthesis of compound 002-2

[0346] A solution of 002-1 (6 g, 26.54 mmol) in 1,4-dioxane (60 mL) was added to a reaction flask, followed by the addition of Lawesson's reagent (7.51 g, 18.58 mmol). The atmosphere was purged with nitrogen and the mixture was heated to 110°C and stirred for 2 hours. The reaction mixture was concentrated and 10 mL of dichloromethane were added. The mixture was then concentrated under reduced pressure to obtain a crude product. 12 mL of dichloromethane were added to the crude product. The mixture was stirred for 0.5 hours and filtered to obtain 002-2. 1HNMR(400 MHz, CDCL) δ = 9.84 (br s, 1H), 7.39 - 7.31 (m, 2H), 6.81 - 6.71 (m, 1H), 3.14 - 3.05 (m, 2H), 2.93 - 2.83 (m, 2H).

[0347] Step 2: synthesis of compound 002-4

[0348] To a reaction flask, 002-2 (540 mg, 2.23 mmol), 002-3 (198.26 mg, 2.68 mmol) and cyclohexanol (10.4 mL) were added. The atmosphere was purged with nitrogen and the mixture was heated to 120°C and stirred for 16 hours. 5 mL of water and 10 mL of ethyl acetate were added to the reaction mixture. The mixture was then extracted and the resulting phases were separated. The organic phase was collected and the aqueous phase was extracted three times with ethyl acetate (10 mL each time). The organic phases were combined and washed sequentially twice with saturated brine (10 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered and Petition 870260002323, dated 09 / 01 / 2026, pp. 294 / 413 71 / 189 concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: (ethyl acetate / methanol = 5 / 1) = 1:0 to 0:1) to obtain 002-4. 1HNMR (400 MHz, CDCL) δ = 7.57 - 7.48 (m, 2H), 7.37 (d, J = 8.5 Hz, 1H), 3.19 - 3.10 (m, 2H), 3.05 - 2.98 (m, 2H), 2.77 (s, 3H).

[0349] Step 3: synthesis of compound 002-5

[0350] To a reaction flask were added 002-4 (475 mg, 1.80 mmol), bis(pinacolate)diboron (548.02 mg, 2.16 mmol), 1,4-dioxane (10 mL), potassium acetate (529.49 mg, 5.40 mmol), tris(dibenzylideneacetone)dipalladium (164.68 mg, 179.84 μmol) and tricyclohexylphosphine (100.87 mg, 359.68 μmol). After the atmosphere was purged with nitrogen, the mixture was heated to 80°C and stirred for 12 hours. To the reaction mixture were added 10 mL of saturated brine and 20 mL of ethyl acetate. The mixture was then extracted and the resulting phases were separated. The organic phase was collected and the aqueous phase was extracted three times with ethyl acetate (20 mL each time). The organic phases were combined and washed sequentially three times with saturated brine (20 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was purified by column chromatography [petroleum ether: (ethyl acetate / methanol = 5 / 1) = 1:0 to 0:1] to obtain 002-5. 1H NMR (400 MHz, CÜ3OD)5 = 7.84 - 7.78 (m, 2H), 7.68 (d, J = 8.5 Hz, 1H), 3.12 - 3.03 (m, 4H), 2.78 (s, 3H), 1.36 (s, 12h); ESI-LCMS: m / z = 312.2 [M+H]+.

[0351] Step 4: synthesis of compounds 002 and 003

[0352] To a reaction flask, 002-5 (56.92 mg, 127.13 μmol), A-1 (30 mg, 105.95 pmol), ethanol (1.6 mL), and a solution of sodium carbonate (12.35 mg, 116.54 μmol) in water (0.3 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphma)palladium (3.67 mg, 3.18 μmol). The atmosphere was again purged with nitrogen, and the mixture was heated to 85°C and stirred for 12 hours. The reaction mixture was concentrated to obtain a product. Petition 870260002323, dated 09 / 01 / 2026, pp. 295 / 413 72 / 189 crude. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1) to obtain a crude product. It was then subjected to chiral resolution (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [carbon dioxide-supercritical ethanol (0.1% ammonia water)]; ethanol (0.1% ammonia water): 30%, isocratic elution) to obtain 002 and 003. The ee value was determined by SFC (chromatographic column: Chiralpak AD3, 150 x 4.6 mm ID, 3 μm; mobile phase: A: supercritical CO2, B: ethanol (0.2% 7M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.5 min), 50 / 50 (3.5 min), 50 / 50 (4.5 min), 90 / 10 (5.0 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 2000 psi.

[0353] Compound 002: ESI-LCMS: m / z = 388.3 [M+H]+; 1H NMR (400 MHz, CDCh) δ = 8.55 (s, 1H), 8.32 (s, 1H), 7.57 (d, J = 9.0 Hz, 1H), 7.32 - 7.29 (m, 2H), 5.73 - 5.66 (m, 1H), 5.41 - 5.34 (m, 1H), 3.22 - 3.16 (m, 2H), 3.10 - 3.04 (m, 2H), 2.82 (s, 3H), 2.71 - 2.55 (m, 2H), 2.30 (q, J = 7.6 Hz, 2H), 2.10 (br t, J = 5.1 Hz, 1H), 1.90 - 1.78 (m, 3H), 1.24 (t, J = 7.6 Hz, 3H); ee = 100%, retention time: 3.778 minutes.

[0354] Compound 003: ESI-LCMS: m / z = 388.3 [M+H]+; 1H NMR (400 MHz,CDCh) δ = 8.55 (s, 1H), 8.32 (s, 1H), 7.57 (d, J = 9.0 Hz, 1H), 7.32 - 7.29 (m, 2H), 5.73 - 5.66 (m, 1H), 5.41 - 5.34 (m, 1H), 3.22 - 3.16 (m, 2H), 3.10 - 3.04 (m, 2H), 2.82 (s, 3H), 2.71 - 2.55 (m, 2H), 2.30 (q, J = 7.6 Hz, 2H), 2.10 (br t, J = 5.1 Hz, 1H), 1.90 - 1.78 (m, 3H), 1.24 (t, J = 7.6 Hz, 3H); ee = 99.86%, retention time: 4.024 minutes.

[0355] Example 3

[0356] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 296 / 413 73 / 189

[0357] Step 1: synthesis of compound 004-2

[0358] To a reaction flask were added 002-2 (2 g, 8.26 mmol), 004-1 (1.48 g, 12.39 mmol), silver acetate (2.76 g, 16.52 mmol, 846.06 μL) and acetonitrile (20 mL). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was filtered and the filter cake was rinsed with 10 mL of acetonitrile. The filtrate was collected and concentrated to obtain crude 004-2. 1H NMR (400 MHz, CDCL) δ = 7.35 (br d, J = 8.3 Hz, 1H), 7.29 (br s, 1H), 7.13 (d, J = 8.4 Hz, 1H), 3.51 (s, 2H), 3.26 (s, 6H), 3.22 (s, 4H), 1.42 (s, 3H).

[0359] Step 2: synthesis of compound 004-3

[0360] To a reaction flask, 004-2 (3 g, 9.17 mmol), hydrochloric acid (12 M, 15 mL), and water (5 mL) were added, and the mixture was stirred at 80°C for 5 hours. A saturated aqueous solution of sodium bicarbonate was added dropwise to the reaction mixture to adjust the pH to 7-8. The mixture was extracted three times with dichloromethane (10 mL each time) and separated, and the organic phases were collected. The crude product was obtained by concentration. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0~0:1) to obtain 004-3. 1H NMR (400 MHz, CDCL) δ = 7.47 (d, J = 2.0 Hz, 1H), 7.46 - 7.41 (m, 1H), 7.38 - 7.33 (m, 1H), 6.79 (s, 1H), 3.07 2.91 (m, 4H), 2.51 (s, 3H).

[0361] Step 3: synthesis of compound 004-4 Petition 870260002323, dated 09 / 01 / 2026, pp. 297 / 413 74 / 189

[0362] To a reaction flask were added 004-3 (230 mg, 874.08 μmol), bis(pinacolate)diboron (443.93 mg, 1.75 mmol), potassium acetate (257.35 mg, 2.62 mmol), tricyclohexylphosphine (49.02 mg, 174.82 μmol), tris(dibenzylideneacetone)dipalladium (80.04 mg, 87.41 pmol), and 1,4-dioxane (7.5 mL). After the atmosphere was purged with nitrogen, the mixture was stirred at 80°C for 16 hours. The reaction mixture was added with water (10 mL) and ethyl acetate (5 mL) and filtered. The filtrate was extracted three times with ethyl acetate (5 mL each time) and the phases were separated. The organic phases were combined and washed with saturated brine (5 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 004-4. ESI-LCMS: m / z = 311.4 [M+H]+.

[0363] Step 4: synthesis of compound 004

[0364] To a reaction flask, 004-4 (65.73 mg, 211.89 μmol), A-1 (40 mg, 141.26 pmol), ethanol (3.2 mL), and a solution of sodium carbonate (16.47 mg, 155.39 pmol) in water (0.52 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (4.90 mg, 4.24 pmol). The atmosphere was again purged with nitrogen, and the mixture was stirred at 85°C for 12 hours. The reaction mixture was concentrated under reduced pressure to obtain a crude product. The crude product was initially separated by preparative thin-layer chromatography (ethyl acetate:methanol = 1:1), then subjected to chiral resolution (column: DAICEL CHIRALPAK AD (250 mm *30 mm, 10 pm); mobile phase: [supercritical isopropanol carbon dioxide (0.1% ammonia)]; isocratic elution: 30% isopropanol (0.1% ammonia)) to obtain compound 004.

[0365] ESI-LCMS: m / z = 387.3 [M+H]+; 1HNMR (400 MHz, CDCL) δ = 8.53 (s, 1H), 8.33 (s, 1H), 7.57 (br d, J = 8.5 Hz, 1H), 7.26 - 7.22 (m, 2H), 6.84 (br s, 1H), 5.79 5.65 (m, 1H), 5.41 - 5.31 (m, 1H), 3.14 - 2.99 (m, 4H), 2.76 - 2.62 (m, 2H), 2.58 (s, 3H), 2.29 (q, J = 7.2 Hz, 2H), 2.14 - 2.06 (m, 1H), 1.86 - 1.78 (m, 3H), 1.23 (br t, J = 7.5 Hz Petition 870260002323, dated 09 / 01 / 2026, pages 298 / 413 75 / 189 3H); SFC method: chromatographic column: Chiralpak AD-3, 150χ4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol (0.2% 7M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.5 min), 50 / 50 (3.5 min), 50 / 50 (4.5 min), 90 / 10 (5.0 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: psi: 2000; ee = 100%; retention time: 4.144 minutes.

[0366] Example 4

[0367] Synthetic route:

[0368] Step 1: Synthesis of compound 005-1

[0369] A-1 (0.1 g, 353.15 μmol), methoxamine hydrochloride (38.34 mg, 459.1 pmol), phosphorus oxychloride (119.12 mg, 776.94 pmol), and toluene (1 mL) were added to a reaction flask. The mixture was stirred at 90°C for 10 hours. The reaction mixture was concentrated, and the concentrate was slowly poured into water (2 mL). A saturated aqueous solution of sodium carbonate was added dropwise to adjust the pH to 9-10. The mixture was extracted three times with dichloromethane (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 005-1.1H NMR (400 MHz, CDCl3)δ ppm 8.56 (s, 1 H), 8.49 (s, 1 H), 5.31 (s, 1 H), 4.53 - 4.62 (m, 1 H), 3.75 (s, 3 H), 2.72 - 2.80 (m, 2 H), 2.38 (qd, J = 7.48, 3.69 Hz, 2 H), 1.97 - 2.07 (m, 2 H), 1.77 - 1.91 (m, 2 H), 1.28 (t, J = 7.50 Hz, 3 H). Step 2: synthesis of compounds 005 and 006 Petition 870260002323, dated 09 / 01 / 2026, pp. 299 / 413 76 / 189

[0370] To a reaction flask, 005-1 (100 mg, 320.30 μmol), 005-2 (110.37 mg, 384.36 μmol), ethanol (4.5 mL), water (1.5 mL), and sodium carbonate (37.34 mg, 352.33 μmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (11.10 mg, 9.61 pmol). The atmosphere was again purged with nitrogen, and the mixture was stirred at 85°C for 12 hours. The reaction mixture was filtered, and the filter cake was washed with dichloromethane (5 mL). The filtrate was collected and concentrated to obtain a crude product.The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 0:1), high-performance preparative liquid chromatography (column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile]; gradient: acetonitrile%: 20%-50%) and chiral resolution (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 pm); mobile phase: [A: supercritical carbon dioxide - B: isopropanol (0.1% ammonia)]; isocratic elution: 35% B) to obtain compounds 005 and 006. The SFC method was subsequently performed: chromatographic column: Chiralpak AD-3, 50χ4.6 mm ID, 3 pm; Mobile phase: A: CO2, B: methanol [0.2% 7M ammonia in methanol]; gradient: A:B=60:40; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi.

[0371] Composto 005: 1H NMR (400 MHz, CDCb^ ppm 8,62 (s, 1 H), 8,33 (s, 1 H), 7,14 - 7,25 (m, 1 H), 7,00 - 7,14 (m, 2 H), 5,34 (br d, J = 10,13 Hz, 1 H), 4,66 (br s, 1 H), 3,73 - 3,81 (m, 3 H), 3,41 (s, 3 H), 2,91 - 3,00 (m, 2 H), 2,72 (br t, J = 7,32 Hz, 3 H), 2,33 - 2,45 (m, 2 H), 2,11 (br s, 1 H), 1,89 (br d, J = 7,00 Hz, 1 H), 1,74 - 1,87 (m, 3 H), 1,30 (t, J = 7,44 Hz, 3 H). ESI-LCMS: m / z = 393,2 [M+H]+; ee = 99,98%, tempo de retenção: 0,805 minutos.

[0372] Composto 006: Ή NMR (400 MHz, CDCb^ ppm 8,59 (br s, 1 H), 8,22 - 8,37 (m, 1 H), 7,17 - 7,21 (m, 1 H), 7,05 - 7,11 (m, 2 H), 5,34 (br d, J = 10,39 Hz, 1 H), 4,60 4,66 (m, 1 H), 3,76 (s, 3 H), 3,41 (s, 3 H), 2,96 (t, J = 7,42 Hz, 2 H), 2,69 - 2,75 (m, 3 H), Petição 870260002323, de 09 / 01 / 2026, pág. 300 / 413 77 / 189 2.36 - 2.42 (m, 2 H), 2.08 (br dd, J = 6.99, 1.92 Hz, 1 H), 1.85 - 1.89 (m, 1 H), 1.74 - 1.83 (m, 3 H), 1.29 - 1.32 (m, 3 H); ESI-LCMS: m / z = 393.2 [M+H]+; ee = 100%, retention time: 0.510 minutes.

[0373] Example 5

[0374] Synthetic route:

[0375] Step 1: synthesis of compound 007-3

[0376] 007-1 (3 g, 12.49 mmol) and tetrahydrofuran (15 mL) were added to a reaction flask. The atmosphere was purged with nitrogen and the mixture was cooled to 0 °C. A solution of lithium bis(trimethylsilyl)amide (1 M, 14.99 mL) was added dropwise and the mixture was stirred at 0 °C for 1 hour. A solution of 007-2 (5.38 g, 37.48 mmol) in tetrahydrofuran (9 mL) was slowly added dropwise and the mixture was stirred at 0 °C for 1 hour. The mixture was then heated to 25 °C and stirred for 1 hour. The reaction mixture was added to a saturated aqueous solution of ammonium chloride (30 mL), extracted with ethyl acetate three times (20 mL each time). The organic phases were combined and washed with saturated brine (20 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 6:1) to obtain 007-3.1H NMR (400 MHz,CDCh) δ = 7.39 (dd, J = 2.2, 8.6. Petition 870260002323, dated 09 / 01 / 2026, pp. 301 / 413 78 / 189 Hz, 1H), 7.25 - 7.21 (m, 1H), 6.85 (d, J = 8.6 Hz, 1H), 3.34 (s, 3H), 2.79 (s, 2H), 1.33 1.28 (m, 2H), 0.76 - 0.68 (m, 2H).

[0377] Step 2: synthesis of compound 007-4

[0378] To a reaction flask, 007-3 (190 mg, 713.93 μmol), bis(pinacolate)diboron (271.94 mg, 1.07 mmol), 1,4-dioxane (4 mL), and potassium acetate (140.13 mg, 1.43 mmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of dichloromethane [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex (58.30 mg, 71.39 μmol). The mixture was stirred at 80°C for 16 hours. The reaction mixture was added with water (2 mL) and extracted three times with ethyl acetate (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 10:1) to obtain 007-4.- 1.27 (m, 2H), 0.74 - 0.66 (m, 2H).

[0379] Step 3: Synthesis of Compound 007

[0380] A-1 (100 mg, 353.15 μmol), 007-4 (132.73 mg, 423.78 μmol), ethanol (8.5 mL), and a solution of sodium carbonate (41.17 mg, 388.47 μmol) in water (1.42 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (12.24 mg, 10.59 μmol). The mixture was stirred at 85°C for 2 hours. The reaction mixture was added with water (2 mL) and extracted three times with ethyl acetate (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially separated by chromatography into Petition 870260002323, dated 09 / 01 / 2026, pages 302 / 413 79 / 189 thin preparative layer (ethyl acetate:methanol = 10:1) and subjected to chiral resolution (chiral column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia)]; isocratic elution: 40% isopropanol (0.1% ammonia)) to obtain 007. 1H NMR (400 MHz, CDCh) δ = 8.51 (s, 1H), 8.31 (s, 1H), 7.20 (dd, J = 1.6, 8.4 Hz, 1H), 7.08 - 7.01 (m, 2H), 5.85 (br d, J = 8.3 Hz, 1H), 5.39 - 5.29 (m, 1H), 3.40 (s, 3H), 2.86 (s, 2H), 2.69 (td, J = 6.0, 15.7 Hz, 2H), 2.30 (q, J = 7.5 Hz, 2H), 2.16 - 2.05 (m, 1H), 1.92 - 1.83 (m, 3H), 1.38 - 1.31 (m, 2H), 1.23 (t, J = 7.6 Hz, 3H), 0.79 - 0.72 (m, 2H). ESI-LCMS: m / z = 390.2 [M+H]+. SFC method: chromatographic column: Chiralpak AD-3, 50χ4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol [0.2% 7M ammonia in methanol]; gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); Flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi. ee = 100%, retention time: 1.465 minutes.

[0381] Example 6

[0382] Synthetic route:

[0383] Step 1: synthesis of compound 008-3

[0384] To a reaction flask were added sequentially 008-1 (0.2 g, 1.23 mmol), N,N-dimethylformamide (4 mL), cesium carbonate (1.09 g, 3.33 mmol) and iodide Petition 870260002323, dated 09 / 01 / 2026, pp. 303 / 413 80 / 189 of potassium (20.50 mg, 123.47 μmol). Under stirring, 008-2 (206.19 mg, 1.23 mmol) was added dropwise to the reaction flask. The atmosphere was purged with nitrogen and the mixture was stirred at 20°C for 2 hours. The reaction mixture was added with water (5 mL) and extracted with ethyl acetate (5 mL). The aqueous phase was collected. The aqueous phase was adjusted to pH 3-4 by adding an aqueous solution of citric acid, extracted three times with ethyl acetate (5 mL each time). The organic phases were combined and washed with saturated brine (5 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain 008-3.1H NMR (400 MHz, DMSO-do) δ = 11.02 - 10.68 (m, 1H), 5.68 (s, 1H), 4.20 (t, J = 7.1 Hz, 2H), 2.78 (t, J = 7.1 Hz, 2H).

[0385] Step 2: synthesis of compound 008-4

[0386] To a reaction flask, 008-3 (180 mg, 833.20 pmol), N,N-dimethylformamide (3 mL), cesium carbonate (325.77 mg, 999.84 pmol), and methyl iodide (473.05 mg, 3.33 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the mixture was stirred at 25°C for 12 hours. The reaction mixture was then supplemented with water (5 mL) and ethyl acetate (10 mL). The resulting phases were separated to collect the organic phase. The aqueous phase was extracted three times with ethyl acetate (30 mL each time). The organic phases were combined and washed twice with saturated brine (30 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain compound 008-4. 1H NMR (400 MHz, CDCL) δ = 5.78 (s, 1H), 4.29 (t, J = 7.1 Hz, 2H), 3.24 (s, 3H), 2.94 (t, J = 7.1 Hz, 2H).

[0387] Step 3: Synthesis of Compound 008

[0388] To a reaction flask were added sequentially 008-4 (28.28 mg, 122.94 pmol), water (0.7 mL), acetonitrile (2.1 mL), methanol (0.7 mL), potassium carbonate (67.96 mg, 491.77 pmol) and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (7.57 mg, 18.44 pmol). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) chloride (4.31 mg, 6.15 pmol) and palladium acetate (1.38 mg, 6.15 pmol). Petition 870260002323, dated 09 / 01 / 2026, pages 304 / 413 81 / 189 μmol). The atmosphere was purged with nitrogen and a solution of crude A-2 (prepared immediately before use according to the synthesis method of Reference Example 2, added based on a theoretical yield of 61 mg, 245.88 μmol) was added dropwise at 40°C. The mixture was stirred at 75°C for 12 hours. The reaction mixture was filtered. The filtrate was collected, dried over anhydrous sodium sulfate and concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane:methanol = 3:1) and chiral resolution (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [A: supercritical carbon dioxide - B: methanol]; isocratic elution: 45% methanol) to obtain 008.

[0389] 1H NMR (400 MHz, CDCh) δ = 8.62 - 8.57 (m, 1H), 8.53 - 8.48 (m, 1H), 5.93 (s, 1H), 5.85 - 5.75 (m, 1H), 5.39 - 5.27 (m, 1H), 4.40 (t, J = 7.1 Hz, 2H), 3.34 (s, 3H), 3.02 (t, J = 7.1 Hz, 3H), 2.30 (br d, J = 7.6 Hz, 2H), 2.22 - 2.00 (m, 2H), 1.87 (br s, 2H), 1.22 (br t, J = 6.8 Hz, 3H); ESI-LCMS: m / z 354.2 [M+H]+. SFC method: chromatographic column: Chiralpak AD-3, 50χ4.6 mm ID, 3 μm; mobile phase: A: supercritical CO2, B: methanol [0.2% 7M ammonia in methanol]; gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi. ee = 99.02%, retention time: 1.532 minutes.

[0390] Example 7

[0391] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pages 305 / 413 82 / 189

[0392] Step 1: synthesis of compound 009-3

[0393] To a reaction flask, 009-1 (2 g, 7.04 mmol), 009-2 (2.44 g, 14.09 mmol), cesium carbonate (4.59 g, 14.09 mmol), toluene (20 mL), and 1,10-phenanthroline (253.91 mg, 1.41 mmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of copper(I) iodide (134.17 mg, 704.49 μmol). The mixture was stirred at 110°C for 24 hours. The reaction mixture was added with 20 mL of water, extracted with ethyl acetate three times (50 mL each time). The organic phases were combined and washed with saturated brine three times (50 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain 009-3.1H NMR (400 MHz, CDCL) δ = 8.35 (d, J = 1.8 Hz, 1H), 8.11 (d, J = 2.6 Hz, 1H), 7.23 (t, J = 2.2 Hz, 1H), 4.95 - 4.86 (m, 1H), 4.34 (ddd, J = 0.8, 6.4, 9.8 Hz, 2H), 4.02 (dd, J = 3.9, 10.4 Hz, 2H), 1.46 (s, 9H).

[0394] Step 2: synthesis of compound 009-4

[0395] To a reaction flask, 009-3 (60 mg, 182.27 μmol), dichloromethane (1 mL), and trifluoroacetic acid (5.38 mmol, 0.4 mL) were sequentially added. The mixture was stirred at 20°C for 1 hour. The reaction mixture was concentrated to obtain 009-4.1H NMR (400 MHz, CDCh) δ = 8.56 - 8.33 (m, 2H), 8.04 (br s, 1H), 5.43 (br d, J = 1.3 Hz, 1H), 4.71 (br s, 2H), 4.37 (br s, 2H), 3.49 - 3.41 (m, 1H). Petition 870260002323, dated 09 / 01 / 2026, pages 306 / 413 83 / 189

[0396] Step 3: synthesis of compound 009-6

[0397] To a reaction flask, 009-4 (60 mg, 261.92 μmol), 009-5 (50.52 mg, 392.89 μmol), dichloromethane (1 mL), and N,N-diisopropylethylamine (67.70 mg, 523.85 μmol) were sequentially added. The mixture was stirred at 25 °C for 12 hours. The reaction mixture was then supplemented with water (1 mL) and dichloromethane (1 mL). The resulting phases were separated to collect the organic phase. The aqueous phase was extracted 3 times with ethyl acetate (1 mL each time). The organic phases were combined and washed twice with saturated brine (1 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 009-6.1H NMR (400 MHz, DMSO-d6) δ = 8.36 (d, J = 1.5 Hz, 1H), 8.27 (d, J = 2.4 Hz, 1H), 7.66 (t, J = 2.1 Hz, 1H), 5.23 (dd = 4,1,1 6.5, 9.7 Hz, 2H), 3.92 (dd, J = 4.5, 9.8 Hz, 2H), 3.22 − 3.14 (m, 2H), 1.23 (t, J = 7.3 Hz, 3H).

[0398] Step 4: synthesis of compound 009

[0399] To a reaction flask, 002-5 (48.51 mg, 108.35 μmol), 009-6 (29 mg, 90.29 μmol), ethanol (2.4 mL), and a solution of sodium carbonate (10.53 mg, 99.32 pmol) in water (0.39 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (3.13 mg, 2.71 μmol). The atmosphere was purged with nitrogen and the mixture was stirred at 85°C for 12 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1) to obtain 009. 1H NMR (400 MHz, CDCh) δ = 8.54 (s, 1H), 8.18 (d, J = 2.3 Hz, 1H), 7.63 - 7.59 (m, 1H), 7.59 - 7.55 (m, 2H), 7.29 - 7.27 (m, 1H), 5.12 - 5.06 (m, 1H), 4.36 (dd, J = 6.5, 9.4 Hz, 2H), 4.19 (dd, J = 4.8, 9.4 Hz, 2H), 3.24 - 3.17 (m, 2H), 3.14 - 3.08 (m, 2H), 3.04 (q, J = 7.4 Hz, 2H), 2.83 (s, 3H), 1.40 (t, J = 7.4 Hz, 3H); ESI-LCMS: m / z Petition 870260002323, dated 09 / 01 / 2026, pages 307 / 413 84 / 189 = 426.1 [M+H]+.

[0400] Example 8

[0401] Synthetic route:

[0402] Step 1: synthesis of compound 010-2

[0403] To a reaction flask, 010-1 (3 g, 13.16 mmol), bis(pinacolate)diboron (5.08 g, 20.02 mmol), potassium acetate (2.01 g, 20.45 mmol), and dioxane (90 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of dichloromethane [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex (512.73 mg, 627.85 μmol). The mixture was stirred at 100°C for 4 hours. The reaction mixture was added with 50 mL of water and 50 mL of dichloromethane and extracted. The resulting phases were separated. The organic phase was collected, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to obtain 010-2. ESI-LCMS: m / z = 276.1 [M+H]+.

[0404] Step 2: synthesis of compound 010-3

[0405] To a reaction flask, 010-2 (2.0 g, 7.27 mmol), N,N-dimethylformamide (15 mL), potassium carbonate (3.01 g, 21.81 mmol), and methyl iodide (1.50 g, 10.54 mmol) were sequentially added. The mixture was stirred at 25°C for 16 hours. The reaction mixture was then added to 10 mL of water and 15 mL of dichloromethane and extracted. The phase Petition 870260002323, dated 09 / 01 / 2026, pages 308 / 413 85 / 189 organic matter was collected, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to obtain 010-3. ESI-LCMS: m / z = 290.1 ​​[M+H]+.

[0406] Step 3: synthesis of compounds 010 and 011

[0407] A crude product of 0103 (0.1 g, 345.86 μmol), A-1 (97.94 mg, 345.86 pmol), ethanol (2 mL), water (0.4 mL), and sodium carbonate (36.66 mg, 345.86 μmol) was sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (19.98 mg, 17.29 μmol). The mixture was stirred at 80°C for 2 hours. The reaction mixture was added with 5 mL of water and 5 mL of dichloromethane and extracted. The resulting phases were separated. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was subjected to preparative thin-layer chromatography (dichloromethane:methanol = 20:1) and chiral resolution (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 pm); mobile phase: [carbon dioxide-supercritical ethanol (0.1% water with ammonia)]; isocratic elution: 45% ethanol (0.1% water with ammonia)) to obtain 010 and 011.The ee value was determined by SFC (chromatographic column: Chiralpak AD-3 (50χ4.6 mm ID, 3 pm); mobile phase: A: supercritical carbon dioxide, B: ethanol (0.05% diethylamine); gradient: 40% B; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1500 psi).

[0408] Compound 010: Ή NMR (400 MHz, CDCL) δ = 8.43 (s, 1H), 8.21 (s, 1H), 7.03 - 6.93 (m, 1H), 6.92 - 6.82 (m, 2H), 5.65 (br d, J = 8.5 Hz, 1H), 5.39 - 5.11 (m, 1H), 4.61 (s, 2H), 3.34 (s, 3H), 2.69 - 2.47 (m, 2H), 2.29 - 2.14 (q, J =7.7 Hz, 2H), 2.06 - 1.92 (m, 1H), 1.84 - 1.69 (m, 3H), 1.19 - 1.07 (t, J = 7.7 Hz, 3H); ESI-LCMS: m / z = 366.1 [M+H]+; ee = 96.72%, retention time: 0.582 minutes.

[0409] Compound 011: Ή NMR (400 MHz, CDCL) δ = 8.41 (br s, 1H), 8.17 (br s, 1H), 7.04 - 6.70 (m, 3H), 5.87 (br s, 1H), 5.26 (br s, 1H), 4.59 (br s, 2H), 3.34 (s, 3H), 2.56 (br s, 2H), 2.20 (br s, 2H), 1.99 (br s, 4H), 1.14 (br s, 3H); ESI-LCMS: m / z = 366.1 [M+H] Petition 870260002323, dated 09 / 01 / 2026, pages 309 / 413 86 / 189 +; ee = 99.98%, retention time: 2.351 minutes.

[0410] Example 9

[0411] Synthetic route:

[0412] Step 1: synthesis of compound 012-2

[0413] To a reaction flask, 010-1 (2.0 g, 8.77 mmol) and toluene (100 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of Lawesson's reagent (7.09 g, 17.54 mmol). The mixture was stirred at 110°C for 16 hours. The reaction mixture was added with 50 mL of water and 50 mL of ethyl acetate and extracted. The resulting phases were separated. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. It was purified by column chromatography (petroleum ether:ethyl acetate = 4:1) to obtain 012-2. 1H NMR (400MHz, CDCL) δ = 9.61 (br s, 1H), 7.19 (s, 1H), 7.13 (dd, J=1.9, 8.4 Hz, 1H), 6.77 (d, J=8.5 Hz, 1H), 4.90 (s, 2H).

[0414] Step 2: synthesis of compound 012-4

[0415] To a reaction flask, 012-2 (1.0 g, 4.10 mmol), 002-3 (364.17 mg, 4.92 mmol) and cyclohexanol (5 mL) were sequentially added. The mixture was stirred at 120°C for 16 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was purified by column chromatography (dichloromethane:methanol = 20:1). Petition 870260002323, dated 09 / 01 / 2026, pages 310 / 413 87 / 189 to obtain 012-4.

[0416] Step 3: synthesis of compound 012-5

[0417] To a reaction flask, 012-4 (0.3 g, 1.13 mmol), bis(pinacolate)diboron (429.44 mg, 1.69 mmol), and 1,4-dioxane (10 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of potassium acetate (171.50 mg, 1.75 mmol) and dichloromethane [1,1'-bis(diphenylphosphine)ferrocene]dichloropalladium(II) complex (46.03 mg, 56.37 μmol). The mixture was stirred at 100°C for 16 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 20:1) to obtain 012-5. ESI-LCMS: m / z = 314.1 [M+H]+.

[0418] Step 4: synthesis of compounds 012 and 013

[0419] To the reaction mixture were sequentially added 012-5 (0.1 g, 319.33 μmol), A-1 (90.42 mg, 319.33 μmol), ethanol (5 mL), water (1 mL), and sodium carbonate (33.85 mg, 319.33 pmol). The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphma)palladium (18.45 mg, 15.97 μmol). The mixture was stirred at 80°C for 1 hour. The reaction mixture was concentrated, then added with water (50 mL) and dichloromethane (50 mL) and extracted. The resulting phases were separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane:methanol = 20:1) and chiral resolution (chromatographic column: DAICEL CHIRALPAK IF (250 mm*30 mm, 10 μm); mobile phase: [A: n-hexane, B: isopropanol / acetonitrile = 4:1]; 100% isocratic elution B) to obtain 012 and 013.The ee value was determined by SFC (chromatographic column: Chiralpak IF 100*4.6 mm 3μm; mobile phase: A: n-hexane (0.1% diethylamine), B: isopropanol / acetonitrile = 2 / 1; elution gradient: A / B = 20 / 8; flow rate: 1 mL / min; column temperature: 35°C).

[0420] Compound 012: ESI-LCMS: m / z = 390.1 [M+H]+; 1H NMR (400 MHz, CDCh). Petition 870260002323, dated 09 / 01 / 2026, pp. 311 / 413 88 / 189 δ = 8.46 (s, 1H), 8.22 (s, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.06 (d, J = 1.8 Hz, 1H), 7.00 (dd, J = 2.0, 8.3 Hz, 1H), 5.77 (br d, J = 8.5 Hz, 1H), 5.28 (s, 3H), 2.77 (m, 3H), 2.65 - 2.44 (m, 2H), 2.22 (q, J = 7.7 Hz, 2H), 2.08 - 1.96 (m, 1H), 1.84 - 1.76 (m, 3H), 1.15 (t, J = 7.5 Hz, 3H); ee = 99.87%, retention time: 3.245 minutes.

[0421] Composto 013: Ή NMR (400 MHz, CDCh) δ = 8,48 (s, 1H), 8,24 (s, 1H), 7,53 (d, J =8,3 Hz, 1H), 7,07 (d, J =1,8 Hz, 1H), 7,03 - 6,94 (m, 1H), 5,65 (br d, J =8,0 Hz, 1H), 5,29 (s, 3H), 2,77 (s, 3H), 2,68 - 2,47 (m, 2H), 2,22 (q, J =7,5 Hz, 2H), 2,09 - 1,89 (m, 1H), 1,85 - 1,69 (m, 3H), 0,77 (br s, 3H); ESI-LCMS : m / z = 390,1 [M+H]+; ee = 98,44%, tempo de retenção: 2,328 minutos.

[0422] Exemplo 10

[0423] Rota sintética:

[0424] Etapa 1: síntese do composto 014-2

[0425] To a reaction flask were added 014-1 (120.00 mg, 761.64 μmol), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (196.15 mg, 1.52 mmol) and 2-(7azabenzotriazol-1-yl)-N,N,N',N-tetramethyluronium hexafluorophosphate (577.06 mg, 1.52 mmol). After stirring at 25°C for 5 minutes, the mixture was further added to A-1-5 hydrochloride (200 mg) and stirred at 25°C for 16 hours. 25 mL of water were added to the reaction mixture, which was then transferred to a separatory funnel and extracted three times with 20 mL of ethyl acetate. The organic phases were combined and washed with saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was... Petition 870260002323, dated 09 / 01 / 2026, pages 312 / 413 89 / 189 purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:1) to give 014-2. 1H NMR (400 MHz, CDCL) δ ppm 8.58 (s, 1 H), 8.53 (s, 1 H), 8.43 (d, J = 3.26 Hz, 1 H), 8.18 (br s, 1 H), 7.86 (d, J = 8.28 Hz, 1 H), 7.86 (d, J = 8.28 Hz, 1 H), Jdd (7, 39). 8.16, 4.39 Hz, 1 H), 5.40 - 5.48 (m, 1 H), 2.72 - 2.92 (m, 2 H), 1.95 - 2.17 (m, 4 H).

[0426] Step 2: Synthesis of compound 014

[0427] To a reaction flask, 014-2 (204 mg, 556.40 μmol), 001-3 (317.32 mg, 1112.8 μmol), ethanol (10 mL), sodium carbonate (117.95 mg, 1.11 mmol), and water (2 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (64.3 mg, 55.64 μmol). The reaction mixture was stirred at 80°C for 20 hours. The reaction mixture was added to 40 mL of semi-saturated brine, then transferred to a separatory funnel and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined and washed with 40 mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was sequentially subjected to preparative thin-layer chromatography (dichloromethane:methanol = 20:1) and chiral resolution [chromatographic column: DAICEL CHIRALCEL OJ (250 mm*30 mm, 10 pm); mobile phase: [carbon dioxide-supercritical ethanol (0.1% water with ammonia)]; Isocratic elution: 30% ethanol (0.1% water with ammonia)] to obtain O14, which was subsequently analyzed by SFC (chromatographic column: Chiralcel OJ-3 50*4.6 mm ID, 3 pm; mobile phase: A: supercritical CO2, B: ethanol (0.05% diethylamine); gradient (B%): 5% to 40% (0 to 2 min), 40% (held for 1.2 min), 5% (held for 0.8 min); flow rate: 3 mL / min; column temperature: 35°C; column pressure: 1500 psi): ee = 100%, retention time 1.834 minutes.ESILCMS: m / z = 445.0 [M+H]+; 1H NMR (400 MHz, CDCL) δ ppm 8.64 (s, 1 H), 8.44 (dd, J =4.52, 1.26 Hz, 1 H), 8.35 (s, 1 H), 8.21 (br d, J = 8.53 Hz, 1 H), 7.8. Hz, 1 H), 7.71 (d, J = 9.54 Hz, 1 H), 7.50 - 7.55 (m, 2 H), 7.44 - 7.50 (m, 1 H), Petition 870260002323, of 09 / 01 / 2026, p. 313 / 413 90 / 189 (dd, J = 8.03, 4.52 Hz, 1 H), 6.79 (d, J = 9.54 Hz, 1 H), 5.49 - 5.56 (m, 1 H), 3.78 (s, 3 H), 2.60 - 2.77 (m, 2 H), 2.16 - 2.25 (m, 1 H), 1.99 - 2.08 (m, 1 H), 1.82 - 1.93 (m, 2 H).

[0428] Example 11

[0429] Synthetic route: Br

[0430] Step 1: synthesis of compound 015-2

[0431] To a reaction flask were sequentially added 015-1 (192.76 mg, 1.37 mmol), N,N-dimethylformamide (4 mL), N,N-diisopropylethylamine (514.89 mg, 3.98 mmol), 1-hydroxybenzotriazole (76.90 mg, 569.13 μmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (109.10 mg, 569.13 pmol). The mixture was stirred at 25°C for 5 minutes, followed by the addition of the A-1-5 hydrochloride salt (300 mg). The reaction mixture was stirred at 25°C for 16 hours. The reaction mixture was added with 25 mL of water, then transferred to a separatory funnel and extracted three times with 20 mL of ethyl acetate. The organic phases were combined and washed with semi-saturated and saturated brine (40 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:1) to obtain O15-2.

[0432] Step 2: Synthesis of compound 015

[0433] To a reaction flask, 015-2 (124 mg, 354.07 μmol), 001-3 (201.92 mg, 708.15 pmol), ethanol (5 mL), sodium carbonate (112.58 mg, 1.06 mmol), and water (1 mL) were sequentially added. The atmosphere was purged with nitrogen, followed Petition 870260002323, dated 09 / 01 / 2026, pages 314 / 413 91 / 189 by the addition of tetrakis(triphenylphosphine)palladium (40.92 mg, 35.41 μmol). The reaction mixture was stirred at 85 °C for 16 hours. The reaction mixture was added to 20 mL of semi-saturated brine, then transferred to a separatory funnel and extracted three times with ethyl acetate (10 mL each time). The organic phases were combined and washed with 20 mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 20:1) and subjected to chiral resolution [chromatographic column: ChiralPak IH, 250*30 mm, 10 μm; mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia water)]; Isocratic elution: 45% ethanol (0.1% ammonia water)] to obtain O15, which was subsequently analyzed by SFC (chromatographic column: Chiralpak AS-3 50*4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol (0.05% diethylamine); gradient (B%): 5% to 40% (0 to 2 min), 40% (held for 1.2 min), 5% (held for 0.8 min); flow rate: 3 mL / min; column temperature: 35°C; column pressure: 1500 psi): ee = 100%, retention time 2.383 minutes.ESI-LCMS: m / z = 429.1 [M+H]+; 1H NMR (400 MHz, CDCh) δ ppm 8.60 (s, 1 H), 8.34 (s, 1 H), 7.69 (d, J = 9.54 Hz, 1 H), 7.42 - 7.56 (m, 3 H), 6.75 (d, J = 9.54 Hz, 1 H), 6.02 (br d, J = 8.28 Hz, 1 H), 5.46 - 5.57 (m, 1 H), 3.76 (s, 3 H), 2.58 - 2.74 (m, 5 H), 2.43 (s, 3 H), 2.15 - 2.25 (m, 1 H), 1.83 - 2.01 (m, 3 H).

[0434] Example 12

[0435] Synthetic route:

[0436] Step 1: synthesis of compound 016

[0437] 009-6 (217 mg) was sequentially added to a reaction flask. Petition 870260002323, dated 09 / 01 / 2026, pp. 315 / 413 92 / 189 675.61 μmol), 010-3 (195.34 mg, 675.61 pmol), ethanol (10 mL), sodium carbonate (143.22 mg, 1.35 mmol), and water (2 mL). The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (39.04 mg, 33.78 pmol). The reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was added to 40 mL of semi-saturated brine, then transferred to a separatory funnel and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined and washed with 40 mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane:methanol = 20:1) and preparative high-performance liquid chromatography [column: C18 100*40 mm; mobile phase: [water (0.075% trifluoroacetic acid)acetonitrile]; gradient: 7% to 37% acetonitrile elution] to obtain O16. ESI-LCMS: m / z = 404.0 [M+H]+. 1H NMR (400 MHz, CDCh) δ ppm 8.55 (s, 1 H), 8.18 (d, J = 2.26 Hz, 1 H), 7.22 - 7.35 (m, 3 H), 7.13 (d, J = 8.28 Hz, 1 H), 5.11 (quin, J = 5.58 Hz, 1 H), 4.73 (s, 2 H), 4.34 - 4.45 (m, 2 H), 4.22 (dd, J = 9.16, 4.64 Hz, 2 H), 3.47 (s, 3 H), 3.09 (q, J = 7.45 Hz, 2 H), 1.45 (t, J = 7.40 Hz, 3 H).

[0438] Example 13

[0439] Synthetic route:

[0440] Step 1: synthesis of compound 017-3 Petition 870260002323, dated 09 / 01 / 2026, pp. 316 / 413 93 / 189

[0441] Palladium acetate (480.24 mg, 2.14 mmol), 2-di-tert-butylphosphamo-2',4',6'-triisopropylbiphenyl (2.04 g, 4.28 mmol), and N,N-dimethylformamide (89 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of O17-1 (8.9 g, 42.78 mmol), triethylamine (34.63 g, 342.25 mmol, 47.64 mL), and O17-2 (41.63 g, 256.69 mmol). The atmosphere was again purged with nitrogen, and the reaction mixture was stirred at 80°C for 12 hours. The reaction mixture was added with 10 mL of water, transferred to a separatory funnel, and extracted with 20 mL of ethyl acetate. The resulting phases were separated. The aqueous phase was further extracted three times with ethyl acetate, 30 mL each time. The organic phases were combined and washed twice with brine, 30 mL each time. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain 017-3. 1H NMR (400 MHz, CDCL) δ = 8.49 (d, J = 16.1 Hz, 1H), 7.48 (d, J = 5.6 Hz, 1H), 7.46 - 7.34 (m, 5H), 7.29 (d, J = 5.7 Hz, 1H), 6.52 (d, J = 16.1 Hz, 1H), 5.29 (s, 2H).

[0442] Step 2: synthesis of compound 017-4

[0443] To a reaction flask, 017-3 (5 g, 17.28 mmol), methanol (175 mL), ammonium chloride (1.02 g, 19.01 mmol), and water (50 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the slow addition of iron powder (4.83 g, 86.41 mmol). The reaction mixture was stirred at 60°C for 2 hours. The reaction mixture was cooled to room temperature and water (100 mL) was added, then transferred to a separatory funnel and extracted with 100 mL of dichloromethane. The resulting phases were separated. The organic phase was collected, and the aqueous phase was extracted three times with dichloromethane (100 mL each time). The organic phases were combined, washed twice with saturated brine (100 mL each time), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product 017-4, which was used directly in the... Petition 870260002323, dated 09 / 01 / 2026, pages 317 / 413 94 / 189 next step without further purification. ESI-LCMS: m / z = 260.1 [M+H]+.

[0444] Step 3: synthesis of compound 017-5

[0445] To a reaction flask, 017-4 (4 g, 15.42 mmol), tributylphosphine (9.36 g, 46.27 mmol), and methanol (70 mL) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was stirred at 70°C for 2 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to 1:1) to obtain 017-5. 1H NMR (400 MHz, CDCL) δ = 7.88 (d, J = 9.3 Hz, 1H), 7.11 - 7.08 (m, 1H), 7.07 - 7.04 (m, 1H), 6.68 (d, J = 9.3 Hz, 1H). ESI-LCMS: m / z = 152.1 [M+H]+.

[0446] Step 4: synthesis of compound 017-6

[0447] To a reaction flask, O17-5 (1 g, 6.61 mmol), N,N-dimethylformamide (20 mL), cesium carbonate (2.59 g, 7.94 mmol), and methyl iodide (3.76 g, 26.46 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the mixture was stirred at 25°C for 2 hours. The reaction mixture was added with water (30 mL), then transferred to a separatory funnel and extracted with ethyl acetate (30 mL). The resulting phases were separated. The organic phase was collected, and the aqueous phase was extracted three times with ethyl acetate (30 mL each time). The organic phases were combined and washed twice with saturated brine (30 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain 017-6.1H NMR (400 MHz, CD3OD) δ = 7.91 (d, J = 9.3 Hz, 1H), 7.22 (q, J = 5.6 Hz, 2H), 6.53 (d, J = 9.3 Hz, 1H), 3.72 (s, 3H).

[0448] Step 5: synthesis of compound 017-7

[0449] To a reaction flask, 017-6 (30 mg, 181.58 μmol) and tetrahydrofuran (0.5 mL) were sequentially added. The atmosphere was purged with nitrogen three times and the mixture was cooled to -78°C before lithium tris(2-butyl)borohydride (1 M in Petition 870260002323, dated 09 / 01 / 2026, pp. 318 / 413 95 / 189 tetrahydrofuran, 297.80 μL) to be added dropwise. The reaction mixture was stirred at -78°C for 1 hour, then slowly heated to 25°C and stirred for 12 hours. The reaction mixture was added with water (1 mL), then transferred to a separatory funnel and extracted with 1 mL of dichloromethane. The resulting phases were separated. The aqueous phase was extracted three times with dichloromethane (1 mL each time). The organic phases were combined and washed twice with saturated brine (1 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:1) to obtain O17-7. 1H NMR (400 MHz, CDCL) δ = 6.80 - 6.77 (m, 1H), 6.76 - 6.73 (m, 1H), 3.32 (d, J = 2.3 Hz, 3H), 2.87 - 2.81 (m, 2H), 2.75 - 2.67 (m, 2H).

[0450] Step 6: synthesis of compound 017-8

[0451] To a reaction flask, 017-7 (10 mg, 59.80 μmol) and dichloromethane (0.2 mL) were sequentially added. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of N-Bromosuccinimide (11.71 mg, 65.78 μmol). The reaction mixture was stirred at 0°C for 0.5 hours. The reaction mixture was added with water (1 mL), then transferred to a separatory funnel and extracted with 1 mL of dichloromethane. The resulting phases were separated and the organic phase was collected. The aqueous phase was extracted three times with dichloromethane (1 mL each time). The organic phases were combined, washed twice with saturated brine (1 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 017-8.1H NMR (400 MHz, CDCL) δ = 6.73 (s, 1H), 3.25 (s, 3H), 2.83 - 2.75 (m, 2H), 2.70 (d, J = 7.6 Hz, 2H).

[0452] Step 7: Synthesis of compound 017 Petition 870260002323, dated 09 / 01 / 2026, pp. 319 / 413 96 / 189

[0453] To a reaction flask were added sequentially 017-8 (20 mg, 81.26 μmol), potassium carbonate (44.92 mg, 325.04 μmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (5.00 mg, 12.19 μmol), water (0.4 mL), acetonitrile (1.2 mL) and methanol (0.4 mL). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium dichloride (2.85 mg, 4.06 μmol) and palladium acetate (912.17 μg, 4.06 μmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a crude solution of A-2 (prepared immediately before use according to the synthesis method of Reference Example 2, added based on a theoretical yield of 40.32 mg, 162.52 μmol) was added dropwise. After the dropwise addition was complete, the reaction mixture was heated to 75°C and stirred for 12 hours.The reaction mixture was filtered through diatomite and anhydrous sodium sulfate, and the filtrate was collected and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (eluent: ethyl acetate:dichloromethane:methanol = 3:1:0.3) to obtain 017. 1H NMR (400 MHz, CDCL) δ = 8.59 - 8.52 (m, 1H), 8.48 - 8.42 (m, 1H), 6.89 (s, 1H), 6.40 - 6.22 (m, 1H), 5.37 - 5.21 (m, 1H), 3.35 (s, 3H), 3.10 - 2.99 (m, 2H), 2.90 (br d, J = 8.0 Hz, 2H), 2.79 (br d, J = 7.8 Hz, 2H), 2.34 (br d, J = 7.4 Hz, 2H), 2.18 (br d, J = 2.9 Hz, 2H), 1.94 - 1.90 (m, 2H), 1.23 1.20 (m, 3H); ESI-LCMS: m / z = 370.2 [M+H]+. SFC analysis (method: chromatographic column: (S,S) -WHELK-O1, 100*4.6 mm ID, 3.5 μm; mobile phase: A: CO2, B: ethanol [0.2% 7M ammonia in methanol]; isocratic: A / B = 40:60; flow rate: 4 mL / min; column temperature: 35°C; pressure: 2000 psi), ee = 94.22%, retention time: 2.467 minutes.

[0454] Example 14

[0455] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pages 320 / 413 97 / 189

[0456] Step 1: synthesis of compound 018-3

[0457] To a reaction flask, 018-1 (10 g, 52.63 mmol), dichloromethane (200 mL), and pyridine (5.00 g, 63.15 mmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of 018-2 (7.79 g, 57.89 mmol). The reaction mixture was stirred at 25°C for 3 hours. The reaction mixture was concentrated to obtain a crude product, which was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain 018-3. 1H NMR (400 MHz, CDCL) δ = 8.30 (t, J = 8.7 Hz, 1H), 7.66 (d, J = 12.0 Hz, 1H), 7.27 - 7.23 (m, 2H), 7.10 (br s, 1H), 5.34 (d, J = 12.1 Hz, 1H), 3.97 (q, J = 7.0 Hz, 2H), 1.37 (t, J = 7.1 Hz, 3H).

[0458] Step 2: synthesis of compound 018-4

[0459] 98% concentrated sulfuric acid (5 mL) and 018-3 (500 mg, 1.74 mmol) were added to a reaction flask. The atmosphere was purged with nitrogen. The reaction

[0460] ionic mixture was stirred at 25°C for 3 hours, then heated to 80°C and stirred for 1 hour. The reaction mixture was poured into ice-cold water and filtered. The filter cake was washed with water and dried under reduced pressure to obtain crude 018-4. It can be used directly in the next step without further purification.

[0461] Step 3: synthesis of compound 018-5

[0462] O18-4 (0.2 g, 826.30 μmol), N,N-dimethylformamide (0.5 mL), and cesium carbonate (538.45 mg, 1.65 mmol) were sequentially added to a reaction flask. A Petition 870260002323, dated 09 / 01 / 2026, pp. 321 / 413 The 98 / 189 atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the slow, dropwise addition of methyl iodide (469.13 mg, 3.31 mmol). The atmosphere was purged again with nitrogen and the mixture was stirred at 25°C for 2 hours. The reaction mixture was added with 2 mL of water, transferred to a separatory funnel, and extracted three times with ethyl acetate (3 mL each time). The organic phases were combined and washed three times with saturated brine (3 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 5:1) to obtain O18-5. 1H NMR (400 MHz, CDCl3) δ = 7.55 (d, J = 9.5 Hz, 1H), 7.50 - 7.37 (m, 2H), 6.76 (d, J = 9.5 Hz, 1H), 3.90 (d, J = 8.4 Hz, 3H).

[0463] Step 4: synthesis of compound 018-6

[0464] To a reaction flask were sequentially added 018-5 (100 mg, 390.52 μmol), dioxane (2 mL), bis(pinacolate)diboron (148.75 mg, 585.78 μmol), potassium acetate (114.98 mg, 1.17 mmol) and dichloromethane [1,1'bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex (15.95 mg, 19.53 pmol). The atmosphere was purged with nitrogen and the reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was filtered and rinsed with ethyl acetate. The filtrate was collected and concentrated to obtain crude 018-6, which was used directly in the next step without purification. ESI-LCMS: m / z = 304.2 [M+H]+.

[0465] Step 5: Synthesis of Compound 018

[0466] To a reaction flask were added sequentially A-1 (0.05 g, 176.58 μmol), potassium carbonate (97.62 mg, 706.31 pmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (10.87 mg, 26.49 pmol), bis(triphenylphosphine)palladium dichloride (6.20 mg, 8.83 pmol), palladium acetate (1.98 mg, 8.83 pmol), water (1.2 mL), acetonitrile (3.6 mL), and methanol (1.2 mL). The atmosphere was purged with nitrogen and the reaction mixture was Petition 870260002323, dated 09 / 01 / 2026, pp. 322 / 413 99 / 189 was heated to 40°C, followed by the dropwise addition of a solution of 018-6 (107.05 mg, 353.15 μmol) in tetrahydrofuran (1.2 mL). The reaction mixture was heated to 75°C and stirred for 2 hours. The reaction mixture was allowed to return to room temperature, 20 mL of water was added, it was transferred to a separatory funnel, and extracted three times with dichloromethane (30 mL each time). The organic phases were combined and washed three times with saturated brine (30 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane: ethyl acetate: methanol = 1:1:0.1) and chiral resolution SFC (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 pm); mobile phase: [CO2 supercritical methanol (0.1% ammonia)]; isocratic elution: 45% methanol (0.1% ammonia)) to obtain compound 018.1H NMR (400 MHz, CD3OD) δ = 8.41 (s, 1H), 8.26 (s, 1H), 7.95 (dd, J = 1.5, 9.5 Hz, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.46 (dd, J = 1.9, 15.3 Hz, 1H), 6.76 (d, J = 9.4Hz, 1H), 5.22 (t, J = 5.7Hz, 1H), 3.96 (d, J = 8.0Hz, 3H), 2.83 - 2.63 (m, 2H), 2.29 (dq, J = 1.9, 7.6Hz, 2H), 2.13 2.00 (m, 1H), 1.94 - 1.72 (m, 3H), 1.19 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 380.2 [M+H]+; SFC analysis was performed (chromatographic column: CHIRALPAK AD-3, 50x4.6 mm ID, 3 pm; mobile phase: A: CO2, B: methanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; temperature: 35°C; retention time: 1.504 min.

[0467] Example 15

[0468] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 323 / 413 100 / 189

[0469] Step 1: synthesis of compound 019-2

[0470] O19-1 (0.96 g, 5.81 mmol) and N,N-dimethylformamide (10 mL) were added to a reaction flask. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of N-bromosuccinimide (1.24 g, 6.97 mmol). After the addition was complete, the reaction mixture was stirred at 25°C for 8 hours. The reaction mixture was sequentially added with water (20 mL) and a saturated aqueous solution of sodium thiosulfate (2 mL) and stirred for 10 minutes. The mixture was then filtered and the filter cake was collected. Dichloromethane (20 mL) was added and the mixture was transferred to a separatory funnel. It was washed with saturated brine (20 mL) and the organic phase was collected. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude O19-2, which was used directly in the next step without further purification.1H NMR (400 MHz, CDCh) δ ppm 8.32 (br s, 1 H), 7.34 (d, J=7.03 Hz, 1 H), 6.61 (d, J = 8.94 Hz, 1 H), 2.95 (t, J = 7.57 Hz, 2 H), 2.59. - 2.69 (m, 2 H).

[0471] Step 2: synthesis of compound 019-3

[0472] To a reaction flask, O19-2 (1.3 g, 5.33 mmol), N,N-dimethylformamide (13 mL), and cesium carbonate (3.47 g, 10.65 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the dropwise addition of methyl iodide (2.27 g, 15.98 mmol). The reaction mixture was stirred at 25°C for 1 hour. Water (20 mL) was added to the reaction mixture. Petition 870260002323, dated 09 / 01 / 2026, pp. 324 / 413 101 / 189 was then transferred to a separatory funnel and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined, washed twice with saturated brine (20 mL each time), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 019-3, which was used directly in the next step without further purification.

[0473] Step 3: synthesis of compound 019-4

[0474] To a reaction flask, 019-3 (1.3 g, 5.04 mmol), dichloroethane (26 mL), N-bromosuccinimide (1.34 g, 7.56 mmol), and 2,2'-azobisisobutyronitrile (165.42 mg, 1.01 mmol) were sequentially added. The system was purged with nitrogen, and the reaction mixture was stirred at 80°C for 2 hours. The reaction mixture was added with water (30 mL), then transferred to a separatory funnel and extracted with ethyl acetate (30 mL * 2). The resulting phases were separated. The organic phases were combined and washed with saturated brine (30 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 30:1 to 3:1) to obtain 019-4. 1H NMR (400 MHz, CDCl3) δ ppm 7.76 (d, J =7.25 Hz, 1 H), 7.58 (d, J =9.51 Hz, 1 H), 7.13 (d, J=10.38 Hz, 1 H), 6.69 (d, J =9.51 Hz, 1 H), 3.67 (s, 3 H).

[0475] Step 4: synthesis of compound 019-5

[0476] To a reaction flask were added sequentially 019-4 (500 mg, 1.95 mmol), 1,4-dioxane (20 mL), bis(pinacolate)diboron (743.75 mg, 2.93 mmol), potassium acetate (574.88 mg, 5.86 mmol) and methanesulfonate(2-dicyclohexylphosphino-2',4',6'-tripropyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (82.64 mg, 97.63 μmol). The atmosphere was purged with nitrogen and the reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was filtered through diatomaceous earth, and the filter cake was rinsed with ethyl acetate:methanol = 10:1 (10 mL). The filtrate was collected and... Petition 870260002323, dated 09 / 01 / 2026, pages 325 / 413 102 / 189 concentrate was used to obtain 019-5 crude, which was used directly in the next step without further purification.

[0477] Step 5: Synthesis of Compound 019

[0478] A-1 (100 mg, 353.15 μmol), water (1.2 mL), acetonitrile (3.6 mL), methanol (1.2 mL), potassium carbonate (195.23 mg, 1.41 mmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (21.75 mg, 52.97 μmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (12.39 mg, 17.66 μmol) and palladium(II) acetate (3.96 mg, 17.66 pmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a solution of crude 019-5 (156.09 mg, 706.31 μmol) in tetrahydrofuran (2 mL) was added dropwise. The reaction mixture was stirred at 75°C for 2 hours. The reaction mixture was allowed to return to room temperature and anhydrous sodium sulfate (5 g) was added to it. The mixture was filtered through diatomaceous earth and the filter cake was rinsed with ethyl acetate (10 mL). The filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially subjected to preparative thin-layer chromatography (dichloromethane: ethyl acetate: methanol = 1:1:0.1) and chiral resolution SFC (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [carbon dioxide-supercritical methanol (0.1% ammonia)]; isocratic elution: 50% methanol (0.1% ammonia)) to obtain 019. 1H NMR (400 MHz, CD3OD) δ ppm 8.44 (s, 1 H), 8.25 (s, 1 H), 7.95 (d, J = 9.51 Hz, 1 H), 7.69 (d, J = 7.88 Hz, 1 H), 7.52 (d, J = 11.88 Hz, - 2.10 (m, 1 H), 1.78 - 1.95 (m, 3 H), 1.20 (t, J=7.63 Hz, 3 H); ESI-LCMS: m / z = 380.2 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak AD-3, 150χ4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide B: methanol (0.2% 7 M ammonia in methanol); gradient: A / B = 50:50; flow rate: 2.5 mL / min; column temperature: Petition 870260002323, dated 09 / 01 / 2026, pp. 326 / 413 103 / 189 35°C; pressure: 2,000 psi), ee = 100%, retention time: 1.797 minutes.

[0479] Example 16

[0480] Synthetic route:

[0481] Step 1: synthesis of compound 020-2

[0482] A-1-1 (0.2 g, 880.67 μmol), dichloromethane (10 mL), and N,N-diisopropylethylamine (682.92 mg, 5.28 mmol) were sequentially added to the reaction mixture. The atmosphere was purged with nitrogen, followed by the addition of O20-1 (140.53 mg, 880.67 μmol). The reaction mixture was stirred at 25°C for 1 hour. The reaction mixture was added with water (10 mL), then transferred to a separatory funnel and extracted with dichloromethane twice (10 mL each time). The resulting phases were separated. The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 3:1) to obtain O20-2.1H NMR (400 MHz, CDCL) δ ppm 8.41 - 8.71 (m, 2 H), 5.97 (br d, J =6.31 Hz, 1 H), 5.39 - 5.53 (m, 1 H), 2.80 - 2.86 (m, 2 H), 2.63 (s, 3 H), 2.42 (s, 3 H), 2.12 - 2.18 (m, 1 H), 1.90 - 1.96 (m, 3 H).

[0483] Step 2: Synthesis of compound 020 Petition 870260002323, dated 09 / 01 / 2026, pp. 327 / 413 104 / 189

[0484] Compound 020-2 (50 mg, 142.77 μmol), water (0.6 mL), acetonitrile (1.8 mL), methanol (0.6 mL), potassium carbonate (78.93 mg, 571.09 pmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (8.79 mg, 21.42 pmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (5.01 mg, 7.14 pmol) and palladium(II) acetate (1.60 mg, 7.14 μmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a solution of O19-5 (63.10 mg, 285.54 pmol) in tetrahydrofuran (1 mL) was added dropwise. The reaction mixture was then heated to 75°C and stirred for 2 hours. The reaction mixture was allowed to return to room temperature and anhydrous sodium sulfate (5 g) was added to it. The mixture was filtered through diatomaceous earth and the filter cake was rinsed with ethyl acetate (10 mL).The filtrate was collected and concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane: ethyl acetate = 1:1) and chiral resolution SFC (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 pm); mobile phase: [carbon dioxide-supercritical methanol (0.1% ammonia)]; isocratic elution: 50% methanol (0.1% ammonia)) to obtain 020. 1H NMR (400 MHz, CD3OD)δ ppm 8.58 (s, 1 H), 8.29 (s, 1 H), 7.95 (d, J = 9.51 Hz, 1 H), 7.70 (d, J = 7.88 Hz, 1 H), 7.53 (d, J = 11.88 Hz, 1 H), 6.69 (d, J = 9.51 Hz, 1 H), 5.43 (t, J = 6.50 Hz, 1 H), 3.76 (s, 3 H), 2.60 - 2.72 (m, 2 H), 2.54 (s, 3 H), 2.38 (s, 3 H), 2.12 - 2.23 (m, 1 H), 1.85 - 2.02 (m, 3H); ESI-LCMS: m / z = 447.3 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak AD-3, 50x4.6 mm ID, 3 pm; mobile phase: A: supercritical carbon dioxide, B: methanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 1.566 minutes.

[0485] Example 17 Petition 870260002323, dated 09 / 01 / 2026, pp. 328 / 413 105 / 189

[0486] Synthetic route:

[0487] Step 1: synthesis of compound 021-2

[0488] To a reaction flask, O21-1 (0.3 g, 1.03 mmol), potassium carbonate (283.93 mg, 2.05 mmol), and N,N-dimethylformamide (6 mL) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of methyl iodide (583.21 mg, 4.11 mmol). The reaction mixture was then heated to 25°C and stirred for 3 hours. The reaction mixture was added with water (30 mL) and extracted three times with ethyl acetate (10 mL each time). The organic phases were combined and washed with saturated brine (20 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:1) to obtain O21-2. 1H NMR (400 MHz, CDCh) δ = 7.97 (s, 1H), 7.76 (dd, J = 1.8, 9.0 Hz, 1H), 7.34 (d, J = 9.0 Hz, 1H), 7.14 (s, 1H), 3.74 (s, 3H).

[0489] Step 2: synthesis of compound 021-3

[0490] To a reaction flask were added sequentially 021-2 (100 mg, 326.71 μmol), bis(pinacolate)diboron (124.45 mg, 490.07 μmol), potassium acetate (96.19 mg, 980.14 pmol) and 1,4-dioxane (2 mL). The atmosphere was purged with nitrogen gas, followed by the addition of dichloromethane complex [1,1' Petition 870260002323, dated 09 / 01 / 2026, pp. 329 / 413 106 / 189 bis(diphenylphosphino)ferrocene]dichloropalladium(II) (26.68 mg, 32.67 μmol). The reaction mixture was stirred at 80°C for 3 hours. The reaction mixture was concentrated to obtain crude O213, which was used directly in the next step without further purification.

[0491] Step 3: Synthesis of Compound 021

[0492] Crude 021-3 (109.75 mg, 310.77 μmol), A-1 (80 mg, 282.52 pmol), sodium carbonate (59.89 mg, 565.04 μmol), water (0.3 mL), and ethanol (1.8 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (32.65 mg, 28.25 pmol). The reaction mixture was stirred at 85°C for 2.5 hours. The reaction mixture was concentrated to obtain a crude product, which was sequentially purified by preparative thin-layer chromatography (ethyl acetate:dichloromethane:methanol = 5:5:1) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK AD (250 mm *30 mm, 10 µm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia)]; isocratic elution: 30% isopropanol (0.1% ammonia)) to obtain O21.1H NMR (400 MHz, CD3OD) δ = 8.42 (s, 1H), 8.25 (s, 1H), 7.89 - 7.82 (m, 1H), 7.80 - 7.73 (m, 2H), 7.17 (s, 1H), 5.24 (t, J = 5.9 Hz, 1H), 3.84 (s, 3H), 2.78 - 2.60 (m, 2H), 2.28 (dq, J = 2.0, 7.6 Hz, 2H), 2.12 - 2.00 (m, 1H), 1.95 - 1.76 (m, 3H), 1.19 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 430.2 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak AD3, 150x4.6 mm ID, 3 pm; mobile phase: A: supercritical carbon dioxide, B: isopropanol (0.2% 7M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.5 min), 50 / 50 (3.5 min), 50 / 50 (4.5 min), 90 / 10 (5.0 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 2000 psi), ee = 100%, retention time: 3.591 minutes.

[0493] Example 18

[0494] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 330 / 413 107 / 189

[0495] Step 1: synthesis of compound 022-2

[0496] To a reaction flask, O22-1 (0.4 g, 1.78 mmol), N,N-dimethylformamide (8 mL), and cesium carbonate (694.95 mg, 2.13 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the dropwise addition of methyl iodide (1.01 g, 7.11 mmol). The reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was added with water (10 mL), then transferred to a separatory funnel and extracted with 10 mL of ethyl acetate. The resulting phases were separated. The organic phase was collected, and the aqueous phase was extracted with ethyl acetate three times (15 mL each time). The combined organic phases were washed twice with saturated brine (10 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude O22-2, which was used directly in the next step without further purification.1H NMR (400 MHz, CDCl3) δ = 8.63 (d, J = 2.4 Hz, 1H), 7.99 (d, J = 2.4 Hz, 1H), 7.58 (d, J = 9.5 Hz, 1H), 6.81 (d, J = 9.5 Hz, 1H), 3.81 (s, 3H).

[0497] Step 2: synthesis of compound 022-3

[0498] Crude 022-2 (0.32 g, 1.34 mmol), 1,4-dioxane (12.8 mL), bis(pinacolate)diboron (509.85 mg, 2.01 mmol), potassium acetate (394.09 mg, 4.02 mmol) and methanesulfonate(2-dicyclohexylphosphino2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (56.65 mg, 66.93 mL) were sequentially added to a reaction flask. Petition 870260002323, dated 09 / 01 / 2026, pp. 331 / 413 108 / 189 μmol). The atmosphere was purged with nitrogen and the reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was filtered and the filter cake was rinsed with ethyl acetate. The filtrate was collected and concentrated to obtain crude O22-3, which was used directly in the next step without further purification. ESI-LCMS: m / z = 205.1 [M+H] + .

[0499] Step 3: Synthesis of Compound 022

[0500] A reaction flask was sequentially filled with A-1 (0.14 g, 494.41 μmol), water (1.6 mL), acetonitrile (4.8 mL), methanol (1.6 mL), potassium carbonate (273.33 mg, 1.98 mmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (30.45 mg, 74.16 μmol). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (17.35 mg, 24.72 μmol) and palladium(II) acetate (5.55 mg, 24.72 pmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a solution of O22-3 (201.71 mg, 988.83 μmol) in tetrahydrofuran (2.8 mL) was added. The reaction mixture was heated to 75°C and stirred for 12 hours. The reaction mixture was allowed to return to room temperature, then anhydrous sodium sulfate was added. The mixture was filtered. The filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially subjected to preparative thin-layer chromatography (ethyl acetate:dichloromethane:methanol = 1:1:0.1) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol]; isocratic elution: 55% isopropanol) to obtain O22. 1H NMR (400 MHz, CDCL) δ = 8.61 (s, 1H), 8.56 (d, J = 2.3 Hz, 1H), 8.35 (s, 1H), 7.82 (d, J = 2.3 Hz, 1H), 7.69 (d, J = 9.5 Hz, 1H), 6.85 (d, J = 9.4 Hz, 1H), 5.83 (br d, J = 8.5 Hz, 1H), 5.44 - 5.31 (m, 1H), 3.89 (s, 3H), 2.76 - 2.60 (m, 2H), 2.31 (q, J = 7.5 Hz, 2H), 2.17 - 2.09 (m, 1H), 1.93 (br s, 6H), 1.24 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 363.2 [M+H]+; SFC analysis was performed (chromatographic column: Chiralpak IG-3, 50χ4.6 mm ID, 3 μm; mobile phase: A: dioxide). Petition 870260002323, dated 09 / 01 / 2026, pp. 332 / 413 109 / 189 supercritical carbon, B: isopropanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; temperature: 35°C; pressure: 1800 psi) ee = 100%; retention time: 2.145 minutes.

[0501] Example 19

[0502] Synthetic route:

[0503] Step 1: Synthesis of compound 023-1

[0504] To a reaction flask, O17-6 (75 mg, 410.36 μmol) and tetrahydrofuran (3 mL) were sequentially added. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of N-Bromosuccinimide (58.43 mg, 328.29 μmol). The reaction mixture was stirred at 0°C for 0.5 hours. The reaction mixture was added to a semi-saturated aqueous solution of sodium thiosulfate (3 mL) and stirred at 25°C for 5 minutes. The mixture was transferred to a separatory funnel and extracted three times with ethyl acetate (3 mL each time). The organic phases were combined and washed with saturated brine (3 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 3:1) to obtain O23-1.1H NMR (400 MHz, CDCL) δ = 7.58 (d, J = 9.4 Hz, 1H), 7.10 (s, 1H), 6.55 (d, J = 9.4 Hz, 1H), 3.64 (s, 3H).

[0505] Step 2: Synthesis of compound 023

[0506] To a reaction flask were added sequentially 023-1 (70 mg, 286.76 μmol), potassium carbonate (158.53 mg, 1.15 mmol), 2-dicyclohexylphosphine-2,6 Petition 870260002323, dated 09 / 01 / 2026, pp. 333 / 413 110 / 189 dimethoxybiphenyl (17.66 mg, 43.01 μmol), water (1.4 mL), acetonitrile (4.2 mL), and methanol (0.4 mL). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium dichloride (10.06 mg, 14.34 μmol) and palladium acetate (3.22 mg, 14.34 μmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a crude solution of A-2 (prepared immediately before use according to the synthesis method of Reference Example 2, added based on a theoretical yield of 142.28 mg, 573.52 μmol) was added. The reaction mixture was heated to 75°C and stirred for 12 hours. The reaction mixture was filtered through diatomite and anhydrous sodium sulfate, and the filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially purified by preparative thin-layer chromatography (ethyl acetate:dichloromethane:methanol = 3:1:0.3) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia)]; isocratic elution: 50% ethanol (0.1% ammonia)) to obtain O23.1H NMR (400 MHz, CDCL) δ = 8.58 - 8.37 (m, 2H), 7.69 (d, J = 9.4 Hz, 1H), 7.05 (s, 1H), 6.61 (d, J = 9.4 Hz, 1H), 5.81 (br d, J = 8.4 Hz, 1H), 5.35 (br d, J = 7.8 Hz, 1H), 3.71 (s, 3H), 2.95 - 2.78 (m, 2H), 2.30 (q, J = 7.5 Hz, 2H), 2.10 (br dd, J = 5.5, 8.6 Hz, 1H), 1.88 (br dd, J = 3.6, 5.8 Hz, 3H), 1.23 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 368.2 [M+H]+.SFC analysis was performed (chromatographic column: Chiralpak IG-3, 100χ4.6 mm ID, 3 pm; mobile phase: A: supercritical carbon dioxide B: ethanol (0.2% 7 M ammonia in methanol); gradient: A / B = 60:40; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%, retention time: 2.762 minutes.

[0507] Example 20

[0508] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 334 / 413 111 / 189

[0509] Step 1: synthesis of compound 024-2

[0510] To a reaction flask, 024-1 (500 mg, 2.51 mmol) and hydrogen chloride / ethyl acetate (4 M, 7.50 mL) were sequentially added. The reaction mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated to obtain 024-2 hydrochloride, which was used directly in the next step without further purification. 1H NMR (400 MHz, CDCL) δ = 3.62 - 3.50 (m, 4H), 2.89 (t, J = 6.4 Hz, 4H).

[0511] Step 2: synthesis of compound 024-3

[0512] To a reaction flask, 024-2 hydrochloride (260 mg) and dichloromethane (2.6 mL) were sequentially added. The reaction mixture was cooled to 0°C, followed by the addition of N,N-diisopropylethylamine (1.02 g, 7.87 mmol) and propionyl chloride (364.01 mg, 3.93 mmol). The reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was added with water (2 mL), then transferred to a separatory funnel and extracted three times with ethyl acetate (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 6:1) to obtain 024-3. 1H NMR (400 MHz, CDCL) δ = 3.99 - 3.66 (m, 4H), 2.56 - 2.33 (m, 6H), 1.21 (t, J = 7.4 Hz, 3H).

[0513] Step 3: synthesis of compound 024-4 Petition 870260002323, dated 09 / 01 / 2026, pp. 335 / 413 112 / 189

[0514] A-1-5 hydrochloride (140 mg), triethylamine (161.25 mg, 1.59 mmol), and methanol (1.4 mL) were sequentially added to a reaction flask. The reaction mixture was stirred at 25°C, followed by the addition of O24-3 (123.66 mg, 796.78 μmol) and acetic acid (76.56 mg, 1.27 mmol). After 10 minutes, sodium cyanoborohydride (100.14 mg, 1.59 mmol) was added. The reaction mixture was stirred at 25°C for 1 hour. The reaction mixture was adjusted to pH 8-9 by adding a saturated sodium bicarbonate solution, transferred to a separatory funnel, and extracted three times with ethyl acetate (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (dichloromethane:methanol = 1:0 to 15:1) to obtain O24-4.1H NMR (400 MHz, CDCL) δ = 8,53 (br s, 2H), 4,59 - 4,36 (m, 1H), 4,18 - 4,03 (m, 1H), 3,75 (br d, J = 16,9 Hz, 1H), 3,60 - 3,41 (m, 1H), 3,27 - 3,15 (m, 1H), 2,98 (br s, 1H), 2,85 (br d, J = 14,3 Hz, 1H), 2,69 - 2,58 (m, 1H), 2,39 - 2,36 (m, 2H), 2,17 - 1,94 (m, 4H), 1,87 (br d, J = 4,4 Hz, 3H), 1,60 (br s, 2H), 1,18 - 1,15 (m, 3H).

[0515] Etapa 4: síntese do composto 024

[0516] To a reaction flask were added sequentially 024-4 (60 mg, 163.80 μmol), water (0.2 mL), acetonitrile (0.6 mL), methanol (0.2 mL), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (10.09 mg, 24.57 μmol) and potassium carbonate (90.56 mg, 655.21 μmol). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (5.75 mg, 8.19 μmol) and palladium(II) acetate (1.84 mg, 8.19 μmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a solution of 001-3 (56.05 mg, 196.56 μmol) in tetrahydrofuran (1.2 mL) was added. The reaction mixture was heated to 75°C and stirred for 12 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was subsequently subjected to preparative thin-layer chromatography (ether of Petition 870260002323, dated 09 / 01 / 2026, pp. 336 / 413 113 / 189 petroleum: ethyl acetate:methanol = 1:1:0.1), high-performance preparative liquid chromatography (chromatographic column: Waters Xbridge BEH C18 100*30mm*10pm; mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile]; gradient: 15%-55% acetonitrile) and chiral resolution SFC (chromatographic column: ChiralPak IH, 250*30 mm, 10 pm; mobile phase: [carbon dioxide-supercritical methanol (0.1% ammonia)]; isocratic elution: 50% methanol (0.1% ammonia)) to obtain 024.1H NMR (400 MHz, CDCl3) δ = 8.62 (br s, 1H), 8.30 (s, 1H), 7.69 (br d, J = 9.5 Hz, 1H), 7.55 - 7.41 (m, 3H), 6.78 (br d, J = 9.5 Hz, 1H), 4.56 - 4.34 (m, 1H), 4.05 (br d, J = 13.0 Hz, 1H), 3.93 - 3.82 (m, 1H), 3.16 (br t, J = 11.6 Hz, 1H), 3.06 - 2.97 (m, 1H), 2.96 - 2.85 (m, 1H), 2.76 - 2.63 (m, 1H), 2.61 - 2.50 (m, 1H), 2.44 - 2.33 (m, 2H), 2.05 (br s, 1H), 1.90 (br s, 4H), 1.79 1.30 (m, 7H), 1.17 (br t, J = 6.6 Hz, 3H); ESI-LCMS: m / z = 445.3 [M+H]+; SFC analysis was performed (chromatographic column: CHIRALPAK IH-3, 50x4.6 mm ID, 3 pm; mobile phase: A: CO2, B: methanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 2.051 minutes.

[0517] Example 21

[0518] Synthetic route:

[0519] Step 1: Synthesis of compound 025-1 Petition 870260002323, dated 09 / 01 / 2026, pp. 337 / 413 114 / 189

[0520] Tetrahydrofuran (2 mL) and trimethylsulfoxonium iodide (554.62 mg, 2.52 mmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of n-butyllithium in hexane (2.5 M, 940.86 pL). The reaction mixture was stirred at 0°C for 0.5 hours and a solution of 001-2 (200 mg, 840.05 pmol) in tetrahydrofuran (1 mL) was added dropwise. The reaction mixture was then heated to 25°C and stirred for 15.5 hours. The reaction mixture was added with water (2 mL), then transferred to a separatory funnel and extracted twice with ethyl acetate (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 5:1) to obtain 025-1. 1H NMR (400 MHz, CDCl3) δ = 7.49 (d, J = 2.4 Hz, 1H), 7.33 (dd, J = 2.4, 8.8 Hz, 1H), 6.82 (d, J = 8.8 Hz, 1H), 3.31 (s, 3H), 2.49 (dt, J = 5.2, 8.0 Hz, 1H), 2.32 (ddd, J = 4.8, 7.6, 9.5 Hz, 1H), 1.65 - 1.61 (m, 1H), 0.64 (q, J = 4.8 Hz, 1H).

[0521] Step 2: synthesis of 025-2

[0522] To a reaction flask were sequentially added 025-1 (140 mg, 555.32 pmol), 1,4-dioxane (2.8 mL), bis(pinacolate)diboron (211.53 mg, 832.98 pmol), potassium acetate (163.50 mg, 1.67 mmol) and dichloromethane [1,1bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex (22.67 mg, 27.77 pmol). The atmosphere was purged with nitrogen and the reaction mixture was stirred at 80°C for 16 hours. The reaction mixture was allowed to return to room temperature and 4 mL of water were added. The mixture was transferred to a separatory funnel and extracted three times with ethyl acetate (3 mL each time). The organic phases were combined and washed three times with saturated brine (3 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a product. Petition 870260002323, dated 09 / 01 / 2026, pp. 338 / 413 115 / 189 crude. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 5:1) to obtain 025-2. 1H NMR (400 MHz, CDCL) δ = 7.81 (d, J = 1.3 Hz, 1H), 7.67 (dd, J = 1.4, 8.2 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 3.34 (s, 3H), 2.56 (dt, J = 5.2, 8.0 Hz, 1H), 2.38 - 2.26 (m, 2H), 1.58 - 1.53 (m, 1H), 1.36 (s, 12h).

[0523] Step 3: synthesis of 025 and 026

[0524] A-1 (75 mg, 264.86 μmol), water (1.2 mL), acetonitrile (3.6 mL), methanol (1.2 mL), potassium carbonate (146.43 mg, 1.06 mmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (16.31 mg, 39.73 μmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (9.30 mg, 13.24 μmol) and palladium(II) acetate (2.97 mg, 13.24 pmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a solution of O25-2 (95.09 mg, 317.84 μmol) in tetrahydrofuran (1.2 mL) was added. The reaction mixture was heated to 75°C and stirred for 2 hours. The reaction mixture was allowed to return to room temperature and 2 mL of water were added. The mixture was transferred to a separatory funnel and extracted three times with dichloromethane (3 mL each time). The organic phases were combined and washed three times with saturated brine (3 mL each time).The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane: ethyl acetate: methanol = 1:1:0.3) and chiral resolution SFC (chromatographic column: ChiralPak IH, 250*30 mm, 10 μm; mobile phase: [carbon dioxide-supercritical ethanol (0.1% ammonia)]; isocratic elution: 35% ethanol (0.1% ammonia)) to obtain O25 and O26. The ee value was subsequently determined by SFC analysis (chromatographic column: CHIRALPAK IH-3, 100χ4.6 mm ID, 3 μm; mobile phase: A: supercritical CO2, B: ethanol (0.2% 7M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.2 min), 50 / 50 (2.4 min), 50 / 50 (3.4 min), 90 / 10 (4.0 min); rate. Petition 870260002323, dated 09 / 01 / 2026, pp. 339 / 413 116 / 189 flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 2000 psi). í°525]Compound 025: 1H NMR (400 MHz, CD3OD) δ ppm 8.35 (s, 1 H) 8.20 (s, 1 H) 7.40 (d, J = 1.43 Hz, 1 H) 7.18 - 7.25 (m, 2 H) 5.22 (t, J = 5.84 Hz, 1 H) 3.37 (s, 3 H) 2.62 - 2.82 (m, 3 H) 2.22 - 2.37 (m, 3 H) 1.99 - 2.08 (m, 1 H) 1.76 - 1.92 (m, 3 H) 1.69 (td, J = 9.00, 4.29 Hz, 1 H = 1, 3 H Hz, 3 H) 0.62 (q, J = 4.65 Hz, 1 H); ESILCMS: m / z = 376.2 [M+H]+; ee = 99.90%, retention time: 2.458 minutes.

[0526] Compound 026: 1H NMR (400 MHz, CD3OD) δ ppm 8.35 (s, 1 H) 8.20 (s, 1 H) 7.40 (d, J = 1.43 Hz, 1 H) 7.18 - 7.26 (m, 2 J, 2, 25,2 = t Hz, 1 H) 3.37 (s, 3 H) 2.60 - 2.82 (m, 3 H) 2.21 - 2.36 (m, 3 H) 1.98 - 2.10 (m, 1 H) 1.74 - 1.95 (m, 3 H) Hz, 3 H) 0.62 (q, J =4.81 Hz, 1 H); ESILCMS: m / z = 376.2 [M+H]+; ee = 99.88%, retention time: 2.804 minutes.

[0527] Example 22

[0528] Synthetic route: 027

[0529] Step 1: synthesis of compound 027-2

[0530] To a reaction flask, O27-1 (300 mg, 1.26 mmol), N,N-dimethylformamide (3 mL), and cesium carbonate (821.12 mg, 2.52 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of methyl iodide (715.41 mg, 5.04 mmol). The reaction mixture was stirred at 25°C for 1 hour. Water (15 mL) was added to the reaction mixture, then Petition 870260002323, dated 09 / 01 / 2026, pages 340 / 413 117 / 189 was transferred to a separatory funnel and extracted three times with ethyl acetate (5 mL each time). The organic phases were combined and washed twice with saturated brine (5 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 6:1) to obtain O27-2. 1H NMR (400 MHz, CDCh) δ = 7.81 (d, J = 2.1 Hz, 1H), 7.66 (dd, J = 2.3, 9.0 Hz, 1H), 7.24 (s, 1H), 6.63 (s, 1H), 3.69 (s, 3H), 2.45 (s, 3H).

[0531] Step 2: synthesis of compound 027-3

[0532] To a reaction flask, 027-2 (210 mg, 832.98 μmol), bis(pinacolate)diboron (423.05 mg, 1.67 mmol), 1,4-dioxane (8.4 mL), and potassium acetate (245.25 mg, 2.50 mmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of methanesulfonate(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (35.25 mg, 41.65 μmol). The reaction mixture was stirred at 80°C for 16 hours to obtain a reaction mixture of 027-3, which was used directly in the next step without further purification. ESI-LCMS: m / z = 300,0 [M+H]+.

[0533] Step 3: Synthesis of Compound 027

[0534] To a reaction flask, A-1 (58.68 mg, 207.24 μmol), water (1 mL), acetonitrile (3 mL), methanol (1 mL), potassium carbonate (114.57 mg, 828.96 pmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (12.76 mg, 31.09 μmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (7.27 mg, 10.36 pmol) and palladium(II) acetate (2.33 mg, 10.36 pmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a reaction mixture of 027-3 was added. The reaction mixture was heated to 75°C and stirred for 4 hours. The reaction mixture was cooled to room temperature and concentrated to obtain a crude product. The crude product was... Petition 870260002323, dated 09 / 01 / 2026, pp. 341 / 413 118 / 189 sequentially subjected to preparative thin-layer chromatography (petroleum ether: ethyl acetate: methanol = 1:1:0.1) and chiral resolution (column: DAICEL CHIRALPAK IG (250 mm*30 mm, 10 μm); mobile phase: [carbon dioxide-supercritical ethanol (0.1% ammonia)]; isocratic elution: 50% ethanol (0.1% ammonia)) to obtain 027. 1H NMR (400 MHz, CD3OD) δ = 8.40 (s, 1H), 8.27 (s, 1H), 7.79 (d, J = 1.9 Hz, 1H), 7.74 - 7.70 (m, 1H), 7.67 - 7.63 (m, 1H), 6.65 (d, J = 1.1 Hz, 1H), 5.23 (t, J = 6.0 Hz, 1H), 4.58 (s, 3H), 3.79 (s, 3H), 2.80 - 2.59 (m, 2H), 2.54 (d, J = 1.1 Hz, 3H), 2.29 (dq, J = 2.0, 7.6 Hz, 2H), 2.12 - 1.98 (m, 1H), 1.91 - 1.87 (m, 1H), 1.20 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 376.2 [M+H]+; SFC analysis was performed (chromatographic column: CHIRALPAK IG3, 50x4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (min), 95.0 / 5.0 min; flow rate: 3.4 mL / min; temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 2.133.

[0535] Example 23

[0536] Synthetic route:

[0537] Step 1: synthesis of compound 028-2

[0538] O28-1 (2 g, 11.59 mmol) and diethyl oxalate (16.94 g, 115.90 mmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of 1,8-diazabicyclo[5.4.0]undec-7-ene (2.03 g, 13.33 mmol). The reaction mixture was stirred at 25°C for 15 hours. The reaction mixture was Petition 870260002323, dated 09 / 01 / 2026, pp. 342 / 413 119 / 189 was poured into ice water (20 mL) and 1M hydrochloric acid (15 mL) was added. The mixture was filtered and the filter cake was collected. The filter cake was added to anhydrous methanol (10 mL), stirred for 10 minutes and filtered. The filter cake was collected to obtain 028-2. 1H NMR (400 MHz, CDCh) δ = 8.96 (s, 1H), 8.26 (s, 1H), 7.26 (d, J = 1.3 Hz, 1H), 6.97 (d, J = 0.9 Hz, 1H), 4.45 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H).

[0539] Step 2: synthesis of compound 028-3

[0540] To a reaction flask, 028-2 (1.7 g, 6.24 mmol), water (3 mL), and tetrahydrofuran (12 mL) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of portions of sodium borohydride (259.49 mg, 6.86 mmol). The reaction mixture was stirred at 0°C for 0.5 hours. The reaction mixture was then mixed with ice-cold water (5 mL) and a saturated aqueous solution of ammonium chloride (5 mL), transferred to a separatory funnel, and extracted three times with ethyl acetate (10 mL each time). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 4:1) to obtain O28-3.1H NMR (400 MHz, CDCh) δ = 8.97 (s, 1H), 7.48 (s, 1H), 4.50 (td, J = 4.2, 8.4 Hz, 1H), 4.30 (dq, J = 3.6, 7.1 Hz, 2H), 3.60 (dd, J = 3.9, 14.0 Hz, 1H), 3.24 (dd, J = 8.4, 13.9 Hz, 1H), 3.01 (d, J = 4.8 Hz, 1H), 1.33 (t, J = 7.2 Hz, 3H).

[0541] Step 3: synthesis of compound 028-4

[0542] To a reaction flask, O28-3 (0.8 g, 2.91 mmol), iron powder (650.70 mg, 11.65 mmol), and acetic acid (12 mL) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was stirred at 70°C for 0.5 hours. Then, 1,4-dioxane (8 mL) and hydrochloric acid (6 M, 5.83 mL) were added. The reaction mixture was then heated to 90°C and stirred for 3.5 hours. The mixture was then cooled to 25°C and poured into a saturated aqueous solution of sodium bicarbonate. Petition 870260002323, dated 09 / 01 / 2026, pp. 343 / 413 120 / 189 (200 mL). After stirring for 0.5 hours, the mixture was filtered and the filter cake was collected. 028-4 was obtained and used directly in the next step without purification. ESILCMS: m / z = 181.0 [M+H]+.

[0543] Step 5: Synthesis of compound 028-5

[0544] To a reaction flask, O28-4 (0.2 g, 1.11 mmol), cesium carbonate (541.25 mg, 1.66 mmol), and N,N-dimethylformamide (4 mL) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of iodomethane (628.77 mg, 4.43 mmol). The reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was added with water (20 mL), then transferred to a separatory funnel and extracted three times with ethyl acetate (10 mL each time). The organic phases were combined and washed with saturated brine (20 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:1) to obtain 028-5. 1H NMR (400 MHz, CDCh) δ = 8.58 (s, 1H), 7.60 (d, J = 9.6 Hz, 1H), 7.48 (s, 1H), 6.95 (d, J = 9.6 Hz, 1H), 3.77 (s, 3H).

[0545] Step 4: synthesis of compound 028

[0546] To a reaction flask were added sequentially 028-5 (60 mg, 308.30 μmol), sodium carbonate (98.03 mg, 924.89 μmol), water (0.3 mL) and 1,4-dioxane (1.8 mL). The atmosphere was purged with nitrogen, followed by the addition of methanesulfonate(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (26.10 mg, 30.83 μmol) and 2-di-tert-butylphosphino-2',4',6'-triisopropylbiphenyl (29.39 mg, 61.66 μmol, 0.2 eq). The reaction mixture was heated to 85°C and a crude solution of A-2 (prepared immediately before use according to the synthetic method of Reference Example 2, added based on a theoretical yield of 114.73 mg, 462.45 μmol) was added. The reaction mixture was stirred to Petition 870260002323, dated 09 / 01 / 2026, pages 344 / 413 121 / 189 The reaction mixture was heated to 85°C for 0.5 hours. The reaction mixture was cooled to room temperature, water (2 mL) was added, it was transferred to a separatory funnel, and extracted three times with dichloromethane (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane: ethyl methanol acetate = 5:5:1) and chiral resolution (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [carbon dioxide-supercritical isopropanol (0.1% ammonia)]; isocratic elution: 50% isopropanol (0.1% ammonia)) to obtain O28.1H NMR (400 MHz, CD3OD) δ = 9.05 (s, 1H), 8.44 (s, 1H), 8.40 (s, 1H), 8.00 (d, J = 9.5 Hz, 1H), 7.83 (s, 1H), 6.97 (d, J = 9.5 Hz, 1H), 5.24 (t, J = 6.1 Hz, 1H), 3.86 (s, 3H), 2.96 - 2.85 (m, 1H), 2.82 - 2.71 (m, 1H), 2.29 (dq, J = 2.1, 7.6 Hz, 2H), 2.13 - 2.00 (m, 1H), 1.96 - 1.76 (m, 3H), 1.20 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 363.2 [M+H]+; SFC analysis was performed (chromatographic column: CHIRALPAK AD-3, 50x4.6 mm ID, 3 pm; mobile phase: A: CO2, B: isopropanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; temperature: 35°C; pressure: 1800 psi), ee = 100%, reaction time: 1.827 minutes.

[0547] Example 24

[0548] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pages 345 / 413 122 / 189 029 or 030 030 or 029

[0549] Step 1: synthesis of compound 029-2

[0550] To a reaction flask, 029-1 (0.45 g, 1.99 mmol), acetic acid (956.25 mg, 15.92 mmol), and isopropanol (4 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of portions of sodium cyanoborohydride (375.26 mg, 5.97 mmol). The reaction mixture was stirred at 75°C for 14 hours. The reaction mixture was adjusted to pH 7-8 by adding a saturated aqueous solution of sodium bicarbonate, transferred to a separatory funnel, and extracted three times with dichloromethane (5 mL each time). The organic phases were combined and washed with saturated brine (5 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 029-2. The crude product was used directly in the next step without purification. 1H NMR (400 MHz, CDCL) δ = 8.60 (s, 1H), 8.57 (s, 1H), 4.88 (t, J = 4.9 Hz, 1H), 2.88 - 2.83 (m, 1H), 2.72 - 2.65 (m, 1H), 2.10 - 1.79 (m, 5H).

[0551] Step 2: synthesis of compound 029-3

[0552] O29-2 (0.4 g, 1.75 mmol) and dichloromethane (4 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of thionyl chloride (312.96 mg, 2.63 Petition 870260002323, dated 09 / 01 / 2026, pages 346 / 413 123 / 189 mmol). The reaction mixture was stirred at 0°C for 1 hour, then heated to 25°C and stirred for 1.5 hours. The reaction mixture was concentrated to obtain crude O29-3, which was used directly in the next step without purification. 1H NMR (400 MHz, CDCL) δ = 8.83 (s, 1H), 8.74 (s, 1H), 5.52 - 5.36 (m, 1H), 3.15 (td, J = 4.5, 19.6 Hz, 1H), 2.93 - 2.80 (m, 1H), 2.40 - 2.22 (m, 3H), 2.15 - 2.05 (m, 1H).

[0553] Step 3: synthesis of compound 029-5

[0554] To a reaction flask, 029-3 (0.36 g, 1.46 mmol), 029-4 (350.95 mg, 1.75 mmol), N,N-diisopropylethylamine (566.19 mg, 4.38 mmol), potassium iodide (242.41 mg, 1.46 mmol), and acetonitrile (5 mL) were sequentially added. The atmosphere was purged with nitrogen, and the mixture was stirred at 40°C for 2 hours. The reaction mixture was subsequently heated to 80°C and stirred for 16 hours. The reaction mixture was cooled to room temperature and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 1:1) to obtain 029-5. 1H NMR (400 MHz, CDCL) δ = 8.79 (s, 1H), 8.51 (s, 1H), 4.49 (br s, 1H), 3.88 (br d, J = 2.5 Hz, 1H), 3.47 (br d, J = 1.3 Hz, 1H), 2.81 (br d, J = 17.3 Hz, 2H), 2.73 - 2.52 (m, 3H), 2.22 (br d, J = 7.5 Hz, 1H), 2.11 (br d, J = 9.3 Hz, 1H), 1.99 (br dd, J = 5.1, 9.3 Hz, 2H), 1.87 (br d, J = 9.9 Hz, 1H), 1.59 - 1.32 (m, 13H).

[0555] Step 4: synthesis of compound 029-6

[0556] To a reaction flask, 029-5 (0.2 g, 487.39 μmol) and hydrogen chloride / ethyl acetate (4 M, 10.00 mL) were sequentially added. The atmosphere was purged with nitrogen and the reaction mixture was stirred at 25°C for 0.5 hours. The reaction mixture was concentrated to obtain 029-6 hydrochloride, which was used directly in the next step without purification. 1H NMR (400 MHz,DMSO-de) δ = 8.98 (s, 1H), 8.75 (s, 1H), 4.69 (br s, 1H), 3.43 - 3.19 (m, 4H), 3.18 - 3.04 (m, 1H), 2.91 - 2.66 (m, 2H), 2.36 - 2.22 (m, 2H), 2.19 - 1.99 (m, 4H), 1.97 - 1.92 (m, 1H), 1.86 - 1.73 (m, 1H). Petition 870260002323, dated 09 / 01 / 2026, pp. 347 / 413 124 / 189

[0557] Step 5: synthesis of compound 029-7

[0558] To a reaction flask, the hydrochloride salt of 029-6 (220 mg), N,N-diisopropylethylamine (410.07 mg, 3.17 mmol), and dichloromethane (5 mL) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of propionic anhydride (99.10 mg, 761.48 μmol). The reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was added with water (2 mL) and extracted three times with dichloromethane (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 029-7. The crude product was purified by preparative thin layer chromatography (dichloromethane: ethyl acetate: methanol = 5:5:1) to obtain 029-7.1H NMR (400 MHz, CDCL) δ = 8,80 (s, 1H), 8,51 (s, 1H), 5,34 (br d, J = 4,6 Hz, 1H), 3,97 - 3,73 (m, 2H), 2,90 - 2,70 (m, 3H), 2,66 - 2,49 (m, 2H), 2,32 - 2,24 (m, 1H), 2,20 (q, J = 7,7 Hz, 2H), 2,11 (br d, J = 5,0 Hz, 1H), 2,04 - 1,95 (m, 2H), 1,90 - 1,82 (m, 1H), 1,67 (br s, 1H), 1,59 - 1,53 (m, 2H), 1,46 (d, J = 6,6 Hz, 1H), 1,17 - 1,12 (m, 3H).

[0559] Etapa 6: síntese dos compostos 029 e 030

[0560] To a reaction flask, 029-7 (0.1 g, 273.00 μmol), 001-3 (93.41 mg, 327.60 μmol), sodium carbonate (57.87 mg, 546.01 μmol), water (0.7 mL), and ethanol (2 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (31.55 mg, 27.30 μmol). The reaction mixture was stirred at 85°C for 2 hours. The reaction mixture was allowed to return to room temperature, water (5 mL) was added, it was transferred to a separatory funnel, and extracted three times with dichloromethane (5 mL each time). The organic phases were combined, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane: acetate of Petition 870260002323, dated 09 / 01 / 2026, pages 348 / 413 125 / 189 ethyl:methanol = 3:3:1) and chiral SFC resolution (chromatographic column: Chiralpak AD-3, 50*4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: ethanol (0.2% 7M ammonia in methanol); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi) to obtain O29 and O30. SFC analysis was subsequently performed (chromatographic column: Chiralpak AD-3, 50*4.6 mm ID, 3 μm; mobile phase: A: carbon dioxide, B: ethanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi).

[0561] Composto 029: Ή NMR (400 MHz, CD3OD) δ = 8,83 (s, 1H), 8,21 (s, 1H), 7,97 (d, J = 9,5 Hz, 1H), 7,73 - 7,68 (m, 2H), 7,67 - 7,63 (m, 1H), 6,74 (d, J = 9,5 Hz, 1H), 4,03 (br dd, J = 5,5, 9,6 Hz, 1H), 3,80 (s, 3H), 3,73 - 3,61 (m, 1H), 3,00 - 2,90 (m, 1H), 2,80 - 2,68 (m, 2H), 2,64 - 2,52 (m, 2H), 2,38 - 2,28 (m, 1H), 2,19 (q, J = 7,5 Hz, 2H), 2,06 - 1,90 (m, 3H), 1,87 - 1,76 (m, 2H), 1,71 - 1,58 (m, 2H), 1,44 (dq, J = 3,7, 11,6 Hz, 1H), 1,13 (t, J = 7,6 Hz, 3H); ESI-LCMS: m / z = 445,3 [M+H]+; ee = 100%, tempo de retenção: 1,489 minutos.

[0562] Compound 030: 1H NMR (400 MHz, CD3OD) δ = 8.83 (s, 1H), 8.21 (s, 1H), 7.97 (d, J = 9.5 Hz, 1H), 7.73 - 7.69 (m, 2H), 7.67 - 7.63 (m, 1H), 6.74 (d, J = 9.5 Hz, 1H), 4.03 (br dd, J = 5.6, 9.5 Hz, 1H), 3.80 (s, 3H), 3.72 - 3.61 (m, 1H), 2.95 (br d, J = 11.3 Hz, 1H), 2.82 - 2.68 (m, 2H), 2.65 - 2.51 (m, 2H), 2.32 (dt, J = 2.1, 11.4 Hz, 1H), 2.19 (q, J = 7.6 Hz, 2H), 2.09 - 1.90 (m, 3H), 1.88 - 1.76 (m, 2H), 1.72 - 1.57 (m, 2H), 1.44 (dq, J = 3.9, 11.6 Hz, 1H), 1.12 (t, J = 7.7 Hz, 3H); ESI-LCMS: m / z = 445.3 [M+H]+; ee = 100%, retention time: 1.806 minutes.

[0563] Example 25

[0564] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 349 / 413 126 / 189

[0565] Step 1: synthesis of compound 031-2

[0566] To a reaction flask, 031-1 (0.3 g, 1.46 mmol), potassium carbonate (402.52 mg, 2.91 mmol), and N,N-dimethylformamide (3 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of chloroacetyl chloride (180.92 mg, 1.60 mmol). The reaction mixture was stirred at 80°C for 2 hours. The reaction mixture was allowed to return to room temperature, water (30 mL) was added, then it was transferred to a separatory funnel and extracted three times with ethyl acetate (10 mL each time). The organic phases were combined and washed with saturated brine (20 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 031-2. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 4:1) to obtain O31-2. 1H NMR (400 MHz, DMSO-d6) δ = 11.01 (br s, 1H), 7.22 (dd, J = 2.0, 9.8 Hz, 1H), 7.08 (t, J = 1.7 Hz, 1H), 4.64 (s, 2H).

[0567] Step 2: synthesis of compound 031-3

[0568] To a reaction flask, O31-2 (0.1 g, 406.45 μmol), cesium carbonate (198.64 mg, 609.67 pmol), and N,N-dimethylformamide (2 mL) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of iodomethane (230.76 mg, 1.63 mmol). The reaction mixture was stirred at 0°C for 1 hour. Water (10 mL) was added to the reaction mixture, then Petition 870260002323, dated 09 / 01 / 2026, pages 350 / 413 127 / 189 was transferred to a separatory funnel and extracted three times with ethyl acetate (3 mL each time). The organic phases were combined and washed with saturated brine (5 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 5:1) to obtain O31-3. 1H NMR (400 MHz, DMSO-d6) δ=7.34 (dd, J = 1.9, 12.1 Hz, 1H), 7.19 (s, 1H), 4.67 (s, 2H), 3.33 (br s, 3H).

[0569] Step 3: synthesis of compound 031-4

[0570] To a reaction flask, 031-3 (100 mg, 384.53 μmol), bis(pinacolate)diboron (146.47 mg, 576.79 μmol), potassium acetate (113.21 mg, 1.15 mmol), and 1,4-dioxane (2 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (28.14 mg, 38.45 μmol). The reaction mixture was stirred at 80°C for 4 hours. The reaction mixture was allowed to return to room temperature and concentrated to obtain crude 031-4, which was used directly in the next step without purification.

[0571] Step 4: synthesis of compound 031

[0572] A-1 (100 mg, 353.15 μmol), 031-4 (108.46 mg, 353.15 μmol), sodium carbonate (74.86 mg, 706.31 μmol), water (0.5 mL), and ethanol (3 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (40.81 mg, 35.32 μmol). The reaction mixture was stirred at 85°C for 1 hour. The reaction mixture was allowed to return to room temperature, diluted with water (5 mL), and extracted with dichloromethane (5 mL x 3). The organic phases were combined, washed with saturated brine (2 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was sequentially purified by column chromatography (ethyl acetate:methanol = 1:0 to 10:1) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK AD). Petition 870260002323, dated 09 / 01 / 2026, pp. 351 / 413 128 / 189 (250 mm*30 mm, 10 μm); mobile phase: [carbon dioxide-supercritical isopropanol (0.1% ammonia)]; isocratic elution: 50% isopropanol (0.1% ammonia)) to obtain 031. 1H NMR (400 MHz, CD3OD) δ = 8.37 (s, 1H), 8.19 (s, 1H), 6.93 (dd, J = 1.8, 13.1 Hz, 1H), 6.88 (d, J = 1.3 Hz, 1H), 5.20 (t, J = 5.8 Hz, 1H), 4.64 (s, 2H), 3.51 (d, J = 5.9 Hz, 3H), 2.78 - 2.62 (m, 2H), 2.27 (dq, J = 1.7, 7.6 Hz, 2H), 2.07 - 1.98 (m, 1H), 1.92 1.76 (m, 3H), 1.19 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 384.2 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak AD-3, 50x4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; Retention time: 1,479 minutes.

[0573] Example 26

[0574] Synthetic route:

[0575] Step 1: synthesis of compound 032-2

[0576] To a reaction flask, O32-1 (0.3 g, 1.46 mmol), potassium carbonate (402.53 mg, 2.91 mmol), and N,N-dimethylformamide (3 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of chloroacetyl chloride (180.92 mg, 1.60 mmol). The reaction mixture was stirred at 80°C for 2 hours. The reaction mixture was allowed to return to room temperature, and water (30 mL) was added. Petition 870260002323, dated 09 / 01 / 2026, pp. 352 / 413 129 / 189 then transferred to a separatory funnel and extracted three times with ethyl acetate (10 mL each time). The organic phases were combined and washed with saturated brine (20 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 4:1) to obtain O32-2. 1H NMR (400 MHz, DMSO-d6) δ = 10.88 (br s, 1H), 7.31 (d, J = 6.4 Hz, 1H), 6.83 (d, J = 9.2 Hz, 1H), 4.59 (s, 2H).

[0577] Step 2: synthesis of compound 032-3

[0578] To a reaction flask, O32-2 (100 mg, 406.45 μmol), cesium carbonate (198.64 mg, 609.67 pmol), and N,N-dimethylformamide (1.5 mL) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of iodomethane (230.76 mg, 1.63 mmol). The reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was added with water (10 mL), then transferred to a separatory funnel and extracted three times with ethyl acetate (5 mL each time). The organic phases were combined and washed with saturated brine (10 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 5:1) to obtain 032-3. 1H NMR (400 MHz, DMSO-d6) δ = 7.36 (d, J = 6.5 Hz, 1H), 7.30 (d, J = 10.1 Hz, 1H), 4.67 (s, 2H), 3.24 (s, 3H).

[0579] Step 3: synthesis of compound 032-4

[0580] To a reaction flask were sequentially added 032-3 (120 mg, 461.43 μmol), bis(pinacolate)diboron (175.76 mg, 692.15 μmol), potassium acetate (135.86 mg, 1.38 mmol), and 1,4-dioxane (3 mL). The atmosphere was purged with nitrogen, followed by the addition of [1,1'-bis(diphenylphospho)ferrocene]dichloropalladium(H) (33.76 mg, 46.14 μmol). The reaction mixture was stirred at 85 °C for 16 hours. The reaction mixture Petition 870260002323, dated 09 / 01 / 2026, pp. 353 / 413 130 / 189 was allowed to return to room temperature and concentrated to obtain crude 032-4, which was used directly in the next step without purification.

[0581] Step 4: synthesis of compound 032

[0582] A-1 (120 mg, 423.78 μmol), 032-4 (130.15 mg, 423.78 μmol), sodium carbonate (89.83 mg, 847.57 μmol), water (0.5 mL), and ethanol (3 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (48.97 mg, 42.38 μmol). The reaction mixture was stirred at 85°C for 1 hour. The reaction mixture was allowed to return to room temperature, water (5 mL) was added, and it was extracted three times with dichloromethane (5 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was sequentially subjected to column chromatography (ethyl acetate:methanol = 1:0 to 10:1, 10 chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia)]; isocratic elution: 50% isopropanol (0.1% ammonia)) to obtain O32. 1H NMR (400 MHz, CD3OD) δ = 8.39 (s, 1H), 8.18 (s, 1H), 7.11 (d, J = 10.6 Hz, 1H), 6.92 (d, J = 6.6 Hz, 1H), 5.22 (br t, J = 5.8 Hz, 1H), 4.66 (s, 2H), 3.39 (s, 3H), 2.73 - 2.51 (m, 2H), 2.27 (dq, J = 2.0, 7.6 Hz, 2H), 2.11 - 1.97 (m, 1H), 1.94 - 1.75 (m, 3H), 1.19 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 384.2 [M+H]+; SFC analysis was performed (chromatographic column: Chiralpak AD-3, 50x4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 1.795 minutes.

[0583] Example 27

[0584] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 354 / 413 131 / 189

[0585] Step 1: synthesis of compound 033-2

[0586] To a reaction flask, 033-1 hydrochloride (2 g, 16.45 mmol), dichloromethane (20 mL), and N,N-diisopropylethylamine (5.32 g, 41.13 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of a propionic anhydride solution (3.00 g, 23.03 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was added with water (10 mL), transferred to a separatory funnel, and extracted with 10 mL of dichloromethane. The resulting phases were separated, and the organic phase was collected. The aqueous phase was extracted three times with a mixed solvent (dichloromethane:methanol=10:1) (10 mL each time). The organic phases were combined and washed twice with saturated brine (10 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 for dichloromethane: methanol = 20:1) to obtain O33-2. 1H NMR (400 MHz, CDCh) δ = 3.94 - 3.85 (m, 4H), 2.70 (t, J = 7.9 Hz, 1H), 2.62 (t, J = 7.9. Hz, 1H), 2.41 - 2.34 (m, 1H), 2.27 (q, J = 7.4 Hz, 1H), 1.21 - 1.16 (m, 3H).

[0587] Step 2: synthesis of compound 033-3

[0588] To a reaction flask was added sequentially an A-1-5 hydrochloride (0.7 g), methanol (7 mL), triethylamine (631.53 mg, 6.24 mmol), O33-2 (734.19 mg, 5.20 Petition 870260002323, dated 09 / 01 / 2026, pp. 355 / 413 (132 / 189 mmol) and acetic acid (249.85 mg, 4.16 mmol). The mixture was stirred for 15 minutes, followed by the addition of sodium cyanoborohydride (653.64 mg, 10.40 mmol). The reaction mixture was then stirred at 25°C for 1 hour. The reaction mixture was adjusted to pH 8-9 by adding saturated sodium bicarbonate solution, transferred to a separatory funnel, and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined and washed with saturated brine (20 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude O33-3. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 10:1 to dichloromethane:methanol = 20:1) to obtain O33-3.1H NMR (400 MHz, CDCh) δ = 8,53 (d, J = 3,4 Hz, 1H), 8,51 - 8,47 (m, 1H), 3,98 - 3,83 (m, 1H), 3,73 - 3,57 (m, 3H), 3,52 - 3,44 (m, 1H), 3,12 (s, 2H), 2,88 - 2,78 (m, 1H), 2,70 - 2,59 (m, 1H), 2,31 - 2,25 (m, 2H), 2,19 - 2,10 (m, 1H), 2,02 - 1,96 (m, 1H), 1,92 (br d, J = 4,0 Hz, 1H), 1,89 - 1,82 (m, 2H), 1,38 (s, 3H).

[0589] Etapa 3: síntese dos compostos 033 e 034

[0590] To a reaction flask were added sequentially 001-3 (553.67 mg, 1.94 mmol), potassium carbonate (894.51 mg, 6.47 mmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (99.64 mg, 242.71 μmol), bis(triphenylphosphine)palladium dichloride (56.79 mg, 80.90 μmol), palladium acetate (18.16 mg, 80.90 μmol), water (5.5 mL), acetonitrile (16.5 mL) and methanol (5.5 mL). The atmosphere was purged with nitrogen and the reaction mixture was maintained at 40°C, followed by the addition of a solution of O33-3 (0.57 g, 1.62 mmol) in tetrahydrofuran (5.5 mL). The reaction mixture was then heated to 75°C and stirred for 2 hours. The reaction mixture was allowed to return to room temperature and filtered through anhydrous sodium sulfate. The filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially purified by preparative thin-layer chromatography (ethyl acetate:dichloromethane:methanol = 1:1:0.3) and chiral resolution SFC (chromatographic column: ChiralPak IH, 250*30 mm, 10. Petition 870260002323, dated 09 / 01 / 2026, pp. 356 / 413 133 / 189 μm); mobile phase: supercritical carbon dioxide-ethanol:acetonitrile = 1:1 (0.1% ammonia)]; isocratic elution: 50% ethanol:acetonitrile = 1:1 (0.1% ammonia)) to obtain O33 and O34. The ee value was determined by SFC analysis (chromatographic column: CHIRALPAK IH-3, 50χ4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol:acetonitrile (0.1% 7M ammonia in methanol); gradient: A / B = 65:35; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi).

[0591] Composto 033: 1H NMR (400 MHz, CD3OD) δ = 8,58 (d, J = 10,6 Hz, 1H), 8,21 (d, J = 3,1 Hz, 1H), 7,97 (d, J = 9,5 Hz, 1H), 7,75 - 7,61 (m, 3H), 6,74 (d, J = 9,5 Hz, 1H), 4,03 - 3,95 (m, 1H), 3,80 (s, 3H), 3,79 - 3,50 (m, 4H), 3,49 - 3,33 (m, 2H), 2,81 - 2,71 (m, 1H), 2,68 - 2,57 (m, 1H), 2,43 - 2,31 (m, 2H), 2,28 - 2,13 (m, 1H), 2,02 (br d, J = 12,1 Hz, 1H), 1,98 - 1,79 (m, 3H), 1,79 - 1,68 (m, 1H), 1,15 (dt, J = 0,8, 7,5 Hz, 3H); ESI-LCMS: m / z = 431,3 [M+H]+; ee = 100%, tempo de retenção 2,289 minutos.

[0592] Compound 034: Ή NMR (400 MHz, CD3OD) δ = 8.60 (s, 1H), 8.22 (d, J = 2.3 Hz, 1H), 7.97 (d, J = 9.5 Hz, 1H), 7.72 - 7.60 (m, 3H), 6.74 (d, J = 9.4 Hz, 1H), 4.03 (td, J = 4.8, 9.6 Hz, 1H), 3.80 (s, 3H), 3.77 (br d, J = 3.1 Hz, 4H), 3.45 (td, J = 7.5, 12.2 Hz, 1H), 3.29 - 3.22 (m, 1H), 2.79 - 2.71 (m, 1H), 2.68 - 2.58 (m, 1H), 2.36 (qd, J = 7.5, 11.7 Hz, 2H), 2.25 - 2.15 (m, 1H), 2.05 - 1.90 (m, 4H), 1.73 (br dd, J = 2.1, 5.7 Hz, 1H), 1.13 (dt, J = 3.5, 7.5 Hz, 3H); ESI-LCMS: m / z = 431.2 [M+H]+; ee = 100% retention time 3,580 minutes.

[0593] Example 28

[0594] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 357 / 413 134 / 189 035-1

[0595] Step 1: synthesis of compound 035-3

[0596] To a reaction flask, 035-1 (2.2 g, 11.82 mmol) and dichloromethane (34 mL) were sequentially added. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of a solution of 035-2 (1.94 g, 14.19 mmol) in dichloromethane (34 mL). The reaction mixture was then heated to 25°C and stirred for 12 hours. The reaction mixture was added with water (10 mL), then transferred to a separatory funnel and extracted three times with dichloromethane (30 mL each time). The resulting phases were separated. The organic phases were combined and washed twice with saturated brine (20 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain O35-3.1H NMR (400 MHz, CDCL) δ ppm 7.57 (d, J =8.50 Hz, 2 H) 7.13 (d, J =8.63 Hz, 2 H) 3.69 (s, 3 H) 3.29 (s, 3 H) 3.23 (s, 2 H).

[0597] Step 2: synthesis of compound 035-4

[0598] To a reaction flask, O35-3 (3.3 g, 11.53 mmol), tetrahydrofuran (33 mL), and an aqueous solution (33 mL) of lithium hydroxide monohydrate (967.98 mg, 23.07 mmol) were sequentially added. The reaction mixture was stirred at 25°C for 12 hours. The reaction mixture was adjusted to a pH of 1 to 2 by the addition of 12 M hydrochloric acid, followed by water (15 mL) and extracted twice with ethyl acetate (30 mL each time). The organic phases were combined and washed with Petition 870260002323, dated 09 / 01 / 2026, pp. 358 / 413 135 / 189 saturated brine (30 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was added with 25 mL of a mixed solvent (petroleum ether: ethyl acetate = 10:1), stirred for 0.5 hours, and filtered. The filter cake was collected and dried to obtain 035-4. 1H NMR (400 MHz, DMSO-d6)δ ppm 7.66 (br d, J=7.63 Hz, 2 H) 7.32 (br d, J=7.63 Hz, 2 H) 3.17 (br s, 3 H) 3.11 (br s, 2 H).

[0599] Step 3: synthesis of compound 035-5

[0600] To a reaction flask, 035-4 (2.8 g, 10.29 mmol) and Eaton's reagent (30.30 g, 127.28 mmol) were sequentially added. The atmosphere was purged with nitrogen and the reaction mixture was stirred at 70°C for 12 hours. The reaction mixture was added to ice water (100 mL), stirred at 0°C for 0.5 hours, and filtered to collect the filter cake. The filter cake was then added to acetonitrile (28 mL), stirred at 25°C for 1 hour and filtered to collect the filter cake, yielding 0355. 1H NMR (400 MHz, DMSO-d6) δ ppm 11.59 (s, 1 H) 7.95 (d, J = 2.38 Hz, 1 H) 7.76 (dd, J = 9.01, 2.38 Hz, 1 H) 7.44 (d, J = 9.01 Hz, 1 H) 5.89 (s, 1 H) 3.51 (s, 3 H).

[0601] Step 4: synthesis of compound 035-6

[0602] To a reaction flask, O35-5 (0.4 g, 1.57 mmol) and N,N-dimethylformamide (10 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of sodium carbonate (166.86 mg, 1.57 mmol). The atmosphere was again purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of iodomethane (335.18 mg, 2.36 mmol). The reaction mixture was stirred at 0°C for 2 hours, then heated to 25°C and stirred for 10 hours. The reaction mixture was added with 10 mL of water, transferred to a separatory funnel, and extracted three times with ethyl acetate (30 mL each time). The organic phases were combined and washed twice with saturated brine (30 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a product. Petition 870260002323, dated 09 / 01 / 2026, pp. 359 / 413 136 / 189 crude. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain 035-6. 1H NMR (400 MHz, DMSO-d6) δ = 7.95 (d, J = 2.1 Hz, 1H), 7.79 (dd, J = 2.2, 9.1 Hz, 1H), 7.48 (d, J = 9.1 Hz, 1H), 6.09 (s, 1H), 3.94 (s, 3H), 3.54 (s, 3H).

[0603] Step 5: synthesis of compound 035-7

[0604] To a reaction flask were added sequentially 035-6 (0.16 g, 596.78 μmol), 1,4-dioxane (7 mL), bis(pinacolate)diboron (227.32 mg, 895.17 μmol), potassium acetate (175.70 mg, 1.79 mmol) and methanesulfonate(2-dicyclohexylphosphino-2,4,6-tripropyl-1,1'-biphenyl)(2-amino-1,1-biphenyl-2-yl)palladium(II) (25.26 mg, 29.84 μmol). The atmosphere was purged with nitrogen and the reaction mixture was stirred at 80°C for 6 hours. The reaction mixture was filtered and the filter cake was rinsed with ethyl acetate. The filtrate was collected and concentrated to obtain crude O35-7. The crude product was used directly in the next step without purification. ESI-LCMS: m / z = 316.2 [M+H]+.

[0605] Step 6: Synthesis of Compound 35.

[0606] A reaction flask was sequentially filled with A-1 (80 mg, 282.52 μmol), water (1.7 mL), acetonitrile (5.1 mL), methanol (1.7 mL), potassium carbonate (156.18 mg, 1.13 mmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (17.40 mg, 42.38 μmol). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (9.92 mg, 14.13 μmol) and palladium(II) acetate (3.17 mg, 14.13 pmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a solution of 035-7 (178.09 mg, 565.04 μmol) in tetrahydrofuran (2.6 mL) was added. The reaction mixture was heated to 75°C and stirred for 2 hours. The reaction mixture was filtered. The filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially subjected to preparative thin-layer chromatography (ethyl acetate:dichloromethane:methanol = 1:1:0.3) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm *30 mm, 10. Petition 870260002323, dated 09 / 01 / 2026, pages 360 / 413 137 / 189 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia)]; isocratic elution: 50% ethanol (0.1% ammonia)) to obtain O35.1H NMR (400 MHz, CDCb) δ = 8.54 (br s, 1H), 8.33 (br s, 1H), 7.91 (d, J = 1.9 Hz, 1H), 7.51 (dd, J = 2.0, 8.6 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 6.09 (s, 1H), 5.81 (br d, J = 8.6 Hz, 1H), 5.40 - 5.33 (m, 1H), 3.96 (s, 3H), 3.72 (s, 3H), 2.74 - 2.54 (m, 2H), 2.30 (q, J = 7.5 Hz, 2H), 2.15 - 2.07 (m, 1H), 1.87 - 1.80 (m, 3H), 1.23 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 392.2 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak IG-3, 100χ4.6 mm ID, 3 μm; mobile phase: A: CO2, B: methanol (0.2% 7 M ammonia in methanol); gradient: A / B = 50:50; flow rate: 4 mL / min; column temperature: 35°C; pressure: 2000 psi), ee = 100%, retention time: 2.119 minutes.

[0607] Example 29

[0608] Synthetic route: Br 036-2 036-3

[0609] Step 1: synthesis of compound 036-2

[0610] To a reaction flask, 036-1 hydrochloride (2 g, 18.60 mmol), dichloromethane (20 mL), and N,N-diisopropylethylamine (4.49 g, 34.72 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of a solution of propionic anhydride (2.53 g, 19.44 mmol) in dichloromethane (5 mL). The reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was poured into 2 mL of water. The resulting phases were separated, and the organic phase was collected and concentrated to obtain crude 036-2, which was used directly in the next step without purification. 1H NMR (400 MHz, CDCh) δ = 4.81 (br d, J = 13.8 Hz, 4H), 2.31 (q, J = 7.5 Hz, 2H), 1.19 (t, J = 7.6 Hz, 3H). Petition 870260002323, dated 09 / 01 / 2026, pp. 361 / 413 138 / 189

[0611] Step 2: synthesis of compound 036-3

[0612] A reaction flask was sequentially filled with A-1-5 hydrochloride (0.5 g), methanol (5 mL), triethylamine (451.09 mg, 4.46 mmol), O36-2 (472.31 mg, 3.71 mmol), and acetic acid (178.46 mg, 2.97 mmol). The reaction mixture was stirred at 25°C for 0.5 hours, followed by the addition of sodium cyanoborohydride (466.89 mg, 7.43 mmol). The atmosphere was purged with nitrogen, and the reaction mixture was stirred at 25°C for 15.5 hours. The reaction mixture was poured into 5 mL of saturated aqueous sodium bicarbonate solution and extracted three times with dichloromethane (5 mL each time). The organic phases were combined and washed three times with saturated brine (5 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (dichloromethane: ethyl acetate: methanol = 1:1:0.1) to obtain O36-3. ESI-LCMS: m / z = 338.0 [M+H]+.

[0613] Step 3: Synthesis of Compound 036

[0614] To a reaction flask were added sequentially 001-3 (50.58 mg, 177.39 μmol), potassium carbonate (81.72 mg, 591.29 μmol), 2-dicyclohexylphosphine-2,6-dimethoxybiphenyl (9.10 mg, 22.17 pmol), bis(triphenylphosphine)palladium dichloride (5.19 mg, 7.39 pmol), palladium acetate (1.66 mg, 7.39 pmol), water (0.4 mL), acetonitrile (1.2 mL) and methanol (0.4 mL). The atmosphere was purged with nitrogen and the reaction mixture was heated to 40°C, followed by the addition of a solution of 036-3 (50 mg, 147.82 pmol) in tetrahydrofuran (0.4 mL). The reaction mixture was heated to 75°C and stirred for 1 hour. The reaction mixture was allowed to return to room temperature, 2 mL of water was added, it was transferred to a separatory funnel and extracted three times with dichloromethane (3 mL each time). The organic phases were combined and washed three times with saturated brine (3 mL each time).The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The product... Petition 870260002323, dated 09 / 01 / 2026, pp. 362 / 413 Crude 139 / 189 was sequentially purified by preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol = 1:1:0.3), preparative high-performance liquid chromatography (chromatographic column: Waters Xbridge Prep OBD C18 150*40 mm*10 μm; mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile]; gradient: 5%-45% 10 mM ammonium bicarbonate) and chiral resolution SFC (chromatographic column: REGIS(S,S) WHELK-O1 (250 mm*25 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol:acetonitrile = 1:1 (0.1% ammonia)]; isocratic elution: 50% isopropanol:acetonitrile = 1:1 (ammonia 0.1%)) to obtain 036.1H NMR (400 MHz, CD3OD) δ = 8.56 (d, J = 3.8 Hz, 1H), 8.24 (s, 1H), 7.97 (d, J = 9.4 Hz, 1H), 7.75 - 7.68 (m, 2H), 7.67 - 7.61 (m, 1H), 6.74 (d, J = 9.4 Hz, 1H), 4.47 - 4.33 (m, 1H), 4.27 - 4.13 (m, 1H), 4.01 - 3.87 (m, 3H), 3.78 (br s, 3H), 3.78 - 3.68 (m, 1H), 2.83 - 2.70 (m, 1H), 2.69 - 2.58 (m, 1H), 2.17 (q, J = 7.5 Hz, 2H), 2.00 - 1.83 (m, 3H), 1.78 - 1.68 (m, 1H), 1.10 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 417.3 [M+H]+; SFC analysis was performed (chromatographic column: (S,S) -WHELK-O1, 50*4.6 mm ID, 3.5 pm; mobile phase: A: CO2 B: 0.1% isopropylamine in (isopropanol: acetitrile:1); gradient: A / B=55:45; flow rate: 4 mL / min; column temperature: 35 °C; pressure: 1800 psi) ee = 99.62%, retention time: 2.720 minutes.

[0615] Example 30

[0616] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 363 / 413 140 / 189

[0617] Step 1: synthesis of compound 037-3

[0618] To a reaction flask were added sequentially 037-2 (26.43 g, 366.51 mmol) and tetrahydrofuran (450 mL). The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of potassium tert-butoxide (38.38 g, 342.07 mmol). The mixture was stirred at 0°C for 30 minutes. A solution of O37-1 (43 g, 244.34 mmol) in tetrahydrofuran (22.5 mL) was added. The mixture was stirred at 0°C for 10 minutes. The reaction mixture was diluted with an aqueous solution of ammonium chloride (300 mL), then transferred to a separatory funnel and extracted three times with ethyl acetate (300 mL each time). The organic phases were combined and washed with saturated brine (300 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 6:1) to obtain O37-3. 1H NMR (400 MHz, CDCh) δ = 8.57 (s, 1H), 8.36 (d, J = 5.6 Hz, 1H), 6.79 (d, J = 5.6 Hz, 1H), 5.91 (tdd, J = 6.8, 10.3, 17.1 Hz, 1H), 5.25 5.12 (m, 2H), 4.13 (t, J = 6.6 Hz, 2H), 2.62 (q, J = 6.6 Hz, 2H). Petition 870260002323, dated 09 / 01 / 2026, pp. 364 / 413 141 / 189

[0619] Step 2: synthesis of compound 037-4

[0620] O37-3 (28.1 g, 123.20 mmol) and N,N-dimethylformamide (281 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of acetic acid (60.46 g, 616.00 mmol), 1,2-bis(diphenylphosphino)ethane (9.82 g, 24.64 mmol), and palladium acetate (2.77 g, 12.32 mmol). The atmosphere was purged again with nitrogen, and the mixture was stirred at 100°C for 2 hours. The reaction mixture was allowed to cool to room temperature, water (1.4 L) was added, then it was transferred to a separatory funnel and extracted three times with ethyl acetate (500 mL each time). The organic phases were combined and washed twice with saturated brine (500 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 1:1) to obtain O37-4.1H NMR (400 MHz, CDCh) δ = 8,72 (s, 1H), 8,26 (d, J = 5,7 Hz, 1H), 6,76 (d, J = 5,7 Hz, 1H), 5,62 (s, 1H), 5,00 (s, 1H), 4,37 - 4,26 (m, 2H), 2,69 (t, J = 5,7 Hz, 2H).

[0621] Etapa 3: síntese do composto 037-5

[0622] To a reaction flask, 037-4 (2 g, 13.59 mmol), tert-butanol (10 mL), acetonitrile (10 mL), and water (10 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of osmium tetroxide (345.48 mg, 1.36 mmol). The reaction mixture was stirred at 25 °C for 0.5 hours. Sodium periodate (5.81 g, 27.18 mmol) was then added, and the mixture was stirred at 25 °C for 4 hours. The reaction mixture was added with water (20 mL), then transferred to a separatory funnel and extracted with a mixed solvent (ethyl acetate:ethanol = 5:1) twice (20 mL each time). The organic phases were combined and washed with saturated brine (50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by Petition 870260002323, dated 09 / 01 / 2026, pp. 365 / 413 142 / 189 column chromatography (petroleum ether: ethyl acetate = 1:0 to 2:1) to obtain 037-5. 1H NMR (400 MHz, CDCh) δ = 9.02 (s, 1H), 8.53 (d, J = 5.9 Hz, 1H), 6.91 (d, J = 5.9 Hz, 1H), 4.70 - 4.56 (m, 2H), 2.93 - 2.79 (m, 2H).

[0623] Step 4: synthesis of compound 037-6

[0624] To a reaction flask, O37-5 (400 mg, 2.68 mmol), tetrahydrofuran (4 mL), A-1-2 (325.05 mg, 2.68 mmol), and tetraethyl titanate (1.84 g, 8.05 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was stirred at 50°C for 16 hours. The reaction mixture was allowed to cool to room temperature and then ethyl acetate (4 mL) and an aqueous solution of sodium glycolate (3.4 mL) were added. The mixture was stirred at 25°C for 30 minutes. The resulting phases were separated. The aqueous phase was extracted twice with ethyl acetate (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 1:1) to obtain 037-6.1H NMR (400 MHz, CDCfi) δ = 9.10 (s, 1H), 8.44 (d, J = 5.8 Hz, 1H), 6.86 (d, J = 5.8 Hz, 1H), 4.53 - 4.35 (m, 2H), 3.62 - 3.50 (m, 1H), 3.45 - 3.33 (m, 1H), 1.34 (s, 9H).

[0625] Step 5: synthesis of compound 037-7

[0626] O37-6 (420 mg, 1.66 mmol) and tetrahydrofuran (4.2 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of 9-borabicyclo[3.3.1]nonane (0.5 M, 9.99 mL). The reaction mixture was heated to 25°C and stirred for 1 hour. The reaction mixture was added to a 20% aqueous citric acid solution (23 mL), adjusted to a pH of 8 to 9 by adding a saturated sodium bicarbonate solution, transferred to a separatory funnel, and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined and washed with saturated brine (20 mL). Petition 870260002323, dated 09 / 01 / 2026, pp. 366 / 413 143 / 189 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (dichloromethane:methanol = 1:0 to 20:1) to obtain O37-7. 1H NMR (400 MHz, CDCh) δ = 8.51 (s, 1H), 8.33 (d, J = 5.8 Hz, 1H), 6.79 (d, J = 5.8 Hz, 1H), 5.31 (s, 1H), 4.73 - 4.61 (m, 1H), 4.40 - 4.31 (m, 2H), 2.25 - 2.10 (m, 2H), 1.25 (s, 9H).

[0627] Step 6: synthesis of compound 037-8

[0628] To a reaction flask, 037-7 (270 mg, 1.06 mmol) and ethanol (5.4 mL) were sequentially added. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of trimethylsilyl chloride (230.66 mg, 2.12 mmol). The reaction mixture was stirred at 25°C for 1 hour. The reaction mixture was concentrated to obtain crude 037-8, which was used directly in the next step without purification. ESILCMS: m / z = 151.3 [M+H]+.

[0629] Step 7: synthesis of compound 037-9

[0630] Crude 037-8, dichloromethane (2 mL), and N,N-diisopropylethylamine (289.16 mg, 2.24 mmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, and the reaction mixture was cooled to 0°C, followed by the addition of a solution of propionic anhydride (194.11 mg, 1.49 mmol) in dichloromethane (1 mL). The mixture was stirred at 0°C for 1 hour. The reaction mixture was added with water (5 mL), then transferred to a separatory funnel and extracted three times with dichloromethane (2 mL each time). The organic phases were combined and washed with saturated brine (2 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by thin-layer chromatography (dichloromethane:ethyl methanol = 10:1) to obtain O37-9. ESI-LCMS: m / z = 207.1 [M+H]+.

[0631] Step 8: synthesis of compound 037-10 Petition 870260002323, dated 09 / 01 / 2026, pp. 367 / 413 144 / 189

[0632] To a reaction flask, 037-9 (95 mg, 460.63 pmol) and sulfuric acid (1 mL) were sequentially added. The atmosphere was purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of α-bromosuccinimide (163.96 mg, 921.25 pmol). The reaction mixture was then heated to 25°C and stirred for 19 hours. The reaction mixture was added to a saturated aqueous solution of sodium bicarbonate (ice water mixture) and the pH was adjusted to 7-8. The mixture was extracted three times with ethyl acetate (5 mL each time). The organic phases were combined and washed with saturated brine (5 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1) to obtain 037-10. 1HNMR(400 MHz, CD3OD) oppm 8.40 (s, 1 H), 8.21 (s, 1 H), 5.18 (t, .7=5,63 Hz, 1 H), 4,41 - 4,55 (m, 2 H), 2,23 - 2,32 (m, 2 H), 2,05 - 2,22 (m, 2 H), 1,16 (t, J=l,63 Hz, 3 H).

[0633] Etapa 9: síntese do composto 037

[0634] To a reaction flask, 005-2 (58.01 mg, 202.01 pmol), 037-10 (48 mg, 168.34 pmol), ethanol (3 mL), and an aqueous solution (0.5 mL) of sodium carbonate (19.63 mg, 185.17 pmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of methanesulfonate(2-dicyclohexylphosphino-2,4,6-triisopropyl-1,1-biphenyl)(2-amino-1,1-biphenyl-2-yl)palladium(II) (4.27 mg, 5.05 pmol). The atmosphere was purged again with nitrogen, and the mixture was stirred at 85°C for 2 hours. The reaction mixture was then concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 30:1) to obtain O37.'H NMR (400 MHz, CD3OD) δ = 8.24 (d, J= 3.2 Hz, 2H), 7.44 (dd, J= 1.6, 8.4 Hz, 1H), 7.40 (s, 1H), 7.19 (d, J= 8.3 Hz, 1H), 5.21 (t, J= 5.5 Hz, 1H), 4.47 - 4.28 (m, 2H), 3.39 (s, 3H), 2.97 (t, J= 7.4 Hz, 2H), 2.66 (t, J= 7.4 Hz, 2H), 2.28 (dq, J= 2.3, 7.6 Hz, 2H), 2.24 - 2.04 (m, 2H), 1.18 (t, J = 7.6 Hz. Petition 870260002323, dated 09 / 01 / 2026, pp. 368 / 413 145 / 189 3H); ESI-LCMS: m / z = 366.2 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak IG-3, 50x4.6 mm ID, 3 μm; mobile phase: A: CO2, B: ethanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; retention time: 2.179 minutes.

[0635] Example 31

[0636] Synthetic route:

[0637] Step 1: synthesis of compound 038-3

[0638] To a reaction flask, 038-2 (18.72 g, 77.29 mmol) and tetrahydrofuran (140 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of triethylamine (15.64 g, 154.57 mmol), magnesium bromide (14.23 g, 77.29 mmol), and a solution of 038-1 (14 g, 77.29 mmol) in tetrahydrofuran (70 mL). The mixture was stirred at 25°C for 2 hours. The reaction mixture was poured into 20 mL of water and extracted three times with dichloromethane (30 mL each time). The organic phases were combined and washed three times with saturated brine (30 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain 038-3. 1H NMR (400 MHz, CDCl3) δ = 8.22 (d, J = 9.2 Hz, 1H), 7.24 (d, J = 17.6 Hz, 1H), 6.97 (dd, J = 2.8, Petition 870260002323, dated 09 / 01 / 2026, pp. 369 / 413 146 / 189 9.1 Hz, 1H), 6.84 (d, J = 2.6 Hz, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.90 (s, 3H), 1.13 (t, J = 7.2 Hz, 3H).

[0639] Step 2: synthesis of compound 038-4

[0640] To a reaction flask were added sequentially 038-3 (1 g, 3.71 mmol), methanol (35 mL), a solution of ammonium chloride (218.55 mg, 4.09 mmol) in water (10 mL), and iron powder (1.04 g, 18.57 mmol). The reaction mixture was then heated to 60°C and stirred for 2 hours. The reaction mixture was allowed to return to room temperature and filtered. The filter cake was collected to obtain crude 038-4, which was used directly in the next step without purification. ESI-LCMS: m / z = 194.1 [M+H]+.

[0641] Step 3: synthesis of compound 038-5

[0642] To a reaction flask, O38-4 (0.4 g, 2.07 mmol) and N,N-dimethylformamide (5 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of cesium carbonate (1.35 g, 4.14 mmol). The atmosphere was again purged with nitrogen and the reaction mixture was cooled to 0°C, followed by the addition of iodomethane (1.18 g, 8.28 mmol). The mixture was stirred at 0°C for 1 hour, then heated to 30°C and stirred for a further 2 hours. The reaction mixture was added to 5 mL of water and filtered through diatomaceous earth. The filtrate was collected, transferred to a separatory funnel, and extracted three times with ethyl acetate (30 mL each time). The organic phases were combined and washed twice with saturated brine (30 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain O38-5. ESI-LCMS: m / z = 208.0 [M+H]+.

[0643] Step 4: synthesis of compound 038-6

[0644] O38-5 (564.51 mg, 2.72 mmol) and dichloromethane (4 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen and the mixture Petition 870260002323, dated 09 / 01 / 2026, pp. 370 / 413 The reaction mixture (147 / 189) was cooled to 0°C, followed by the addition of boron tribromide (2 M, 5.45 mL). The mixture was stirred at 0°C for 1 hour. The reaction mixture was added to ice-cold water, concentrated to remove dichloromethane, and filtered. The filter cake was collected to obtain crude 038-6, which was used directly in the next step without purification. 1H NMR (400 MHz, CD3OD) δ = 7.59 (d, J = 9.9 Hz, 1H), 7.45 (d, J = 9.1 Hz, 1H), 7.13 (dd, J = 2.6, 9.1 Hz, 1H), 7.03 (d, J = 2.7 Hz, 1H), 3.76 (s, 3H).

[0645] Step 5: synthesis of compound 038-7

[0646] To a reaction flask, 038-6 (197.93 mg, 1.02 mmol) and dichloromethane (2 mL) were sequentially added. The atmosphere was purged with nitrogen and the reaction mixture was cooled to -20°C, followed by the addition of pyridine (129.68 mg, 1.64 mmol) and trifluoromethanesulfonic anhydride (346.91 mg, 1.23 mmol). The mixture was stirred at 20°C for 0.5 hours and then heated to 0°C and stirred for 2 hours. The reaction mixture was added with water (10 mL), then transferred to a separatory funnel and extracted four times with dichloromethane (10 mL each time). The organic phases were combined, washed twice with saturated brine (10 mL each time). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:1) to obtain O38-7. ESI-LCMS: m / z = 325.9 [M+H]+.

[0647] Step 6: synthesis of compound 038-8

[0648] To a reaction flask were sequentially added 038-7 (90 mg, 276.72 μmol), 1,4-dioxane (1 mL), bis(pinacolate)diboron (105.41 mg, 415.08 μmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (30.37 mg, 41.51 pmol), and potassium acetate (81.47 mg, 830.17 μmol, 3 eq). The atmosphere was purged with nitrogen and the mixture was stirred at 100°C for 3 hours. The reaction mixture was filtered. The filtrate was collected and concentrated to obtain crude 038-8, which was used directly in step

[0648] . Petition 870260002323, dated 09 / 01 / 2026, pp. 371 / 413 148 / 189 following without purification. ESI-LCMS: m / z = 304.0 [M+H]+.

[0649] Step 7: Synthesis of compound 038

[0650] A reaction flask was sequentially filled with A-1 (50 mg, 176.58 μmol), water (1 mL), acetonitrile (3 mL), methanol (1 mL), potassium carbonate (97.62 mg, 706.31 pmol), and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (10.87 mg, 26.49 μmol). The atmosphere was purged with nitrogen, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (6.20 mg, 8.83 μmol) and palladium(II) acetate (1.98 mg, 8.83 μmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 40°C and a solution of crude 038-8 (80.29 mg, 264.86 μmol) in tetrahydrofuran (1.5 mL) was added. The reaction mixture was heated to 75°C and stirred for 2 hours. The reaction mixture was allowed to return to room temperature and filtered through anhydrous sodium sulfate. The filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially subjected to preparative thin-layer chromatography (ethyl acetate:dichloromethane:methanol = 1:1:0.5) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia)]; isocratic elution: 50% ethanol (0.1% ammonia)) to obtain O38. 1H NMR (400 MHz, CD3OD) δ = 8.40 (s, 1H), 8.25 (s, 1H), 7.79 (d, J = 9.5 Hz, 1H), 7.74 - 7.68 (m, 2H), 7.66 - 7.59 (m, 1H), 5.23 (br t, J = 5.8 Hz, 1H), 3.86 (s, 3H), 2.78 - 2.63 (m, 2H), 2.29 (dq, J = 2.2, 7.6 Hz, 2H), 2.09 - 2.00 (m, 1H), 1.94 - 1.77 (m, 3H), 1.20 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 380.1 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak IG-3, 50 x 4.6 mm ID, 3 pm; mobile phase: A: CO2, B: ethanol (0.2% 7 M ammonia in methanol); isocratic elution: 50%; flow rate: 4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%, retention time: 1.345 minutes.

[0651] Example 32 Petition 870260002323, dated 09 / 01 / 2026, pp. 372 / 413 149 / 189

[0652] Synthetic route:

[0653] Step 1: synthesis of compound 039-3

[0654] To a reaction flask, 039-1 (0.5 g, 2.69 mmol) and 039-2 (892.90 mg, 5.37 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was heated to 130°C and stirred for 12 hours. The reaction mixture was returned to room temperature and concentrated to obtain crude 039-3. The crude product was used directly in the next step without purification.

[0655] Step 2: synthesis of compound 039-4

[0656] To a reaction flask, 039-3 (822.6 mg, 2.69 mmol) and sulfuric acid (4.60 g, 45.96 mmol) were sequentially added. The atmosphere was purged with nitrogen, and the reaction mixture was heated to 95°C and stirred for 1 hour. The reaction mixture was allowed to return to room temperature, water (7.5 mL) was added, then transferred to a separatory funnel and extracted twice with ethyl acetate (7.5 mL each time). The organic phases were combined and washed with saturated brine (7.5 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 20:1 to 5:1) to obtain 039-4. 1H NMR (400 MHz, CDCh) δ ppm 7.98 (s, 1 H), 7.74 (dd, J = 8.97, 2.17 Hz, 1 H), 7.33 (d, J = 9.16 Hz, 1 H), 6.97 (s, 1 H), 6.64 - 6.93 (m, 1 H), 3.73 (s, 3 H). Petition 870260002323, dated 09 / 01 / 2026, pp. 373 / 413 150 / 189

[0657] Step 3: synthesis of compound 039-5

[0658] To a reaction flask were sequentially added 039-4 (0.33 g, 1.15 mmol), 1,4-dioxane (6 mL), bis(pinacolate)diboron (436.32 mg, 1.72 mmol), potassium acetate (337.25 mg, 3.44 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (83.82 mg, 114.54 μmol). The atmosphere was purged with nitrogen and the reaction mixture was stirred at 80°C for 18 hours. The reaction mixture was allowed to return to room temperature and filtered through diatomaceous earth. The filter cake was rinsed with ethyl acetate (5 mL). The filtrate was collected and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to 3:1) to obtain O39-5. ESI-LCMS: m / z = 336.0 [M+H]+.

[0659] Step 4: synthesis of compound 039

[0660] A-1 (100 mg, 353.15 μmol), 039-5 (177.54 mg, 529.73 μmol), ethanol (5 mL), and sodium carbonate (74.86 mg, 706.31 pmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (40.81 mg, 35.32 pmol). The atmosphere was again purged with nitrogen, and the mixture was heated to 85°C and stirred for 2 hours. The reaction mixture was allowed to return to room temperature, and anhydrous sodium sulfate (5 g) was added. The mixture was filtered through diatomaceous earth, and the filter cake was rinsed with ethyl acetate (10 mL). The filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane: ethyl methanol acetate = 1:1:0.1) and chiral resolution (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 pm); mobile phase: [supercritical carbon dioxide-ispropanol (0.1% ammonia)]; isocratic elution: 50% isporopanol (0.1% ammonia)) to obtain 039. 1H NMR (400 MHz, CD3OD) δ ppm 8.41 (s, 1 H), 8.26 (s, 1 H), 7.87 (s, 1 H), 7.80 (d, J = 8.80 Hz, 1 H), 7.73 (br d, J = 8.80 Hz, 1 H), 7.05 - 7.33 (m, 1 H), 6.99 (s, 1 H), 5.24 (br t, J = 5.56 Hz, 1 H),. Petition 870260002323, dated 09 / 01 / 2026, pp. 374 / 413 151 / 189 3.83 (s, 3 H), 2.62 - 2.76 (m, 2 H), 2.24 - 2.31 (m, 2 H), 2.03 (br d, J = 11.98 Hz, 1 H), 1.78 - 1.91 (m, 3 H), 1.20 (t, J = 7.64 Hz, 3 H). ESI-LCMS: m / z = 412.2 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak AD-3, 50x4.6 mm ID, 3 μm; mobile phase: A: CO2, B: isopropanol (0.2% 7 M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 1.808 minutes.

[0661] Example 33

[0662] Synthetic route:

[0663] Step 1: synthesis of compound 040-2

[0664] To a reaction flask, 040-1 (5 g, 36.45 mmol), triethylamine (4.06 g, 40.09 mmol), and dichloromethane (100 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of a solution of 035-2 (5.47 g, 40.09 mmol) in dichloromethane (7.5 mL). The mixture was stirred at 25°C for 10 minutes. The reaction mixture was dried on a rotary evaporator, dissolved in ethyl acetate (100 mL), and washed sequentially once each with 1 N citric acid (50 mL) and saturated brine (50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 040-2, which was used directly in the next step without further purification. 1H NMR (400 MHz, CDCL) δ = 7.19 - 7.11 (m, 2H), 6.97 - 6.88 Petition 870260002323, dated 09 / 01 / 2026, pp. 375 / 413 152 / 189 (m, 2H), 3.83 (s, 3H), 3.68 (s, 3H), 3.27 (s, 3H), 3.22 (s, 2H).

[0665] Step 2: synthesis of compound 040-3

[0666] Crude 040-2 (8.5 g), an aqueous solution of sodium hydroxide (1 M, 42.50 mL), and methanol (42.5 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, and the mixture was stirred at 25°C for 2 hours. The reaction mixture was concentrated and extracted once with ethyl acetate (30 mL). The aqueous phase was collected, and its pH was adjusted to 3-4 with 1N hydrochloric acid. The mixture was extracted three times with ethyl acetate (50 mL each time). The organic phases were combined and washed with saturated brine (50 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 040-3, which was used directly in the next step. 1H NMR (400 MHz, CDCb) δ = 7.14 - 7.07 (m, 2H), 7.00 - 6.94 (m, 2H), 3.85 (s, 3H), 3.32 (s, 3H), 3.13 (s, 2H).

[0667] Step 3: synthesis of compound 040-4

[0668] Crude 040-3 (8 g) and Eaton's reagent (60.60 g, 254.57 mmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen and the mixture was stirred at 70°C for 3 hours. The reaction mixture was cooled to 25°C, poured into ice-cold water (250 mL) and filtered. The filter cake was collected. The mixture was added with acetonitrile (100 mL), stirred for 0.5 hours and filtered. The filter cake was collected to obtain 040-4. 1H NMR (400 MHz, DMSO-d6) δ = 11.52 (br s, 1H), 7.46 (d, J = 9.3 Hz, 1H), 7.34 (d, J = 3.0 Hz, 1H), 7.27 (dd, J = 3.0, 9.1 Hz, 1H), 5.95 (s, 1H), 3.81 (s, 3H), 3.54 (s, 3H).

[0669] Step 4: Synthesis of Compound 040-5

[0670] Phosphorus tribromide (8.59 g, 29.97 mmol) and N,N-dimethylformamide (41 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of portions of compound 040-4 (4.1 g, 19.98 mmol). The mixture was stirred at 80°C for 3 hours. The reaction mixture was cooled to 25°C and poured Petition 870260002323, dated 09 / 01 / 2026, pp. 376 / 413 153 / 189 in ice water (200 mL) and filtered. The filtration cake was collected and dried to obtain 040-5, which was used directly in the next step. 1H NMR (400 MHz, CDCL) δ = 7.44 (d, J = 2.9 Hz, 1H), 7.34 - 7.31 (m, 1H), 7.26 - 7.22 (m, 1H), 7.17 (s, 1H), 3.92 (s, 3H), 3.71 (s, 3H).

[0671] Step 5: synthesis of compound 040-6

[0672] To a reaction flask, 040-5 (1 g, 3.73 mmol), N-fluorobenzenesulfonimide (2.35 g, 7.46 mmol), and tetrahydrofuran (30 mL) were sequentially added. After purging the atmosphere with nitrogen, the mixture was cooled to -78°C and n-butyllithium (2.5 M, 4.48 mL) was added. The mixture was stirred at -78°C for 1 hour. Water (10 mL) was added to dilute the reaction mixture, followed by extraction with ethyl acetate three times (10 mL each time). The organic phases were combined, washed with saturated brine (10 mL), and the organic phase was collected. It was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1:0 to 1:1) to obtain 040-6. 1H NMR (400 MHz, CDCL) δ = 7.38 - 7.32 (m, 1H), 7.28 (d, J = 2.9 Hz, 1H), 7.26 - 7.24 (m, 1H), 6.43 (d, J = 11.3 Hz, 1H), 3.90 (s, 3H), 3.70 (s, 3H).

[0673] Step 6: synthesis of compound 040-7

[0674] To a reaction flask, 040-6 (170 mg, 820.46 μmol) and dichloromethane (4 mL) were sequentially added. The atmosphere was purged with nitrogen and the mixture was cooled to 0°C, followed by the addition of boron tribromide (2 M solution in dichloromethane, 1.64 mL). The mixture was stirred at 0°C for 1 hour. The reaction mixture was concentrated to obtain 040-7 and the crude product was used directly in the next step.

[0675] Step 7: synthesis of compound 040-8

[0676] Crude 040-7 (0.16 g) was added sequentially to a reaction flask. Petition 870260002323, dated 09 / 01 / 2026, pp. 377 / 413 154 / 189 and dichloromethane (6 mL). After the atmosphere was purged with nitrogen, the mixture was kept at 0°C, followed by the addition of pyridine (196.55 mg, 2.48 mmol) and trifluoromethanesulfonic anhydride (467.37 mg, 1.66 mmol). The mixture was stirred at 0°C for 0.5 hours. The reaction mixture was added with water (2 mL) and extracted three times with dichloromethane (2 mL each time). The organic phases were combined and washed with saturated brine (5 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether:ethyl acetate = 1:1) to obtain 040-8. 1H NMR (400 MHz, CDCh) δ = 7.75 (d, J = 2.8 Hz, 1H), 7.61 - 7.55 (m, 1H), 7.51 - 7.46 (m, 1H), 6.52 (d, J = 10.9 Hz, 1H), 3.72 (s, 3H).

[0677] Step 8: synthesis of compound 040-9

[0678] To a reaction flask, 040-8 (150 mg, 461.20 μmol), pinacol boronate (175.68 mg, 691.81 μmol), potassium acetate (135.79 mg, 1.38 mmol), and 1,4-dioxane (3 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (33.75 mg, 46.12 pmol). The mixture was stirred at 90°C for 4 hours. The reaction mixture was concentrated to obtain crude 040-9, which was used directly in the next step.

[0679] Step 9: synthesis of compound 040

[0680] Crude 040-9 (135.42 mg), A-1 (115 mg, 406.13 pmol), sodium carbonate (86.09 mg, 812.25 μmol), water (0.5 mL), and ethanol (3 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of tetrakis(triphenylphosphine)palladium (46.93 mg, 40.61 pmol). The mixture was stirred at 85°C for 1 hour. The reaction mixture was concentrated to obtain a crude product. The crude product was sequentially purified by column chromatography (ethyl acetate:methanol = 1:0 to 20:1), preparative thin-layer chromatography (dichloromethane:ethyl acetate:methanol = 5:5:1), and high-performance preparative liquid chromatography. Petition 870260002323, dated 09 / 01 / 2026, pp. 378 / 413 155 / 189 (chromatographic column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (ammonium bicarbonate 10 mM)-acetonitrile]; gradient: 20%-50% acetonitrile) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK AD, 250 mm*30 mm, 10 pm; mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia)]; isocratic elution: 50% isopropanol (0.1% ammonia)) to obtain 040. 1H NMR (400 MHz, CDCl3) δ = 8.56 (s, 1H), 8.33 (s, 1H), 7.76 (d, J = 1.7 Hz, 1H), 7.64 - 7.56 (m, 1H), 7.53 - 7.46 (m, 1H), 6.46 (d, J = 11.0 Hz, 1H), 5.80 (br d, J = 8.7 Hz, 1H), 5.46 - 5.32 (m, 1H), 3.75 (s, 3H), 2.74 - 2.55 (m, 2H), 2.30 (q, J = 7.6 Hz, 2H), 2.15 - 2.08 (m, 1H), 1.91 - 1.76 (m, 3H), 1.23 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 380.2 [M+H]+. The analysis of SFC was performed (chromatographic column: Chiralpak AD-3, 50χ4.6 mm ID, 3 pm; mobile phase: A: supercritical carbon dioxide, B: isopropanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 1.484 minutes.

[0681] Example 34

[0682] Synthetic route:

[0683] Step 1: synthesis of compound 041-2

[0684] To a reaction flask, 041-1 (0.85 g, 4.98 mmol) and sodium methoxide (5.4 M in methanol, 8.5 mL) were sequentially added. The mixture was stirred at 80°C. Petition 870260002323, dated 09 / 01 / 2026, pp. 379 / 413 156 / 189 for 1 hour. The reaction mixture was allowed to return to 25°C, water (5 mL) was added, and it was extracted with 10 mL of dichloromethane. The organic phase was collected, and the aqueous phase was extracted with dichloromethane (10 mL x 3). The organic phases were combined and washed with saturated brine (10 mL x 2). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain crude 041-2, which was used directly in the next step. 1H NMR (400 MHz, CDCL) δ = 8.88 (s, 1H), 8.21 (d, J = 8.9 Hz, 1H), 6.91 (d, J = 8.9 Hz, 1H), 4.03 (s, 3H).

[0685] Step 2: synthesis of compound 041-3

[0686] Crude 041-2 (0.26 g) and hydrobromic acid (58.70 g, 239.40 mmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen and the mixture was stirred at 130°C for 2 hours. The reaction mixture was returned to 25°C, concentrated to obtain crude 041-3, which was used directly in the next step. 1H NMR (400 MHz, DMSO-d6) δ= 9.10 (s, 1H), 8.21 (d, J = 9.0 Hz, 1H), 6.72 (d, J = 9.0 Hz, 1H).

[0687] Step 3: synthesis of compound 041-4

[0688] Crude 041-3 (0.38 g), N,N-dimethylformamide (8 mL), and potassium carbonate (690.26 mg, 4.99 mmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, and the mixture was cooled to 0°C, followed by the addition of methyl iodide (1.42 g, 9.99 mmol). The mixture was stirred at 0°C for 2 hours, then 10 mL of water was added, and 10 mL of ethyl acetate was extracted. The resulting phases were separated. The organic phase was collected, and the aqueous phase was extracted with ethyl acetate (30 mLχ3). The organic phases were combined and washed with saturated brine (30 mLχ2). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:0) to obtain 041-4. 1H NMR (400 MHz, CDCl3) δ = 8.58 (s, 1H), 8.00 (d, J = 9.7 Hz, 1H), 6.68 (d, J = 9.5 Hz, 1H), 3.74 (s, 3H). Petition 870260002323, dated 09 / 01 / 2026, pages 380 / 413 157 / 189

[0689] Step 4: Synthesis of Compound 041-5

[0690] To a reaction flask, 041-4 (50 mg, 300.84 μmol) and tetrahydrofuran (1 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of zinc chloride (0.7 M in tetrahydrofuran, 429.77 pL). The mixture was cooled to -5°C and lithium bis(trimethylsilyl)amide (1 M in tetrahydrofuran, 601.68 pL) was added dropwise. The mixture was then heated to 10°C and stirred for 1 hour. The 041-5 reaction mixture was used directly in the next step without further treatment.

[0691] Step 5: Synthesis of Compound 041

[0692] A-1 (85.15 mg, 300.71 pmol) and N,N-dimethylformamide (3 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of methanesulfonate(2-dicyclohexylphosphino-2',6'-dimethoxy-1,r-biphenyl)(2'amino-1,1'-biphenyl-2-yl)palladium(II) (7.04 mg, 9.02 pmol). The atmosphere was again purged with nitrogen. The temperature was increased to 100°C and the reaction mixture from 041-5 was added. The mixture was stirred at 100°C for 12 hours. The reaction mixture was concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (ethyl acetate:dichloromethane:methanol = 1:1:0.3) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 pm); mobile phase: [supercritical methanol carbon dioxide (0.1% ammonia)]; gradient: 45% to 54% methanol (0.1% ammonia)) to obtain 041.1H NMR (400 MHz, CD3OD) δ = 8.71 (s, 1H), 8.48 (s, 1H), 8.13 (d, J = 9.5 Hz, 1H), 6.69 (d, J = 9.5 Hz, 1H), 5.24 (br s, 1H), 3.80 (s, 3H), 3.18 (br s, 1H), 3.15 - 3.10 (m, 1H), 2.29 (dq, J = 1.5, 7.6 Hz, 2H), 2.09 - 1.84 (m, 5H), 1.19 (t, J = 7.7 Hz, 3H); ESI-LCMS: m / z = 369.1 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak AD-3, 50χ4.6 mm ID, 3 pm; mobile phase: A: supercritical carbon dioxide, B: methanol (0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min). Petition 870260002323, dated 09 / 01 / 2026, pp. 381 / 413 158 / 189 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 1,968 minutes.

[0693] Example 35

[0694] Synthetic route:

[0695] Step 1: synthesis of compound 042-3

[0696] To a reaction flask, 2-di-tert-butylphosphino2',4',6'-tri-isopropylbiphenyl (530.70 mg, 1.11 mmol), palladium acetate (124.97 mg, 556.62 μmol), and N,N-dimethylformamide (74 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of 042-1 (3.7 g, 11.13 mmol), triethylamine (9.01 g, 89.06 mmol), and 042-2 (10.83 g, 66.79 mmol). The atmosphere was purged again with nitrogen, and the mixture was stirred at 100°C for 16 hours. The reaction mixture was cooled to 25°C, water (370 mL) was added, and it was extracted with ethyl acetate (50 mL x 3). The organic phases were collected and washed with saturated brine (100 mL x 2). The collected organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (petroleum ether: ethyl acetate = 1:0 to 5:1) to obtain O42-3.1H NMR (400 MHz, DMSO-d6) δ = 7.71 (d, J = 16.5 Hz, 1H), 7.47 - 7.33 (m, 6H), 6.68 (d, J = 8.9 Hz, 1H), 6.48 (d, J = 16.4 Hz, 1H), 5.85 (s, 2H), 5.24 (s, 2H).

[0697] Step 2: synthesis of compound 042-4

[0698] O42-3 (2.18 g, 5.95 mmol), methanol (22 mL), and tributylphosphine (3.61 g, 17.84 mmol) were sequentially added to a reaction flask. The mixture was stirred to Petition 870260002323, dated 09 / 01 / 2026, pp. 382 / 413 159 / 189 70°C for 1.5 hours. The reaction mixture was concentrated directly to obtain crude O424, which was used directly in the next step. 1H NMR (400 MHz, DMSO-d6) δ = 12.14 (br s, 1H), 8.10 (d, J = 9.9 Hz, 1H), 7.82 (d, J = 8.9 Hz, 1H), 7.31 (s, 1H), 6.66 (d, J = 9.8 Hz, 1H).

[0699] Step 3: synthesis of compound 042-5

[0700] Crude 042-4 (5.5 g), N,N-dimethylformamide (55 mL), and potassium carbonate (5.88 g, 42.55 mmol) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen, followed by the addition of methyl iodide (12.08 g, 85.11 mmol). The mixture was stirred at 25°C for 16 hours. The reaction mixture was added with water (50 mL) and filtered. The filter cake was collected to obtain a crude product. The crude product was purified by column chromatography (petroleum ether:ethyl acetate = 1:0 to 3:1) to obtain 042-5. 1H NMR (400 MHz, DMSO-d6) δ = 8.14 (d, J = 9.9 Hz, 1H), 7.93 (d, J = 9.1 Hz, 1H), 7.49 (d, J = 9.3 Hz, 1H), 6.78 (d, J = 9.9 Hz, 1H), 3.61 (s, 3H).

[0701] Step 4: synthesis of compound 042-6

[0702] To a reaction flask, 042-5 (200 mg, 733.88 μmol), pinacol boronate (279.54 mg, 1.10 mmol), 1,4-dioxane (4 mL), and potassium acetate (144.05 mg, 1.47 mmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (53.70 mg, 73.39 μmol). The atmosphere was purged again with nitrogen, and the mixture was stirred at 80°C for 16 hours. The reaction mixture was cooled to 25°C and filtered. The filter cake was rinsed with dichloromethane. The filtrate was collected and concentrated under reduced pressure to obtain crude 042-6, which was used directly in the next step.

[0703] Step 5: Synthesis of Compound 042

[0704] A-1 (141.76 mg, 500.64 μmol), water (1.2 mL), acetonitrile (3.6 mL), methanol (1.2 mL), carbonate were added sequentially to a reaction flask. Petition 870260002323, dated 09 / 01 / 2026, pages 383 / 413 160 / 189 potassium (276.77 mg, 2.00 mmol) and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (30.83 mg, 75.10 μmol). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) chloride (17.57 mg, 25.03 μmol) and palladium acetate (5.62 mg, 25.03 μmol). The temperature was increased to 40°C and a crude solution of 042-6 (240 mg) in tetrahydrofuran (7.2 mL) was added. The atmosphere was again purged with nitrogen and the mixture was heated to 75°C and stirred for 2 hours. The reaction mixture was filtered and rinsed with dichloromethane. The filtrate was collected and concentrated under reduced pressure. The resulting product was purified by preparative high-performance liquid chromatography (chromatographic column: 2_Phenomenex Gemini C18, 75*40 mm*3 μm; mobile phase: [water (ammonium bicarbonate 10 mM)-acetonitrile]; gradient: 10% to 40% acetonitrile) to obtain 042.1H NMR (400 MHz, DMSO-d6) δ = 8.41 (s, 1H), 8.38 - 8.25 (m, 1H), 8.25 - 8.17 (m, 2H), 7.70 - 7.63 (m, 1H), 7.62 - 7.46 (m, 1H), 6.82 (d, J = 9.9 Hz, 1H), 5.11 (br d, J = 6.3 Hz, 1H), 3.69 (s, 3H), 2.40 - 2.31 (m, 2H), 2.23 - 2.13 (m, 2H), 1.92 - 1.65 (m, 4H), 1.07 (dt, J = 3.8, 7.6Hz, 3H); ESI-LCMS: m / z = 396.1 [M+H]+.

[0705] Example 36

[0706] Synthetic route: 043-4 Cl N 043-5

[0707] Step 1: synthesis of compound 043-3

[0708] To a reaction flask, 043-1 (500 mg, 1.97 mmol), dichloromethane (5 mL), and pyridine (187.19 mg, 2.37 mmol) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of 043-2 (291.91 mg, 2.17 mmol). The mixture was Petition 870260002323, dated 09 / 01 / 2026, pages 384 / 413 161 / 189 stirred at 20°C for 3 hours. The reaction mixture was concentrated to obtain a crude product, which was then purified by silica gel column chromatography (petroleum ether: ethyl acetate = 5:1 to 1:1) to obtain 043-3. 1H NMR (400 MHz, CDCh) δ = 7.74 - 7.57 (m, 3H), 7.42 (dd, J = 1.8, 8.2 Hz, 1H), 5.29 (d, J = 12.0 Hz, 1H), 3.96 (q, J = 7.0 Hz, 2H), 1.36 (s, 15H).

[0709] Step 2: synthesis of compound 043-4

[0710] To a reaction flask were added sequentially 043-3 (149.02 mg, 423.78 μmol), potassium carbonate (195.24 mg, 1.41 mmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (21.75 mg, 52.97 μmol), bis(triphenylphosphine)palladium(II) dichloride (12.39 mg, 17.66 μmol), palladium acetate (3.96 mg, 17.66 μmol), water (1.6 mL), acetonitrile (4.8 mL) and methanol (1.6 mL). The atmosphere was purged with nitrogen and the mixture was heated to 45°C, followed by the addition of a solution of A-1 (100 mg, 353.15 μmol) in tetrahydrofuran (1.6 mL). The reaction mixture was further heated to 75°C and stirred for 2 hours. The reaction mixture was added to 2 mL of water and extracted with dichloromethane (3 mLχ3). The organic phases were combined and washed with saturated brine (3 mLχ3). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was purified by preparative thin layer chromatography (dichloromethane: ethyl acetate: methanol = 1:1:0.3) to obtain 043-4. 1H NMR (400 MHz, CDCh) δ = 8.57 (br d, J = 2.1 Hz, 1H), 8.41 - 8.09 (m, 1H), 7.69 (dd, J = 3.1, 12.0 Hz, 1H), 7.62 - 7.49 (m, 1H), 7.40 7.32 (m, 1H), 5.54 - 5.42 (m, 1H), 5.40 - 5.32 (m, 1H), 5.31 - 5.23 (m, 1H), 4.14 - 3.91 (m, 2H), 3.02 - 2.91 (m, 2H), 2.44 - 2.28 (m, 4H), 2.21 - 2.12 (m, 2H), 1.39 (br t, J = 6.7 Hz, 3H), 1.23 - 1.19 (m, 3H).

[0711] Step 3: synthesis of compound 043-5

[0712] Concentrated sulfuric acid (1.5 mL) was added to a reaction flask. The mixture was cooled to 0°C, followed by the addition of compound 043-4 (90 mg, 210.32 μmol). Petition 870260002323, dated 09 / 01 / 2026, pages 385 / 413 162 / 189 The atmosphere was purged with nitrogen and the mixture was stirred at 25°C for 2 hours. The reaction mixture was added with water and its pH was adjusted to 7-8 with a saturated aqueous solution of sodium bicarbonate. It was then extracted with ethyl acetate (3 mL x 3). The organic phases were combined and washed with saturated brine (3 mL x 3). The organic phase was collected, then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain crude O43-5, which was used directly in the next step. 1H NMR (400 MHz, CD3OD) δ = 8.44 (s, 1H), 8.25 (d, J = 4.5 Hz, 1H), 8.17 (s, 1H), 7.97 (d, J = 9.6 Hz, 1H), 7.66 - 7.58 (m, 1H), 7.18 (d, J = 5.4 Hz, 1H), 5.31 - 5.18 (m, 1H), 2.88 - 2.79 (m, 2H), 2.56 - 2.47 (m, 2H), 2.27 - 2.22 (m, 2H), 2.05 - 1.99 (m, 2H), 1.18 (s, 3H).

[0713] Step 4: synthesis of compound 043

[0714] Crude 043-5 (40 mg), N,N-dimethylformamide (0.5 mL), and cesium carbonate (68.26 mg, 209.50 μmol) were sequentially added to a reaction flask. The mixture was cooled to 0°C, followed by the addition of methyl iodide (22.30 mg, 157.13 μmol). The atmosphere was purged with nitrogen, and the mixture was stirred at 0°C for 1 hour. The reaction mixture was poured into 2 mL of water and extracted three times with ethyl acetate (3 mL each time). The organic phases were combined and washed with saturated brine (3 mL each time). The organic phase was collected, then dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product.The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane: ethyl acetate: methanol = 1:1:0.3) and chiral resolution SFC (chromatographic column: ChiralPak IH, 250*30 mm, 10 μm; mobile phase: [carbon dioxide-supercritical isopropanol (0.1% ammonia)]; isocratic elution: 50% isopropanol (0.1% ammonia)) to obtain 043. 1H NMR (400 MHz, DMSO-d6) δ = 8.41 (s, 1H), 8.39 - 8.25 (m, 1H), 8.21 (s, 1H), 7.93 (dd, J = 9.7, 18.6 Hz, 1H), 7.82 - 7.61 (m, 2H), 6.74 - 6.62 (m, 1H), 5.18 - 5.04 (m, 1H), 3.65 (s, 3H), 2.42 - 2.33 (m, 2H), 2.25 - 2.10 (m, 2H), 1.95 - 1.74 (m, 2H), 1.74 - 1.61 (m, 2H),. Petition 870260002323, dated 09 / 01 / 2026, pages 386 / 413 163 / 189 1.07 (dt, J = 3.4, 7.5 Hz, 3H); ESI-LCMS: m / z = 396.1 [M+H]+. SFC analysis was performed (chromatographic column: CHIRALPAK IH-3, 100x4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: isopropanol (0.2% 7M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.2 min), 50 / 50 (2.4 min), 50 / 50 (3.4 min), 90 / 10 (4.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 2000 psi), ee = 93.92%, retention time: 3.194 minutes.

[0715] Example 37

[0716] Synthetic route:

[0717] Step 1: synthesis of compound 044

[0718] To a reaction flask were added sequentially 001-3 (120.00 mg, 420.85 μmol), water (1 mL), acetonitrile (3 mL), methanol (1 mL), potassium carbonate (193.89 mg, 1.40 mmol) and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (21.60 mg, 52.61 μmol). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (12.31 mg, 17.54 μmol) and palladium(II) acetate (3.94 mg, 17.54 pmol). The atmosphere was again purged with nitrogen. The reaction mixture was heated to 45°C and a solution of O37-10 (100 mg, 350.71 pmol) in tetrahydrofuran (6 mL) was added. The reaction mixture was heated to 75°C and stirred for 16 hours.The reaction mixture was concentrated to obtain a crude product, which was sequentially subjected to preparative thin-layer chromatography (petroleum ether: ethyl acetate = 0:1), a second preparative thin-layer chromatography (dichloromethane: methanol = 10:1) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK AD (250. Petition 870260002323, dated 09 / 01 / 2026, pp. 387 / 413 164 / 189 mm*30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-isopropanol (0.1% ammonia)]; isocratic elution: 40% isopropanol (0.1% ammonia)) to obtain 044. 1H NMR (400 MHz, CD3OD) δ = 8.31 (d, J = 15.0 Hz, 2H), 7.98 (d, J = 9.5 Hz, 1H), 7.90 7.84 (m, 2H), 7.68 (s, 1H), 6.72 (d, J = 9.5 Hz, 1H), 5.24 (s, 1H), 4.53 - 4.28 (m, 2H), 3.79 (s, 3H), 2.33 - 2.26 (m, 2H), 2.25 - 2.07 (m, 2H), 1.19 (t, J = 7.6 Hz, 3H); ESILCMS: m / z = 364.2 [M+H]+. SFC analysis was performed (chromatographic column: Chiralcel AD-3, 150x4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: isopropanol (0.2% 7M ammonia in methanol); gradient: A / B = 90 / 10 (0 min), 90 / 10 (0.5 min), 50 / 50 (3.5 min), 50 / 50 (4.5 min), 90 / 10 (5.0 min); flow rate: 2.5 mL / min; column temperature: 35°C; pressure: 2000 psi), ee = 100%, retention time: 3.894 minutes.

[0719] Example 38

[0720] Synthetic route:

[0721] Step 1: Synthesis of compound 045-1

[0722] To a reaction flask, O23-1 (120 mg, 491.59 μmol), triisopropyl borate (309.72 mg, 1.65 mmol), and tetrahydrofuran (1.2 mL) were sequentially added. The atmosphere was purged with nitrogen and the mixture was cooled to -5°C, followed by the addition of isopropylmagnesium chloride-lithium chloride complex (1.3 M, 567.21 μL). The mixture was stirred at -5°C for 0.5 hours. Additional isopropylmagnesium chloride-lithium chloride complex (1.3 M in tetrahydrofuran, 378.14 μL) was added and the mixture was stirred at -5°C for 1 hour. Additional isopropylmagnesium chloride-lithium chloride complex (1.3 M in tetrahydrofuran, 567.21 pL) and triisopropyl borate (92.45 mg, 491.59 pmol) were added, and the mixture was stirred at 0°C for 0.5 hours. Petition 870260002323, dated 09 / 01 / 2026, pages 388 / 413 165 / 189 reaction mixture was added to 0.9 mL of methanol and the resulting 045-1 mixture was used directly in the next step.

[0723] Step 2: Synthesis of compound 045

[0724] To a reaction flask were added sequentially 037-10 (69.57 mg, 243.98 μmol), tetrahedrofuran (0.9 mL), water (0.3 mL), acetonitrile (0.3 mL), potassium carbonate (134.88 mg, 975.94 μmol) and 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (15.02 mg, 36.60 μmol). The atmosphere was purged with nitrogen, followed by the addition of bis(triphenylphosphine)palladium(II) dichloride (8.56 mg, 12.20 μmol) and palladium(II) acetate (2.74 mg, 12.20 μmol). The atmosphere was again purged with nitrogen. The reaction mixture was added to a reaction mixture of 045-1 at 45°C, then heated to 75°C and stirred for 16 hours. The reaction mixture was concentrated to obtain a crude product.The crude product was sequentially purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 0:1), a second preparative thin-layer chromatography (dichloromethane: methanol = 10:1), and high-performance preparative liquid chromatography (chromatographic column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (ammonium bicarbonate 10 mM)-acetonitrile]; gradient: 10% to 43% acetonitrile) to obtain 045. 1H NMR (400 MHz, CD3OD) δ = 8.67 (s, 1H), 8.28 - 8.19 (m, 1H), 7.97 - 7.90 (m, 1H), 7.74 (s, 1H), 6.56 (d, J = 9.3 Hz, 1H), 5.23 (s, 1H), 4.66 - 4.46 (m, 2H), 3.76 (s, 3H), 2.32 - 2.27 (m, 2H), 2.26 (br s, 2H), 1.19 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z = 370.1 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak AD-3, 50x4.6 mm ID, 3 pm; mobile phase: A: supercritical carbon dioxide, B: 0.2% 7M ammonia in methanol); gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 1.479 minutes.

[0725] Example 39 Petition 870260002323, dated 09 / 01 / 2026, pp. 389 / 413 166 / 189

[0726] Synthetic route:

[0727] Step 1: Synthesis of compound 046-1

[0728] To a reaction flask, 017-8 (0.25 g, 1.02 mmol) and tetrahydrofuran (6.25 mL) were sequentially added. The atmosphere was purged with nitrogen and the mixture was frozen at -15 to -20°C, followed by the dropwise addition of isopropylmagnesium chloride-lithium chloride complex (1.3 M in tetrahydrofuran, 1.95 mL). The mixture was stirred at -15 to -20°C for 0.5 hours. Triisopropyl borate (353.59 mg, 3.40 mmol) was added and the mixture was stirred for a further 0.5 hours. 0.5 mL of methanol was added to the reaction mixture and the resulting 046-1 reaction mixture was used directly in the next step.

[0729] Step 2: Synthesis of compound 046

[0730] To a reaction flask, 037-10 (0.13 g, 455.92 μmol), potassium phosphate (193.56 mg, 911.84 μmol), isopropanol (7.2 mL), and water (1.2 mL) were sequentially added. The atmosphere was purged with nitrogen, followed by the addition of dichlorodi-tert-butyl-(4-dimethylaminophenyl)phosphine palladium(II) (32.28 mg, 45.59 μmol). The atmosphere was again purged with nitrogen, and the mixture was heated to 45°C, followed by the addition of the 046-1 reaction mixture described above. After the addition was complete, the mixture was heated to 75°C and stirred for 2 hours. The reaction mixture was filtered through anhydrous sodium sulfate. The filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially purified by column chromatography (petroleum ether: ethyl acetate = 10:1 to dichloromethane: methanol = 1:1) and preparative high-performance liquid chromatography (chromatographic column: Waters Xbridge BEH C18 100*30 mm*10 μm; mobile phase: [water (ammonium bicarbonate 10 mM)-acetonitrile]; 15% to 50%). Petition 870260002323, dated 09 / 01 / 2026, pages 390 / 413 167 / 189 acetonitrile, isocratic elution) to obtain 046. 1H NMR (400 MHz, CD3OD) δ = 8.57 (br s, 1H), 8.14 (br s, 1H), 7.36 (s, 1H), 5.19 (t, J = 5.5 Hz, 1H), 4.64 - 4.42 (m, 2H), 3.34 (s, 3H), 2.93 - 2.84 (m, 2H), 2.77 - 2.66 (m, 2H), 2.34 - 2.08 (m, 4H), 1.18 (t, J = 7.6 Hz, 3H); ESI-LCMS: m / z =372.2 [M+H] +; SFC analysis was performed (chromatographic column: Chiralpak AD-3, 50χ4.6 mm ID, 3 μm; mobile phase: A: supercritical carbon dioxide, B: 0.2% 7M ammonia in methanol; gradient: A / B = 95 / 5 (0 min), 95 / 5 (0.2 min), 50 / 50 (1.2 min), 50 / 50 (2.2 min), 95 / 5 (2.6 min), 95 / 5 (3.0 min); flow rate: 3.4 mL / min; column temperature: 35°C; pressure: 1800 psi), ee = 100%; retention time: 1.431 minutes.

[0731] Example 40

[0732] Synthetic route:

[0733] ​​Step 1: synthesis of compound 047-2

[0734] To a reaction flask, 047-1 (350 mg, 2.06 mmol), methanol (7 mL), and sodium methoxide (5.4 M in methanol, 2 mL) were sequentially added. The mixture was heated to 100°C in a microwave reactor and stirred for 5 hours. Three batches of the same scale reaction were conducted in parallel and combined for processing. After combining the reaction mixture and concentration, 20 mL of water and 20 mL of ethyl acetate were added. The mixture was extracted, and the resulting phases were separated. The aqueous phase was collected and extracted with ethyl acetate (10 mLχ2). The organic phases were combined and washed with saturated brine. The phase Petition 870260002323, dated 09 / 01 / 2026, pages 391 / 413 168 / 189 organic matter was collected, dried over anhydrous sodium sulfate, filtered and concentrated to obtain crude 047-2. 1H NMR (400 MHz, CDCL) δ ppm 8.00 (d, J = 8.53 Hz, 1H), 7.67 (d, J = 5.52 Hz, 1H), 7.41 (d, J = 5.52 Hz, 1H), 6.77 (d, J = 8.53 Hz, 1H), 4.02 (s, 3H).

[0735] Step 2: synthesis of compound 047-3

[0736] To a reaction flask, 047-2 (0.9 g), acetic acid (9 mL), and hydrobromic acid (9 mL, 66.29 mmol, 40% concentration) were sequentially added. After the atmosphere was purged with nitrogen, the mixture was stirred at 85°C for 18 hours. The reaction mixture was concentrated under reduced pressure to obtain crude 047-3. 1H NMR (400 MHz, CD3OD) δ ppm 8.73 (d, J = 9.29 Hz, 1H), 8.32 (d, J = 5.52 Hz, 1H), 7.44 (d, J = 5.52 Hz, 1H), 7.07 (d, J = 9.03 Hz, 1H).

[0737] Step 3: synthesis of compound 047-4

[0738] To a reaction flask, 047-3 (1.43 g) and N,N-dimethylformamide (30 mL) were sequentially added, followed by the addition of potassium tert-butoxide (3.18 g, 28.38 mmol) at 0 °C. The mixture was stirred at 0 °C for 15 minutes, followed by the dropwise addition of iodomethane (1.47 mL, 23.65 mmol). The mixture was heated to 20 °C and stirred for 18 hours. The mixture was diluted with 40 mL of ethyl acetate, added with 80 mL of hydrochloric acid (1 M), and extracted. The resulting phases were separated. The aqueous phase was extracted with ethyl acetate (40 mLχ5). The organic phases were combined and washed with saturated brine (140 mLχ3). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain a crude product. The crude product was purified by column chromatography (ethyl acetate:petroleum ether = 10 to 100%) to obtain O47-4.1H NMR (400 MHz, CD3OD) δ ppm 7.97 (d, J = 9.29 Hz, 1H), 7.89 (d, J = 5.52 Hz, 1H), 7.32 (d, J = 5.52 Hz, 1H), 6.55 (d, J = 9.29 Hz, 1H), 3.75 (s, 3H).

[0739] Step 4: Synthesis of Compound 047-5

[0740] To a reaction balloon were added sequentially 047-4 (213 mg, 1.29 Petition 870260002323, dated 09 / 01 / 2026, pp. 392 / 413 169 / 189 mmol) and tetrahydrofuran (12 mL). The atmosphere was purged with nitrogen and the mixture was cooled to 0°C, followed by the addition of a solution of N-bromosuccinimide (210 mg, 1.18 mmol) in tetrahydrofuran (12 mL). The mixture was stirred at 0°C for 1 hour. The reaction mixture was added with a semi-saturated aqueous solution of sodium thiosulfate (40 mL), stirred at 25°C for 5 minutes and extracted with ethyl acetate (20 mL x 3). The organic phase was collected, dried over anhydrous sodium sulfate, filtered and concentrated to obtain a crude product, which was separated and purified by preparative thin-layer chromatography (petroleum ether: ethyl acetate = 1:5) to obtain O47-5. 'H NMR (400 MHz, CDCh) δ ppm 8.14 (s, 1H), 7.62 (d, J= 5.52 Hz, 1H), 7.06 (d, J= 5.52 Hz, 1H) ,3.81 (s, 3H).

[0741] Step 5: synthesis of compound 047-6

[0742] To a reaction flask, 047-5 (174 mg, 712.80 pmol) and tetrahydrofuran (4 mL) were sequentially added. The atmosphere was purged with nitrogen. The mixture was cooled to 0°C and isopropylmagnesium chloride-lithium chloride complex (2 M in tetrahydrofuran, 534.60 pL) was added dropwise. The mixture was stirred at 20°C for 0.5 hours. The mixture was cooled to 0°C and a solution of trimethyl borate (161.02 pL, 1.43 mmol) in tetrahydrofuran (4 mL) was added dropwise. The mixture was heated to 20°C and stirred for 0.5 hours. 1 mL of methanol was added to the reaction mixture and the resulting 047-6 mixture was used directly in the next step.

[0743] Step 6: Synthesis of Compound 047

[0744] Al (222.03 mg, 784.10 pmol), potassium carbonate (394.06 mg, 2.85 mmol), 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl (43.89 mg, 106.92 pmol), acetonitrile (8 mL), and water (1.6 mL) were sequentially added to a reaction flask. After purging the atmosphere with nitrogen, bis(triphenylphosphine)palladium(II) chloride (25.02 mg, 35.64 pmol) and palladium(II) acetate (8.00 mg, 35.64 pmol) were added. After purging the atmosphere with nitrogen, the reaction mixture described in 047-6 was obtained. Petition 870260002323, dated 09 / 01 / 2026, pages 393 / 413 170 / 189 above was added dropwise. After the addition was complete, the mixture was heated to 75°C and stirred for 1 hour. The reaction mixture was filtered through a funnel containing anhydrous sodium sulfate, and the filtrate was collected and concentrated to obtain a crude product. The crude product was sequentially purified by preparative thin-layer chromatography (dichloromethane:methanol = 15:1) and chiral resolution SFC [chromatographic column: DAICEL CHIRALCEL OJ (250 mm*30 mm, 10 μm); mobile phase: [carbon dioxide-supercritical ethanol (0.1% ammonia)]; isocratic elution: 25% ethanol (0.1% ammonia)], preparative high-performance liquid chromatography [chromatographic column: Welch Xtimate C18 150*30 mm*5 μm; Mobile phase: [water (0.225% formic acid)-acetonitrile]; gradient: 5% to 35% acetonitrile] to obtain 047.1H NMR (400 MHz, CDCL) δ ppm 8.51 (br s, 1H), 8.28 (s, 1H), 7.72 (s, 1H), 7.65 - 7.70 (m, 1H), 7.13 (d, J = 5.52 Hz, 1H), 5.92 (br s, 1H), 5.30 - 5.37 (m, 1H), 3.80 (s, 3H), 2.41 (br s, 2H), 2.27 (q, J = 7.53 Hz, 2H), 2.00 - 2.10 (m, 1H), 1.73 - 1.93 (m, 3H), 1.21 (t, J = 7.53 Hz, 3H); ESI-LCMS: m / z = 368.1 [M+H]+. SFC analysis was performed (chromatographic column: Chiralcel OJ-3 50χ4.6 mm ID, 3 pm; mobile phase: A: supercritical carbon dioxide B: ethanol (0.05% diethylamine); gradient: 5% to 40% B (2 min), 40% B (held for 1.2 min), 5% B (held for 0.5 min); flow rate: 3.0 mL / min; column temperature: 35°C; pressure: 1500 psi), ee = 98.58%, retention time 1.394 minutes.

[0745] Example 41

[0746] Synthetic route: Petition 870260002323, dated 09 / 01 / 2026, pp. 394 / 413 171 / 189

[0747] Step 1: synthesis of compound 048-2

[0748] To a reaction flask, 048-1 (0.819 g, 3.86 mmol) and tetrahydrofuran (10 mL) were sequentially added. After stirring to dissolve, tetraethyl titanate (1.60 mL, 7.72 mmol) was added, followed by the dropwise addition of a tetrahydrofuran solution (10 mL) of A-1-2 (468.13 mg, 3.86 mmol). The mixture was stirred at 75°C for 1 hour. The reaction mixture was allowed to return to room temperature and sequentially added with 40 mL of ethyl acetate and 40 mL of saturated aqueous sodium bicarbonate solution. The mixture was filtered through diatomaceous earth and the filter cake was rinsed sequentially with ethyl acetate, water, and ethyl acetate (40 mL x 2). The filtrate was collected and the resulting phases were separated. The organic phase was collected and washed sequentially with a saturated aqueous solution of sodium bicarbonate and saturated brine (100 mL at a time).The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by column chromatography (ethyl acetate:petroleum ether = 10 to 30%) to obtain 048-2. 1H NMR (400 MHz, CDCh) δ ppm 8.90 (s, 1H), 8.73 (s, 1H), 3.50 - 3.63 (m, 2H), 3.10 - 3.22 (m, 2H), 1.34 (s, 9H).

[0749] Step 2: synthesis of compound 048-3

[0750] O48-2 (255 mg, 808.94 μmol) and tetrahydrofuran (10 mL) were sequentially added to a reaction flask. The atmosphere was purged with nitrogen. A Petition 870260002323, dated 09 / 01 / 2026, pp. 395 / 413 172 / 189 A solution of 9-borabicyclo[3.3.1]nonane (0.5 M in tetrahydrofuran, 4.04 mL) was added dropwise at 0°C and the mixture was heated to 20°C and stirred for 16 hours. The reaction mixture was added to a saturated aqueous solution of ammonium chloride (30 mL) and extracted with ethyl acetate (20 mL). The organic phase was collected and washed with saturated brine (30 mL). The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 10:1) to obtain 048-3.

[0751] Step 3: synthesis of compound 048-4

[0752] To a reaction flask, 048-3 (170 mg, 535.86 μmol) and ethanol (9 mL) were sequentially added. The mixture was brought to 0°C, followed by the addition of trimethylsilyl chloride (136.02 μL, 1.07 mmol). The mixture was heated to 20°C and stirred for 2 hours. The reaction mixture was concentrated to obtain crude 048-4, which was used directly in the next step without purification. ESI-LCMS: m / z = 213.0 [M+H]+.

[0753] Step 4: Synthesis of Compound 048-5

[0754] To a reaction flask, 048-4 (115 mg, 539.72 pmol), dichloromethane (9 mL), and N,N-diisopropylethylamine (159.23 pL, 914.17 μmol) were sequentially added. The mixture was kept at 0°C, and a solution of propionic anhydride (72 pL, 558.78 pmol) in dichloromethane (9 mL) was added. The mixture was stirred at 0°C for 1 hour. 10 mL of water were added, and the resulting phases were separated. The aqueous phase was extracted with dichloromethane (10 mL). The organic phases were combined and washed with 20 mL of saturated brine. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The crude product was purified by preparative thin-layer chromatography (dichloromethane:methanol = 15:1, with 1% triethylamine) to obtain O48-5. ESI-LCMS: m / z = 269.1 [M+H]+. Petition 870260002323, dated 09 / 01 / 2026, pages 396 / 413 173 / 189

[0755] Step 5: Synthesis of Compound 048

[0756] To a reaction flask, the following were sequentially added: 048-5 (58 mg, 215.50 pmol), 1,4-dioxane (5 mL), 001-3 (155.08 mg, 431.01 pmol), potassium carbonate (119.14 mg, 862.01 pmol), 2-dicyclohexylphosphamo-2,6-dimethoxybiphenyl (13.27 mg, 32.33 μmol), and water (1 mL). The atmosphere was purged with nitrogen, and palladium acetate (2.42 mg, 10.78 μmol) and bis(triphenylphosphamo)palladium(II) chloride (7.56 mg, 10.78 μmol) were added. The mixture was stirred at 75°C for 2 hours. Additional 001-3 (155.08 mg, 431.01 μmol) was added and the mixture was stirred at 75°C for 18 hours. The reaction mixture was returned to 20°C and filtered through anhydrous sodium sulfate. The filter cake was washed with 15 mL of ethyl acetate. The filtrate was collected and concentrated to obtain a crude product.The crude product was sequentially subjected to preparative thin-layer chromatography (dichloromethane:methanol = 20:1) and chiral resolution SFC (chromatographic column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 μm); mobile phase: [supercritical carbon dioxide-ethanol (0.1% ammonia)]; isocratic elution: 40% ethanol (0.1% ammonia)) to obtain 048. µH NMR (400 MHz, CDCh) δ ppm 8.56 (br s, 2H), 7.72 (d, J = 9.29 Hz, 1H), 7.60 - 7.68 (m, 2H), 7.48 (d, J = 8.53 Hz, 1H), 6.78 (d, J = 9.29 Hz, 1H), 5.78 (br d, J= 7.03 Hz, 1H), 5.69 (q, J= 7.70 Hz, 1H), 3.78 (s, 3H), 2.98 - 3.12 (m, 2H), 2.63 - 2.74 (m, 1H), 2.32 (q, J= 7.53 Hz, 2H), 1.82 - 1.92 (m, 1H), 1.22 - 1.26 (m, 3H); ESI-LCMS: m / z = 348.2 [M+H]+. SFC analysis was performed (chromatographic column: Chiralpak AD-3 50χ4.6 mm ID, 3 pm; mobile phase: A: supercritical carbon dioxide B: ethanol (0.05% diethylamine); gradient: 5% to 40% B (1.5 min), 40% B (held for 1.0 min), 5% B (held for 0.5 min); flow rate: 4 mL / min; column temperature: 35°C; pressure: 1500 psi), ee = 100%, retention time 1.927 minutes.

[0757] Biological assessment Petition 870260002323, dated 09 / 01 / 2026, pp. 397 / 413 174 / 189

[0758] Experimental example 1: In vitro activity assay of human CYP11B2 overexpressing monoclonal cells

[0759] The human renal leiomyoma cell line G402, which overexpresses human CYP11B2, was selected to serve as a compound activity screening system. Details are as follows:

[0760] 1) Information on cells, reagents and instruments is provided in Tables 1 and 2.

[0761] Table 1: Information on cells and reagents Cells and reagents Supplier G402 ATCC Cells Aldosterone Detection Kit Cisbio 11-Deoxycorticosterone Med Chem Express (MCE) 11-Deoxycortisol Med Chem Express (MCE)

[0762] Table 2: Instrument information Product Name Company Model / Specification Low-speed benchtop centrifuge Xiangyi Centrifuge Instrument Co., Ltd., Changsha High-Tech Industrial Development Zone TDZ5-WS Thermostat water bath with digital display Guohua (Changzhou) Instrument Manufacturing Co., Ltd. HH-6 Petition 870260002323, dated 09 / 01 / 2026, pages 398 / 413 175 / 189 SelinsBio EVE™ Plus Cell Counter; BMG Labtech Microplate Reader; PHERAstar FSX Microplate Reader; Suzhou Jiemei Electronics Co., Ltd. OS-07U Horizontal Microplate Shaker; Eppendorf High-Speed, Low-Temperature Refrigerated Centrifuge; 5810 R Centrifuge; Waters XEVO TQ-S Mass Spectrometry; Waters ACQUITY UPLC Class I Plus Micro Liquid Chromatography

[0763] 2) Compound details: The test compound was prepared as a working concentration of 10 μM using DMSO.

[0764] 3) Experimental procedure

[0765] Day 1: The cells were digested and human renal leiomyoma G402 cells overexpressing human CYP11B2 were resuspended at 1χ105 cells / mL, with 100 pL seeded in a 96-well plate.

[0766] Day 2: The medium was replaced with DMEM / F12 containing 2.5% uncharred fetal bovine serum; test compounds were added: 5 pL of the test compound were added to the cell culture medium to achieve final concentrations of 10000, 2500, 625, 156.25, 39.06, 9.77, 2.44, 0.61, 0.15, and 0 nM (with a DMSO content of 0.1%).

[0767] After one hour, the substrate was added: 11-deoxycorticosterone 30 mM was diluted 1500 times with culture medium and 5 pL were dispensed per well to achieve a final concentration of 1 pM, followed by incubation for 16 hours.

[0768] Day 3: The cell supernatant was collected and added to 200 µL of a solution Petition 870260002323, dated 09 / 01 / 2026, pages 399 / 413 176 / 189 of methanol containing internal standards (internal standards: 35 ng / mL ketoprofen or 7.5 ng / mL carbamazepine or 5 ng / mL diphenhydramine or 10 ng / mL tolbutamide). The mixture was vortexed and centrifuged (4000xg, 4°C, 5 min). Then, 100 μL of the supernatant were removed and mixed with 100 μL of pure water. The mixture was centrifuged (4000 g, 4°C, 15 min) and the supernatant was analyzed by ESI-LCMS / MS.

[0769] 4) Data Analysis:

[0770] Ratio = Aldosterone peak area / Internal standard peak area

[0771] % of control activity = (Test compound ratio / DMSO ratio)χ100%

[0772] Test compound ratio represents the ratio values ​​at different concentrations of the test compound.

[0773] DMSO Ratio represents the Ratio value without the addition of the test compound.

[0774] X = Log (compound concentration)

[0775] Y = % of control activity

[0776] The IC50 of the test compound was determined by fitting a non-linear regression equation using XLfit 5.5.0. The test results are presented in Table 3.

[0777] Table 3: Results for the in vitro activity assay of human CYP11B2 overexpressing monoclonal cells Human CYP11B2 Compound, IC50 (nM) Human CYP11B2 Compound, IC50 (nM) Compound 001 11.96 Compound 025 65.49 Compound 005 19.47 Compound 027 62.74 Compound 010 71.45 Compound 030 48.71 Compound 011 59.73 Compound 031 22.59 Compound 014 20.65 Compound 032 30.15 Compound 015 31.82 Compound 037 14.19 Petition 870260002323, dated 09 / 01 / 2026, pages 400 / 413 177 / 189 Compound 016 63.64 Compound 041 42.17 Compound 017 2.09 Compound 042 40.99 Compound 018 20.66 Compound 044 32.87 Compound 019 17.31 Compound 045 42.70 Compound 020 25.48 Compound 046 13.30 Compound 022 48.75 Compound 048 7.02 Compound 023 12.53

[0778] Experimental conclusion: The compounds in this disclosure exhibited a significant inhibitory effect against human CYP11B2, effectively suppressing aldosterone production. They are clinically applicable for the treatment of primary aldosteronism, resistant hypertension, and other aldosterone-related metabolic syndromes.

[0779] Experimental Example 2: In vitro activity assay of human CYP11B1 overexpressing monoclonal cells

[0780] The human renal leiomyoma cell line G402, which overexpresses human CYP11B1, was selected to serve as a compound selectivity screening system. Details are as follows:

[0781] 1) The cells, reagents and instrument information were consistent with Experimental Example 1 (activity of human CYP11B2 overexpressing monoclonal cells).

[0782] 2) Compound details: The test compound was prepared as a working concentration of 50 μM using DMSO.

[0783] 3) Experimental procedure

[0784] Day 1: The cells were digested and G402 human renal leiomyoma cells overexpressing CYP11B1 were resuspended at 1^105 cells / mL, with 100 pL seeded in a 96-well plate. Petition 870260002323, dated 09 / 01 / 2026, pages 401 / 413 178 / 189

[0785] Day 2: The medium was replaced with DMEM / F12 containing 2.5% non-charcoal fetal bovine serum.

[0786] Test compounds were added: 5 μL of test compound were added to the cell culture medium to achieve final concentrations of 50000, 12500, 3125, 1526, 781.25, 260.42, 86.81, 28.94, 9.65 and 0 nM (with a DMSO content of 0.5%).

[0787] After one hour, the substrate was added: 11-deoxycortisol 30 mM was diluted 1500 times with culture medium and 5 μL were dispensed per well to achieve a final concentration of 1 pM, followed by incubation for 16 hours.

[0788] Day 3: Cell supernatant was collected and added to 200 pL of a methanol solution containing internal standards (internal standards: 35 ng / mL ketoprofen or 7.5 ng / mL carbamazepine or 5 ng / mL diphenhydramine or 10 ng / mL tolbutamide). The mixture was vortexed and centrifuged (4000 g, 4°C, 5 min). Then, 100 pL of the supernatant were removed and mixed with 100 pL of pure water. The mixture was centrifuged (4000 g, 4°C, 15 min) and the supernatant was analyzed by ESI-LCMS / MS.

[0789] 4) Data Analysis:

[0790] Ratio = Peak cortisol area / Internal standard peak area

[0791] % of control activity = (Test compound ratio / DMSO ratio)χ100%

[0792] Test compound ratio represents the ratio values ​​at different concentrations of the test compound.

[0793] DMSO Ratio represents the Ratio value without the addition of the test compound.

[0794] X = Log (concentration of the compound)

[0795] Y = % of control activity

[0796] The IC50 of the test compound was determined by fitting a non-linear regression equation using XLfit 5.5.0. Test results are presented in Table 4.

[0797] Table 4: Results for the in vitro activity assay of human CYP11B1 overexpressing monoclonal cells Petition 870260002323, dated 09 / 01 / 2026, pages 402 / 413 179 / 189 Human CYP11B1 Compound, IC50 (nM) Human CYP11B1 Compound, IC50 (nM) Compound 001 2472 Compound 030 2181 Compound 005 1416 Compound 031 4738 Compound 010 6880 Compound 032 5648 Compound 011 6912 Compound 037 3472 Compound 017 322 Compound 041 6750 Compound 018 3811 Compound 044 19474 Compound 019 1684 Compound 045 34928 Compound 020 1127 Compound 046 1569 Compound 022 6894 Compound 048 2486 Compound 023 1742

[0798] Experimental conclusion: The compounds in this disclosure exhibited weak inhibition against human CYP11B1 and minimally affected cortisol synthesis, thus demonstrating improved clinical safety.

[0799] Experimental Example 3: In vivo pharmacokinetic study in rats

[0800] Experimental objective: Male SD rats were used as test animals to determine plasma concentrations of compounds after a single administration and to evaluate pharmacokinetic behavior.

[0801] Experimental procedure: Two healthy adult male SD rats were selected for the oral administration group. The vehicle in the oral administration group was a mixture of 20% PEG400, 10% solutol, and 70% water. After mixing the compound to be tested with the vehicle, the mixture was vortexed and sonicated to prepare a clear solution of 0.25 mg / mL. After oral administration of 2 mg / kg to rats, whole blood was collected over a period of time to prepare plasma, and the drug concentration was analyzed by LC-MS / MS. Petition 870260002323, dated 09 / 01 / 2026, pages 403 / 413 180 / 189 then, the pharmacokinetic parameters were calculated using the Phoenix WinNonlin software (Pharsight, USA). The results are shown in Table 5.

[0802] Table 5: PK test results of compounds from the present disclosure in rats Compound No. Cmax (nM) AUCo-24h (nM.h) T1 / 2 (h) F (%) Compound 001 7635 59097 4.61 80 Compound 005 1315 7802 2.77 111 Compound 017 4165 8129 1.34 115 Compound 023 6916 44234 3.6 109 Compound 037 8285 49894 2.36 157 Compound 046 7855 36571 3.23 71

[0803] Experimental conclusion: The compounds in this disclosure exhibited a long half-life, high oral exposure, and good oral bioavailability in in vivo oral pharmacokinetic studies in rats, demonstrating favorable pharmacokinetic characteristics suitable for an oral drug.

[0804] Experimental Example 4: In vivo pharmacokinetic study in cynomolgus monkeys

[0805] Experimental objective: Cynomolgus monkeys were used as test animals to determine plasma concentrations of compounds after a single administration and to evaluate pharmacokinetic behavior.

[0806] Experimental procedure: Two healthy male cynomolgus monkeys were selected for the oral administration group. The vehicle used in the oral administration group was a mixture of 20% PEG400, 10% solutol, and 70% water. The test compound was mixed with the vehicle, vortexed, and ultrasonically agitated to prepare a clear solution of 0.6 mg / mL. The oral administration dose for monkeys Petition 870260002323, dated 09 / 01 / 2026, pages 404 / 413 The dose of 181 / 189 cynomolgus was 1 mg / kg or 3 mg / kg. After oral administration, whole blood was collected over a period of time to prepare plasma, and the drug concentration was analyzed by LC-MS / MS. Then, pharmacokinetic parameters were calculated using Phoenix WinNonlin software (Pharsight, USA). The results are shown in Table 6.

[0807] Table 6: PK test results of compounds from the present disclosure in cynomolgus monkeys Compound No. Dose (mg / kg) Cmax (nM) AUCo-24h( nM.h) T1 / 2 (h) F (%) Compound 001 3 4005 23174 4.99 120 Compound 017 1 1071 7292 5.30 66 Compound 018 1 1310 7586 5.35 — Compound 019 3 3795 23864 4.65 113 Compound 023 1 1320 8916 4.80 76.5 Compound 037 1 1320 10039 5.75 67

[0808] Note: -- indicates that the test was not performed.

[0809] Experimental conclusion: The compounds in this disclosure exhibited a long half-life, high oral exposure, and good oral bioavailability in in vivo oral pharmacokinetic studies in cynomolgus monkeys, demonstrating favorable pharmacokinetic characteristics suitable for an oral drug.

[0810] Experimental Example 5: Permeability Test

[0811] Experimental objective: The permeability-to-efflux ratio of the compound in this disclosure was determined using the MDR1MDCKII monolayer cell model to evaluate its membrane permeability and potential for P-gp-mediated efflux transport.

[0812] Experimental protocol: MDR1-MDCKII cells (obtained from the Netherlands Cancer Institute) were seeded in 96-well plates (obtained from Corning) at a Petition 870260002323, dated 09 / 01 / 2026, pages 405 / 413 182 / 189 cells with a cell density of 3.33χ10⁵ cells / mL were cultured for 4 to 7 days to form confluent cell monolayers. Hank's balanced saline solution containing 10 mM HEPES (pH 7.40) was used as a transport buffer. The test compound was evaluated for bidirectional transport at a concentration of 2 μM, with the DMSO concentration in the incubation system maintained below 1%. After sample addition, the cell plate was incubated at 37±1°C, 5% CO₂, and saturated humidity for 2.5 hours. All samples were quantitatively analyzed using the LC-MS / MS method. The apparent permeability coefficient (Papp, cm / s) and efflux ratio (ER) were calculated using the following formula. The apparent permeability coefficient (Papp, cm / s) was calculated using the following formula: Papp = (dCr / dt) x Vr / (A x co).Here, dCr / dt represents the cumulative concentration of the compound at the receiving end per unit time (pM / s); vr is the volume of the solution at the receiving end (with solution volumes at the apical and basolateral ends being 0.075 mL and 0.250 mL, respectively); A is the relative surface area of ​​the cell monolayer (0.143 cm²); Co is the initial concentration of the test substance at the dosing end (pM) or the peak area ratio of the reference substance. The efflux rate was calculated using the following formula: ER = Papp (BA) / Papp (AB). The results are shown in Table 7.

[0813] Table 7: Permeability test results of the compounds Compound Apparent permeability coefficient (Papp (AB), 10-6 cm / s) Efflux ratio (ER) Compound 001 17.2 1.76 Compound 005 23.1 0.70 Compound 011 24.3 0.89 Compound 017 23.2 0.95 Compound 018 24.6 1.32 Compound 019 21.5 1.55 Petition 870260002323, dated 09 / 01 / 2026, pages 406 / 413 183 / 189 Compound 020 14.0 2.47 Compound 023 20.8 1.28 Compound 031 20.0 0.89 Compound 032 22.6 0.86 Compound 037 10.7 1.88 Compound 044 11.0 2.46 Compound 045 16.7 1.30 Compound 046 18.0 1.17

[0814] Experimental conclusion: The compounds in this publication exhibited high permeability and low efflux, demonstrating good pharmacopability.

[0815] Example 6: In vitro metabolic stability study of the liver microsome

[0816] Experimental objective: To evaluate the metabolic stability of the test compounds in human liver microsomes.

[0817] Experimental materials: Purchased from Corning or Xenotech and stored in a freezer at -80°C; Reduced Nicotinamide Adenine Dinucleotide Phosphate (NADPH), Supplier: Chem-impex international; Control compounds: testosterone, diclofenac, propafenone.

[0818] Experimental procedure:

[0819] 1. Preparation of the working solution

[0820] Stock solution: 10 mM in DMSO. Preparation of working concentration: The stock solution was diluted to 100 μM using 100% acetonitrile (organic phase content: 99% acetonitrile, 1% DMSO).

[0821] 2. Experimental Procedure

[0822] Two incubation plates, designated as T60 incubation plate and NCF60 incubation plate, were prepared and the incubation plates were pre-warmed for 10 minutes. Petition 870260002323, dated 09 / 01 / 2026, pages 407 / 413 184 / 189

[0823] Liver microsomes were diluted to a protein concentration of 0.56 mg / mL using 100 mM potassium phosphate buffer.

[0824] 445 μE of microsomal working solution (with a liver microsomal protein concentration of 0.56 mg / mL) were transferred to pre-warmed T60 and NCF60 incubation plates and pre-incubated at 37°C in a water bath for 10 minutes.

[0825] After pre-incubation, 5 μE of the test compound or working solution of the control compound were added to the T60 incubation plate and the NCF60 incubation plate and mixed well. 50 μE of potassium phosphate buffer were added to each well of the NCF60 incubation plate and mixed thoroughly, and the reaction was initiated.

[0826] In the T0 stop plate, 180 μE of stop solution (acetonitrile solution containing 200 ng / mL tolbutamide and 200 ng / mL labetalol) and 6 μE of working solution from the NADPH regeneration system were added. 54 μE of sample were transferred from the T60 incubation plate to the T0 stop plate (generated T0 sample). 44 μE of working solution from the NADPH regeneration system per well were added to the T60 incubation plate to initiate the reaction. Only 54 μE of microsomal working solution, 6 μE of working solution from the NADPH regeneration system, and 180 μE of stop solution were added to the blank plate.Therefore, in the samples containing the test compounds or control compounds, the final concentrations of the compounds, testosterone, diclofenac, and propafenone in the reaction were 1 μM, the concentration of liver microsomes was 0.5 mg / mL, and the final concentrations of DMSO and acetonitrile in the reaction system were 0.01% (v / v) and 0.99% (v / v), respectively.

[0827] After incubation for appropriate durations (5, 15, 30, 45, 60 minutes), 180 μE of stopping solution were added to each sample well of the stopping plate, followed by the transfer of 60 μE of sample from the T60 incubation plate to the stopping plate. Petition 870260002323, dated 09 / 01 / 2026, pages 408 / 413 185 / 189 to end the reaction.

[0828] All sample plates were vortexed and subsequently centrifuged at 4°C for 20 minutes (4000 rpm). 80 μL of supernatant were taken from each well, transferred to 240 μL of pure water for dilution, and mixed for 10 minutes. LC-MS / MS analysis was performed. The results are shown in Table 8.

[0829] Table 8: Results of the stability test of the compounds of the present disclosure in human liver microsomes Compound No. Intrinsic hepatic clearance CLint(liver) (mL / min / kg) Compound No. Intrinsic hepatic clearance CLint(liver) (mL / min / kg) Compound 001 <8.6 Compound 023 <8.6 Compound 011 <8.6 Compound 031 <8.6 Compound 017 <8.6 Compound 032 <8.6 Compound 018 <8.6 Compound 037 <8.6 Compound 019 <8.6 Compound 046 <8.6 Compound 020 12.9

[0830] Experimental conclusion: The compounds in this disclosure showed low clearance in human liver microsomes, demonstrating relatively good metabolic stability.

[0831] Experimental Example 7: Plasma Protein Binding Rate Test of Compounds

[0832] Experimental objective: To evaluate the protein binding rate of the compounds from this disclosure in the plasma of SD rats, cynomolgus monkeys, and humans using Petition 870260002323, dated 09 / 01 / 2026, pp. 409 / 413 186 / 189 equilibrium dialysis.

[0833] Test Protocol:

[0834] Blank plasma from humans, SD rats and cynomolgus monkeys (796 μL, purchased from BioreclamationIVT) was enriched with working solutions of the test compound or warfarin to achieve final concentrations of 2 pM for the test compound and warfarin in the plasma samples.

[0835] The sample was thoroughly mixed. The final concentration of the organic phase DMSO was 0.5%. A 50 pL volume of the test compound and warfarin plasma sample was transferred to the sample receiving plate, followed by the immediate addition of the corresponding volume of blank plasma or buffer solution to achieve a final volume of 100 pL per sample well. The plasma to dialysis buffer volume ratio was 1:1. A stopping solution was then added to these samples, and this sample was designated as sample T0 for recovery and stability determination.

[0836] The test compound and warfarin plasma samples were added to the dosing end of each dialysis well, and the blank dialysis buffer was added to the corresponding receiving end. The dialysis plate was then sealed with a gas-permeable membrane and placed in a 5% humidified CO2 incubator, where it was incubated at 37°C with agitation at 100 rpm for 4 hours.

[0837] After dialysis, 50 pL of the dialysed buffer sample and the dialysed plasma sample were transferred to a new sample receiving plate. Appropriate volumes of corresponding blank plasma or buffer solution were added to the samples, resulting in a final volume of 100 pL per sample well, with a plasma buffer to dialysis volume ratio of 1:1.

[0838] Data analysis:

[0839] All samples were subjected to protein precipitation followed by Petition 870260002323, dated 09 / 01 / 2026, pages 410 / 413 187 / 189 LC / MS / Ms analysis. The free fraction and plasma protein binding rate of the compound were calculated using the following formulas: Free fraction (%) = 100 * Fc / Tc, Plasma protein binding rate of the compound (%) = 100% - Free fraction of the compound (%), where Fc is the concentration of the compound in the buffer compartment of the dialysis plate; Tc is the concentration of the compound in the plasma compartment of the dialysis plate; To is the concentration of the compound in the plasma sample at time zero.

[0840] The results are shown in Table 9.

[0841] Table 9: Results of the plasma protein binding rate of the compounds in this disclosure Compound No. Plasma protein binding rate (%) in SD rats Plasma protein binding rate (%) in cynomolgus monkeys Human plasma protein binding rate (%) Compound 001 92.1 74.6 76.1 Compound 005 89.8 87.3 89.4 Compound 011 86.1 75.5 75.5 Compound 017 94.9 78.1 82.7 Compound 018 92.0 79.5 80.9 Compound 019 87.1 75.2 76.2 Compound 020 91.7 90.3 85.6 Compound 023 90.4 69.0 69.6 Compound 031 85.9 79.7 80.7 Compound 032 84.9 79.5 84.9 Compound 037 90.8 54.9 64.6 Compound 044 97.6 66.4 70.5 Petition 870260002323, dated 09 / 01 / 2026, pp. 411 / 413 188 / 189 Compound 045 96.9 68.0 76.1 Compound 046 97.6 69.6 83.4

[0842] Experimental conclusion: The compounds in this disclosure exhibited moderate binding to plasma proteins in different species, with an appropriate proportion of free drug in plasma, indicating good pharmacological potential.

[0843] Experimental Example 8: Human Liver Microsome CYP Inhibition Assay

[0844] Experimental objective: To evaluate the inhibitory activity of the test substance on human hepatic microsomal cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4) using a 5-in-1 probe substrate for CYP isoenzymes.

[0845] Mixed human liver microsomes (HLM) were purchased from Corning Inc. (Steuben, New York, USA) and stored at temperatures below -70°C prior to use.

[0846] The working solution of the test substance, which had been diluted to a range of concentrations, was added to an incubation system containing human liver microsomes, probe substrates, and circulatory system auxiliary factors. A control containing solvent but no test substance served as an enzymatic activity control (100%). The concentration of metabolites produced from probe substrates in the samples was determined using the Liquid Chromatography-Tandem Mass Spectrometry (LC-MS / MS) method. Nonlinear regression analysis of the mean percent activity of the test substance with respect to its concentration was performed using SigmaPlot (v.11). IC50 values ​​were calculated using a three-parameter or four-parameter inverse logarithmic equation.The results are shown in Table 10.

[0847] Table 10: Maximum inhibitory concentration of half of the cytochrome P450 isoenzyme IC50 (μM) Petition 870260002323, dated 09 / 01 / 2026, pp. 412 / 413 189 / 189 Compound No. CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4 Compound 001 >50 >50 >50 >50 >50 Compound 011 >50 >50 >50 >50 >50 Compound 017 >50 45.1 >50 >50 >50 Compound 023 >50 >50 >50 >50 >50 Compound 037 >50 >50 >50 >50 >50 Compound 046 >50 >50 >50 >50 >50

[0848] Experimental conclusion: The compounds in this disclosure did not exhibit an inhibitory effect on the CYP enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, indicating a very low risk of drug interactions.

Claims

1. Compound of formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, characterized in that ring A is selected from the group consisting of ring A1 and ring A2; ring A1 is selected from the group consisting of ring A2, wherein ring A2 is selected from the group consisting of H, which are each independently and optionally substituted by 1, 2 or 3 R1; Petition 870250103729, 12 / 11 / 2025, p. 12 / 753 2 / 24 ring B is selected from the group consisting of ring B1 and ring B2; ring B1 is selected from the group consisting of phenyl, pyridyl and pyridazinyl, wherein phenyl, pyridyl and pyridazinyl are each independently and optionally substituted by 1, 2 or 3 R1; Ring B2 is a 5-membered heteroaryl, where the 5-membered heteroaryl is optionally replaced by 1, 2, or 3 Rho; T is selected from the group consisting of a single bond, CH2, NH, and O; Ti is selected from the group consisting of O and CR4R5; Ri is selected from the group consisting of H, =NR, C1-3 alkyl, and C1-3 haloalkyl;Each R2, R3, R4, and R5 is independently selected from the group consisting of H, F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 haloalkoxy, wherein not all four of R2, R3, R4, and R5 are simultaneously H; alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl; alternatively, R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl; alternatively, R3 and R4 together with the carbon atom to which they are attached form a double bond or a cyclopropyl; each Rho is independently selected from the group consisting of H, F, Cl, Br, I, and C1-3 alkyl; The structural fraction Rs is selected from the group consisting of O R71; R7i is a 4- to 6-membered heterocycloalkyl group, wherein the 4- to 6-membered heterocycloalkyl group is optionally replaced by i, 2 or 3 Ra; R8i is selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl;Petition 870250103729, dated 12 / 11 / 2025, p. 13 / 753 3 / 24 the C ring is selected from the group consisting of the C1 ring and the C2 ring; the C1 ring is C5-6 cycloalkyl substituted by 1 R9, wherein R9 is selected from the group consisting of -NHC(=O)-C1-3 alkyl, 5- to 6-membered -NH-C(=O)-heteroaryl, 4- to 6-membered -NH-heterocycloalkyl, 4- to 6-membered heterocycloalkyl, and H,N. .NR R , wherein the 5- to 6-membered -NHC(=O)-Ci-3 alkyl, 4- to 6-membered -NH-C(=O)-heteroaryl, and 4- to 6-membered NH heterocycloalkyl are each independently and optionally substituted by 1, 2, or 3 Rb; the C2 ring is selected from the group consisting of F, Cl, Br, I, C1-3 alkyl, and -S(=O)2-Ci-3 alkyl; each Rb is independently selected from the group consisting of F, Cl, Br, I, C1-3 alkyl, -C(=O)-Ci-3 alkyl, and -NH-C(=O)-Ci-3 alkyl;Rc and Rd, together with the carbon atom to which they are attached, form a 5- to 6-membered C3-5 cycloalkyl or heterocycloalkyl; each Re is independently selected from the group consisting of F, Cl, Br, I, =O, C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino, -NHC(=O)-C1-3 alkyl, -NHC(=O)-C1-3 alkoxy, -NHC(=O)-C1-3 alkylamino and =NR; R is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, wherein the C1-3 alkyl and C1-3 alkoxy are each independently and optionally substituted by 1, 2 or 3 halogens; n is 0 or 1; is a single bond or a double bond; Petition 870250103729, dated 12 / 11 / 2025, p. 14 / 753 4 / 24 the term hetero in 5-membered heteroaryl, 5- to 6-membered heteroaryl and 4- to 6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatomic groups, each independently selected from the group consisting of O, S and N; provided that 1) when ring A is Ai and ring B is Bi, then ring C is C2; or,; 2) when ring A is A1, ring B is Bi and ring C is C5-6 cycloalkyl substituted by H,N^NR 1 R9, then R9 is R.

2. Compound according to claim 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, characterized in that the compound satisfies either of the following conditions: (1) R is selected from the group consisting of CH3, CH2CH3, CF3, OCH3 and OCF3; (2) Ra is -S(=O)2-CH2CH3; (3) each Rb is independently selected from the group consisting of F, Cl, Br, I, CH3, -C(=O)-CH2CH3 and -NHC(=O)-CH2CH3; (4) Rc and Rd, together with the carbon atom to which they are attached, form or (5) Re is selected from the group consisting of -NHC(=O)-CH2CH3, =NCH3 and =NOCH3; (6) R1 is CH3; (7) each R2, R3, R4 and R5 is independently selected from the group consisting of H, F, Cl, Br, CH3, CHF2, CF3, CH2CH3, OCH3, and OCH2CH3, wherein not all four of R2, R3, R4, and R5 are simultaneously H; (8) R71 is Petition 870250103729, dated 12 / 11 / 2025, p. 15 / 753 5 / 24 (9) R9 is selected from the group consisting of -NHC(=O)-CH2CH3, -NH-C(=O)pyridyl, -NH-C(=O)-isoxazolyl, -NH-piperidinyl, -NH-pyrrolidinyl, -NH-azetidinyl, H ,N. .NR piperidinyl and R , where -NHC(=O)-CH2CH3, -NH-C(=O)pyridyl, -NH-C(=O) -isoxazolyl, -NH-piperidinyl, -NH-pyrrolidinyl, -NH-azetidinyl and piperidinyl are each independently and optionally replaced by 1, 2 or 3 Rb; (10) the Bi ring is selected from the group consisting of , in , F , , , , ; , N 1 N (11) the Cl , Cl , A2 ring is selected from the group consisting of , Petition 870250103729, 12 / 11 / 2025, p. 16 / 753 6 / 24 (12) ring C1 is selected from the group consisting of 3. Compound, according to claim 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, characterized in that the compound satisfies any of the following conditions: --NH (1) R9 is selected from the group consisting of and , wherein Petition 870250103729, 12 / 11 / 2025, p. 17 / 753 7 / 24 --NH and are each independently and optionally substituted by 1, 2 or 3 Rb; (2) ring B2 is selected from the group consisting of tienyl, thiazolyl, imidazolyl and pyrazolyl, wherein tienyl, thiazolyl, imidazolyl and pyrazolyl are each independently and optionally substituted by 1, 2 or 3 Ra; (3) the C2 ring is selected from the group consisting of , where the , and NH are each independently and optionally substituted by 1, 2 or 3 Re.

4. Compound according to claim 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,characterized in that the compound satisfies any of the following conditions: Petition 870250103729, 12 / 11 / 2025, p. 18 / 753 8 / 24 --NH (1) R9 is selected from the group consisting of (2) ring B2 is selected from the group consisting of (3) ring C2 is selected from the group consisting of 5. Compound according to claim 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, characterized in that the compound is selected from the group consisting of: Petition 870250103729, 12 / 11 / 2025, p. 19 / 753 9 / 24 in which it is selected from the group consisting of a single bond and a double bond; T2 is selected from the group consisting of CH and N; T4 is selected from the group consisting of CH and N; T3 is selected from the group consisting of C and N; ring E is selected from the group consisting of m; m is selected from the group consisting of 0, 1, 2, and 3; p is selected from the group consisting of 0,1 and 2; ring B is selected from the group consisting of ring B1 and ring B2; ring B1 is selected from the group consisting of phenyl, pyridyl and pyridazinyl; ring B2 is a 5-membered heteroaryl; Petition 870250103729, dated 12 / 11 / 2025, p. 20 / 753 10 / 24 T, Ti, Ri, R2, R3, R6, L, R7, and R8 are as defined in claim 1.

6. Compound according to claim 1, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, characterized in that the compound is selected from the group consisting of: and in which ring B is selected from the group consisting of phenyl, pyridyl, pyridazinyl and 5-membered heteroaryl; Ti is selected from the group consisting of O and CR4R5; Each R2, R3, R4, and R5 is independently selected from the group consisting of H, F, Cl, Br, I, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, and C1-3 haloalkoxy; alternatively, R2 and R3 together with the carbon atom to which they are attached form a cyclopropyl group; alternatively,R4 and R5 together with the carbon atom to which they are attached form a cyclopropyl; alternatively, R3 and R4 together with the carbon atom to which they are attached form a double bond or a cyclopropyl; each R6 is independently selected from the group consisting of H, F, Cl, Br, I and C1-3 alkyl; R9 is selected from the group consisting of -NHC(=O)-C1-3 alkyl, 5- to 6-membered -NH-C(=O)heteroaryl, 4- to 6-membered -NH-heterocycloalkyl, 4- to 6-membered heterocycloalkyl and R, wherein the -NHC(=O)-C1-3 alkyl, -NH-C(=O)-heteroaryl Petition 870250103729, dated 12 / 11 / 2025, p. 21 / 753 11 / 24 of 5 to 6 members, -NH- heterocycloalkyl of 4 to 6 members and heterocycloalkyl of 4 to 6 members are each independently and optionally substituted by 1, 2 or 3 Rb; each Rb is independently selected from the group consisting of F, Cl, Br, I, C1-3 alkyl, -C(=O)-C1-3 alkyl and -NH-C(=O)-C1-3 alkyl; each Re is independently selected from the group consisting of F, Cl, Br, I, =0,C1-3 alkyl, C1-3 alkoxy, C1-3 alkylamino, -NHC(=O)-C1-3 alkyl, -NHC(=O)-C1-3 alkoxy, -NHC(=O)-C1-3 alkylamino and =NR; R is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy, wherein the C1-3 alkyl and C1-3 alkoxy are each independently and optionally substituted by 1, 2 or 3 halogens; m is selected from the group consisting of O, 1, 2 and 3; is a single bond or a double bond; The term hetero in 5-membered heteroaryl, 5- to 6-membered heteroaryl and 4- to 6-membered heterocycloalkyl represents 1, 2, 3 or 4 heteroatoms or heteroatomic groups, each independently selected from the group consisting of O, S and N.

7. Compound, characterized in that it is represented by one of the following formulas, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, Petition 870250103729, 12 / 11 / 2025, p. 22 / 753 12 / 24 Petition 870250103729, 12 / 11 / 2025, p. 23 / 753 13 / 24 Petition 870250103729, 12 / 11 / 2025,Page 24 / 753 14 / 24 Petition 870250103729, dated 12 / 11 / 2025, p. 25 / 753 15 / 24 OMe OMe .

8. Compound, according to claim 7, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, characterized in that the compound is selected from the group consisting of Petition 870250103729, dated 12 / 11 / 2025, p. 26 / 753 16 / 24 Petition 870250103729, dated 12 / 11 / 2025, p. 27 / 753 17 / 24 Petition 870250103729, dated 12 / 11 / 2025, p. 28 / 753 18 / 24 ο ο ο Petition 870250103729, dated 12 / 11 / 2025, p. 29 / 753 19 / 24 Petition 870250103729, dated 12 / 11 / 2025, p. 30 / 753 20 / 24 Petition 870250103729, dated 12 / 11 / 2025, p. 31 / 753 21 / 24 Petition 870250103729, dated 12 / 11 / 2025, p. 32 / 753 22 / 24 Petition 870250103729, dated 12 / 11 / 2025, p. 33 / 753 23 / 24 Petition 870250103729, dated 12 / 11 / 2025, p. 34 / 753 24 / 24 9. Use of the compound, as defined in any one of claims 1 to 8, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,characterized in that it is for the manufacture of a medicament for the treatment of a disease associated with elevated aldosterone levels.

10. Use of the compound, as defined in any one of claims 1 to 8, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, characterized in that it is for the manufacture of a medicament for the treatment of resistant hypertension.